Articles

Dihydrotestosterone (DHT) is a potent androgen hormone that can significantly impact hair loss. Its activity, however, isn’t just restricted to the scalp. What’s more, hair loss is a multifactorial condition, with a wide range of causes. As such, the solution to hair loss is much more complicated than simply eliminating DHT.

Many natural or pharmaceutical therapies seek to reduce, or rather, rebalance DHT levels. While lowering DHT can slow or even reverse hair loss, the hormone itself plays vital roles in sexual function, mood regulation, and overall well-being. Therefore, the goal should not be total suppression, but rather modulation that considers the balance between hair health and systemic androgen levels.

In this article, we will rank both natural and pharmaceutical DHT blockers from weakest to strongest, based on research, effectiveness, and risk of side effects.

Oral Dutasteride From our partners at Ulo

Most Powerful Rx DHT Blocker

Dutasteride inhibits both type 1 and type 2 5-alpha reductase for max DHT control. Prescribed 100% online. Choose a multi-month plan and get up to 25% plus a free gift bundle.

Free full-size gifts with 3-month+ plans Prescribed online, shipped to your door

Claim up to 25% off + Free Gifts

Dual 5-AR inhibitionMax DHT inhibition

*Only available in the U.S. Prescription requires an online medical consultation at no extra cost. Off-label products are not endorsed by the FDA. Free gifts included with select multi-month plans while supplies last. Ulo is a partner of Perfect Hair Health; we may earn a commission on purchases.

Understanding DHT: Why Blocking It Helps (and Hurts)

DHT is derived from testosterone through the enzyme 5-alpha-reductase. Once formed, DHT binds to androgen receptors and plays a major role in androgenic alopecia (AGA). In hair follicles genetically sensitive to DHT, such as those on the crown and frontal scalp, the hormone acts as a signal for miniaturization. Over time, the follicle shrinks, producing thinner, shorter hairs until it eventually becomes dormant.^[1]York, K., Meah, N., Bhoyrul, B., & Sinclair, R. (2020). A review of the treatment of male pattern hair loss. Expert Opinion on Pharmacotherapy. 21(5). 603-612. Available at: … Continue reading

By reducing DHT levels or blocking its receptor binding, therapies can interrupt this miniaturization cascade. The goal is to prevent DHT from triggering the cellular changes that cause follicles to shrink and enter a premature resting (telogen) phase. AGA is influenced not just by DHT levels but also by individual receptor sensitivity, local inflammation, and oxidative stress.

However, because of DHT’s wide-reaching activity, side effects of its reduction can include sexual dysfunction, decreased motivation, and mood changes, especially in individuals who are more hormonally sensitive. As such, careful consideration of different therapies and their potential impacts is essential if you choose to use a DHT-blocking treatment.^[3]Traish, A. M., Melcangi, R. C., Bortolato, M., Garcia-Segura, L. M., & Zitzmann, M. (2015). Adverse effects of 5α-reductase inhibitors: what do we know, don’t know, and need to know?. Reviews … Continue reading

Ranking the DHT Blockers: From Mild to Potent

We’ll rank DHT blockers based on their potency, as well as on the quality of evidence supporting their use for hair loss. You can learn more about our treatment metrics, including evidence quality, in our article.

Tier 1 – Mild / Natural DHT Blockers

Natural treatments, typically based on oils and herbs, are generally more gentle than pharmaceutical options. They tend to be less potent, but have far fewer side effects and are not typically subject to the same stringent regulation as pharmaceuticals.

EGCG (Evidence Quality – 6%)

Epigallocatechin gallate (EGCG), a catechin compound found in green tea, is another naturally derived compound that has attracted interest for its potential to influence hair follicle biology. As a potent antioxidant and anti-inflammatory molecule, EGCG helps protect follicular cells from oxidative stress and inflammation, both of which are exacerbated by androgen activity. 

 

EGCG appears to enhance cell-survival pathways such as Akt and Erk, supporting follicular cell proliferation while suppressing apoptotic signals that can trigger hair follicle regression.^[5]Kwon, O. S., Han, J. H., Yoo, H. G., Chung, J. H., Cho, K. H., Eun, H. C., & Kim, K. H. (2007). Human hair growth enhancement in vitro by green tea epigallocatechin-3-gallate (EGCG). … Continue reading

Laboratory studies also indicate that EGCG can partially inhibit 5AR, reducing the local generation of DHT.^[6]Hiipakka, R. A., Zhang, H. Z., Dai, W., Dai, Q., & Liao, S. (2002). Structure–activity relationships for inhibition of human 5α-reductases by polyphenols. Biochemical Pharmacology. 63(6). … Continue reading However, while this study showed that EGCG can inhibit 5AR in cell-free experiments, it did not have the same impact in cells. This suggests that it may not be able to enter cells and would have reduced impacts in humans.

This seems to be the case, and clinical evidence for EGCG in the treatment of hair loss remains limited. A small pilot study of topical EGCG found no visible changes in hair, although this research was conducted in people with no hair loss disorders.^[7]Kwon, O. S., Han, J. H., Yoo, H. G., Chung, J. H., Cho, K. H., Eun, H. C., & Kim, K. H. (2007). Human hair growth enhancement in vitro by green tea epigallocatechin-3-gallate (EGCG). … Continue reading Despite the lack of large-scale human trials, molecular findings do suggest EGCG contributes meaningfully to the cellular environment that supports hair growth and protection.

Catechins from green tea infusions are generally well tolerated. However, supplements should be used cautiously at high doses, particularly above 800 mg per day, as they have been linked to liver enzyme elevations in sensitive individuals.^[8]EFSA Panel on Food Additives and Nutrient Sources added to Food (ANS), Younes, M., Aggett, P., Aguilar, F., Crebelli, R., Dusemund, B., Filipič, M., Frutos, M. J., Galtier, P., Gott, D., … Continue reading

You can read more about the evidence for using EGCG for hair loss in our article here.

Pumpkin Seed Oil (Evidence Quality – 49%)

Pumpkin seed oil (PSO) is one of the most extensively studied non-pharmaceutical treatments for hair loss. In general, it is mild and well-tolerated. Its effects appear to arise from its profile of phytosterols and essential fatty acids, such as linoleic and oleic acid. These compounds have been shown to exhibit mild 5AR inhibitory activity in laboratory studies, potentially reducing local DHT formation in scalp tissues.^[9]Azizi, A., Mumin, N. H., & Shafqat, N. (2021). Phytochemicals with anti 5-alpha-reductase activity: a prospective for prostate cancer treatment. F1000Research. 10. 221. Available at: … Continue reading,^[10]Liang, T., & Liao, S. (1992). Inhibition of steroid 5α-reductase by specific aliphatic unsaturated fatty acids. Biochemical Journal. 285(2). 557-562. Available at: … Continue reading

Beyond hormonal modulation, pumpkin seed oil provides antioxidant and anti-inflammatory support, which can help protect hair follicles from oxidative damage and microinflammation – two key contributors to progressive miniaturization.^[11]Fahim, A. T., Abd-El Fattah, A. A., Agha, A. M., & Gad, M. Z. (1995). Effect of pumpkin-seed oil on the level of free radical scavengers induced during adjuvant-arthritis in rats. Pharmacological … Continue reading

A clinical trial carried out in Korea made waves in 2014 when it reported a 40% increase in hair count after 24 weeks. However, the formulation, Octa-Sabal Plus, included multiple additional herbal compounds, alongside pumpkin seed powder, not oil. This means we can’t attribute the growth reported to pumpkin seed oil.^[12]Cho, Y. H., Lee, S. Y., Jeong, D. W., Choi, E. J., Kim, Y. J., Lee, J. G., & Cha, H. S. (2014). Effect of pumpkin seed oil on hair growth in men with androgenetic alopecia: a randomized, … Continue reading 

You can read more about the controversial PSO study here.

Cold-pressed pumpkin seed oil is typically taken orally at doses ranging from 400 to 1000 mg daily, with results accumulating gradually over several months. The compound is generally well tolerated, with gastrointestinal discomfort being rare and mild.^[13]Hong, H., Kim, C. S., & Maeng, S. (2009). Effects of pumpkin seed oil and saw palmetto oil in Korean men with symptomatic benign prostatic hyperplasia. Nutrition Research and Practice. 3(4). … Continue reading Although PSO alone is unlikely to reverse established AGA, it may serve as a gentle adjunct for individuals seeking natural or preventive strategies to support long-term scalp and hair health.

Saw Palmetto (Evidence Quality – 54%)

Saw palmetto (Serenoa repens) is one of the most widely studied natural 5AR inhibitors and is sometimes called “nature’s finasteride.” It appears to reduce DHT by inhibiting Type II 5AR, reducing the binding of DHT to androgen receptor sites and increasing the conversion of DHT to a weaker metabolite called androstanediol.^[14]Suzuki, M., Ito, Y., Fujino, T., Abe, M., Umegaki, K., Onoue, S., Noguchi, H., & Yamada, S. (2009). Pharmacological effects of saw palmetto extract in the lower urinary tract. *Acta … Continue reading

Importantly, saw palmetto appears to reduce DHT selectively, with research showing decreases in DHT in the prostate but not in the blood. As such, it may cause fewer side effects than systemic DHT reducers.^[15]Fagelman, E., & Lowe, F. C. (2001). Saw palmetto berry as a treatment for BPH. Reviews in Urology. 3(3). 134-138. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1476047/

Clinical studies have shown modest impacts of saw palmetto on hair loss. In one study, participants using oral extracts over several months showed reductions in hair shedding, increases in hair density, and subjective improvements in scalp coverage and hair quality.{ Importantly, however, this was an open-label study, where participants and researchers both knew what product they were receiving, so is not as strong a form of evidence as a randomzied controlled trial (RCT).^[16]Rossi, A., Mari, E., Scarno, M., Garelli, V., Maxia, C., Scali, E., Iorio, A., & Carlesimo, M. (2012). Comparative effectiveness of finasteride vs Serenoa repens in male androgenetic alopecia: a … Continue reading 

Hair Growth Supplement From our partners at Ulo

Active Ingredients for Growth Support

Ulo's Hair Growth Supplement combines nutrients linked to follicle health in one daily dose, built to pair with topical and oral treatments. Choose a multi-month plan and get up to 20% plus a free gift bundle.

Free full-size gifts with 3-month+ plans No prescription needed

Claim up to 20% off + Free Gifts

Daily supportPairs with any Ulo treatment

Free gifts included with select multi-month plans while supplies last. Ulo is a partner of Perfect Hair Health; we may earn a commission on purchases. These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.

In a recent RCT, a standardized, proprietary saw palmetto extract was given as either a 400mg oral capsule or 5 ml of topical formulation and compared to relevant controls. The study found a significant reduction in hair shedding in both oral and topical groups compared to their controls, alongside an increase in hair density of 5% and 7.5% respectively. However, this study also had significant drawbacks. For example, measurements of hair density were not well defined and may therefore include vellus hairs, which do not contribute to visible hair. Despite this, the study does provide some support for the use of saw palmetto in decreasing hair shedding and increasing hair thickness.^[17]Sudeep, H. V., Rashmi, S., Jestin, T. V., Richards, A., Gouthamchandra, K., & Shyamprasad, K. (2023). Oral and topical administration of a standardized saw palmetto oil reduces hair fall and … Continue reading

Evidence from benign prostatic hyperplasia suggests that an oral dose of 320 mg per day is optimal, with increases in dose above that resulting in no further improvements. For topical use, concentrations around 0.5 – 1% applied once or twice daily are common. Both routes are well tolerated, with infrequent reports of mild gastrointestinal discomfort or skin irritation. 

You can read about the differences between saw palmetto and finasteride in our article here.

Tier 2 – Over-the-Counter Pharmaceutical Options

Over-the-Counter Pharmaceutical Options bridge the gap between gentle natural therapies and prescription-strength DHT blockers, potentially offering clinically supported benefits with relatively low systemic risk.

Ketoconazole Shampoo (Evidence Quality – 54%)

Originally developed as an antifungal agent, ketoconazole helps normalize the scalp environment by reducing inflammation, fungal overgrowth, and excess sebum, all of which can worsen AGA. Beyond its antifungal activity, laboratory and clinical research suggest that ketoconazole exerts mild local antiandrogenic effects, likely through partial inhibition of 5AR and modulation of DHT activity within the scalp. 

Clinical evidence for men is stronger than for women. One 21-month study using 2% ketoconazole shampoo showed progressive improvement in hair shaft diameter and percentage of hairs in the growth (anagen) phase, reversing the slow decline seen in untreated AGA.^[18]Piérard-Franchimont, C., De Doncker, P., Cauwenbergh, G., & Piérard, G. E. (1998). Ketoconazole shampoo: effect of long-term use in androgenic alopecia. Dermatology. 196(4). 474-477. Available … Continue reading

Another study, which compared Ketoconazole with other shampoos, found that 1% ketoconazole reduced hair shedding by 17%, improved anagen hair by 4.9%, and lowered scalp sebum levels.^[19]Piérard-Franchimont, C., Goffin, V., Henry, F., Uhoda, I., Braham, C., & Piérard, G. E. (2002). Nudging hair shedding by antidandruff shampoos: A comparison of 1% ketoconazole, 1% piroctone … Continue reading Studies also show that ketoconazole performs well as an adjunct therapy, with synergistic effects when combined with finasteride.^[20]Perez, B. S. H. (2004). Ketoconazole as an adjunct to finasteride in the treatment of androgenetic alopecia in men. Medical Hypotheses. 62(1). 112-115. Available at: … Continue reading 

Evidence in women is limited, with only one published study investigating ketoconazole solution, rather than shampoo. They compared 2% ketoconazole to 2% minoxidil and reported meaningful regrowth in both groups, with ketoconazole producing improvements by the six-month mark and causing far fewer side effects.^[21]El-Garf, A., Mohie, M., & Salah, E. (2019). Trichogenic effect of topical ketoconazole versus minoxidil 2% in female pattern hair loss: a clinical and trichoscopic evaluation. Biomedical … Continue reading

Ketoconazole is generally well tolerated. Mild irritation, dryness, or temporary scalp tightness may occur, especially with 2% formulations or frequent use. Most regimens recommend applying it 2–3 times per week, leaving the shampoo on the scalp for 3–5 minutes before rinsing.

You can read our breakdown of the research into ketoconazole shampoos here.

You can also read about why 2% ketoconazole might be a better choice than 1% here.

Tier 3 – Prescription Pharmaceutical DHT Blockers

Prescription Pharmaceutical DHT Blockers represent the most potent and clinically validated options, offering stronger and more predictable suppression of DHT than natural therapies but with a greater need for careful monitoring of side effects.

Topical Finasteride (Evidence Quality – 69%)

Topical finasteride represents a new, more targeted approach to DHT inhibition, delivering the drug directly to the scalp while aiming to minimize systemic exposure. Like its oral counterpart, it blocks the Type II 5-alpha reductase enzyme. However, by focusing this activity locally within the hair follicle, topical formulations can achieve substantial reductions in scalp DHT while maintaining serum levels that are a fraction of those seen with oral dosing. This distinction is clinically important for individuals concerned about systemic side effects such as decreased libido or hormonal shifts.

Clinical research has consistently shown that topical finasteride can achieve similar improvements in hair density and regrowth as oral therapy. One 24-week study showed a 34.5% decrease in DHT, compared to 55.6% for oral finasteride. However, plasma concentrations were 100 times lower, indicating that systemic exposure is greatly reduced.^[22]Piraccini, B. M., Blume-Peytavi, U., Scarci, F., Jansat, J. M., Falqués, M., Otero, R., Tamarit, M. L., Galván, J., Tebbs, V., Massana, È., on behalf of the Topical Finasteride Study Group. … Continue reading

Topical finasteride is particularly appealing to men who respond well to oral therapy but wish to lower the risk of systemic adverse effects. When applied once daily at concentrations between 0.1% and 0.25%, it can stabilize shedding within four to six months, with visible improvements generally continuing over the course of a year.^[23]Mazzarella, G. F., Loconsole, G. F., Cammisa, G. A., Mastrolonardo, G. M., & Vena, G. A. (1997). Topical finasteride in the treatment of androgenic alopecia. Preliminary evaluations after a … Continue reading For optimal results, it can be combined with topical minoxidil to stimulate regrowth through complementary pathways.^[24]Wang, H., Chen, B., & Hong, X. (2020). The efficacy and safety of finasteride combined with topical minoxidil for androgenetic alopecia: A systematic review and meta-analysis. *Journal of … Continue reading  

Our members can find the ultimate guide to finasteride here.

Dutasteride (Evidence Quality – 77%)

Dutasteride is the most potent 5AR inhibitor currently available, targeting both Type I and Type II isoenzymes. This dual inhibition results in serum DHT reductions of up to 90 – 95%, creating a profoundly anti-androgenic environment within scalp follicles.^[25]Roehrborn, C. G., Marks, L. S., Fenter, T., Freedman, S., Tuttle, J., Gittleman, M., Morrill, B., & Wolford, E. T. (2004). Efficacy and safety of dutasteride in the four-year treatment of men … Continue reading Clinically, this translates into faster and often more pronounced regrowth compared to finasteride, particularly in individuals with advanced hair thinning.

Because dutasteride suppresses DHT more comprehensively, it may pose a slightly higher risk of hormonal side effects such as gynecomastia or reduced libido. However, head-to-head studies have suggested superior efficacy for dutasteride in both short-term and long-term endpoints. 

A meta-analysis, which combines results from multiple studies, indicated that dutasteride showed better efficacy in treating AGA.^[26]Zhou, Z., Song, S., Gao, Z., Wu, J., Ma, J., & Cui, Y. (2019). The efficacy and safety of dutasteride compared with finasteride in treating men with androgenetic alopecia: a systematic review and … Continue reading These results suggest that dutasteride is ~3 times more potent than finasteride in blocking Type II 5α-reductase and up to 100 times more potent against Type I. This dual inhibition reduces scalp DHT levels by over 50%, compared to approximately 41% with finasteride, leading to greater prevention of follicular miniaturization and enhanced regrowth response with similar levels of adverse effects.

Dutasteride has a relatively low evidence quality score compared to finasteride, though this is largely due to there being fewer studies. The studies that do investigate dutasteride have shown higher potency and effectiveness.

For detailed information on clinical trials, including dutasteride, check out our comprehensive summary.

Topical dutasteride formulations are now under active investigation. Concentrations ranging from 0.01% to 0.05% have produced significant gains in target-area hair counts, with studies suggesting that improvements associated with oral formulations can be achieved without drops in serum DHT.^[27]Panuganti, V. K., Madala, P. K., Grandhi, V. R., Alluri, C. V., Mohammad, J., KSSVV, S. R., & Dundigalla, M. R. (2025). A randomized, double-blind, placebo and active controlled Phase II study to … Continue reading

 

A 2018 randomized clinical study further demonstrated that topical dutasteride (0.02%) combined with microneedling significantly improved hair shaft thickness and patient satisfaction compared with microneedling alone, without notable systemic absorption or hormonal side effects. These findings suggest that localized delivery of dutasteride may enhance follicular response while minimizing systemic exposure and related adverse effects.^[29]Nada, E.A., El Sharkawy, R.E.E.D., Abd El-Maged, W. M., & Abo Elmagd, M. A. (2018). Topical dutasteride with microneedling in treatment of male androgenetic alopecia. Sohag Medical Journal. … Continue reading

Similarly, research published in 2024 looked into the impact of microneedling. However, in this study, topical dutasteride was combined with minoxidil. They found similar improvements in hair density and hair width in participants who had topical dutasteride and minoxidil treatment to those in patients who had oral dutasteride and topical minoxidil.^[30]Abu Obeid, M. N., Abdel Fattah, N. S., Elfangary, M. M., & Al Husseni, R. M. (2024). Comparison between Topical Minoxidil 5% Alone versus Combined with Dutasteride (Topical 0.02% through … Continue reading These results suggest that, in combination with other therapies (minoxidil or microneedling), topical dutasteride may be able to produce similar results to oral formulations but with a significantly lower chance of side effects.

A newly published Phase II trial has also drawn significant attention because it is the first study to test topical dutasteride alone, without microneedling. The results appear impressive: all topical doses improved hair parameters versus placebo, showed minimal impact on serum DHT (suggesting good scalp localization), and 1 ml daily of 0.05% topical dutasteride reportedly outperformed oral finasteride in key regrowth metrics.^[31]Panuganti, V. K., Madala, P. K., Grandhi, V. R., Alluri, C. V., Mohammad, J., Kssvv, S. R., & Dundigalla, M. R. (2025). A randomized, double-blind, placebo- and active-controlled phase II study … Continue reading

However, the study reports unusually high baseline hair counts, as well as inconsistencies in the placement and size of the 1 cm² target areas used for serial hair counts. These issues can dramatically skew results, creating the illusion of improvement even when none exists. Real-world data from users of low-dose topical dutasteride (0.01–0.02% applied daily or near-daily) also paint a more modest picture: good localization and serum DHT stability, but primarily maintenance rather than regrowth exceeding oral finasteride

For more information on the emerging potential of topical dutasteride formulations, read our article here.

Oral Finasteride (Evidence Quality – 99%)

As you can see from our evidence quality score, oral finasteride remains the most clinically validated pharmacological treatment for AGA. It acts as a selective inhibitor of the Type II 5AR enzyme, reducing systemic and scalp DHT levels by approximately 60–70%.^[32]Drake, L., Hordinsky, M., Fiedler, V., Swinehart, J., Unger, W. P., Cotterill, P. C., Thiboutot, D. M., Lowe, N., Jacobson, C., Whiting, D., Stieglitz, S., Kraus, S. J., Griffin, E. I., Weiss, D., … Continue reading This substantial suppression slows or halts follicular miniaturization, prolongs the growth (anagen) phase, and enables partial regrowth in many users. The standard 1 mg daily dose for AGA has been extensively studied and represents the optimal balance between efficacy and safety for most men.

Clinical trials have consistently confirmed the effectiveness of finasteride in both the short and long term. A 4-year, randomized study found that 1 mg of finasteride led to increased hair weight (46% vs placebo) and hair count (20% vs. placebo).^[33]Price, V. H., Menefee, E., Sanchez, M., & Kaufman, K. D. (2006). Changes in hair weight in men with androgenetic alopecia after treatment with finasteride (1 mg daily): three- and 4-year results. … Continue reading

You can find an in-depth overview of the clinical studies on finasteride here.

While highly effective, oral finasteride is not without potential drawbacks. A small percentage of users report side effects related to sexual function, including reduced libido, erectile difficulty, and diminished ejaculate volume. Most of these effects are mild and resolve upon discontinuation, although persistent symptoms have been reported in rare cases. Some users also report changes in mood or motivation, likely reflecting individual hormonal sensitivity. For those wishing to minimize systemic exposure, transitioning to topical finasteride or titrating to a lower dose (e.g., 0.25-0.5 mg daily) may be a suitable option.^[34]Gupta, A. K., Venkataraman, M., Talukder, M., & Bamimore, M. A. (2022). Finasteride for hair loss: a review. Journal of Dermatological Treatment. 33(4). 1938-1946. Available at: … Continue reading

There have also been reports of a condition that’s been named ‘post-finasteride syndrome’. While not widely accepted by the medical community, similar symptoms have been reported in a number of individuals who are taking finasteride. These symptoms can include sexual dysfunction, such as loss of libido and erectile dysfunction, neuropsychiatric symptoms like depression and anxiety, and physical changes like muscle atrophy and fatigue. Importantly, there have been cases where these symptoms have persisted after users have stopped taking the drug.

While the authors who published the original article on post-finasteride syndrome do highlight the lack of consistent evidence for persistent side effects found in clinical trials, they suggest that finasteride may act to worsen symptoms associated with sexual dysfunction and psychiatric conditions for some users who already have these issues.^[35]Pereira, A. F. J. R., & Coelho, T. O. A. (2020). Post-finasteride syndrome. Anais Brasileiros de Dermatologia. 95(3). 271-277. Available at: https://doi.org/10.1016/j.abd.2020.02.001

Overall, oral finasteride remains the gold standard for DHT suppression, providing robust and predictable results when used consistently. It’s also important to consider the potential side effects when choosing to take finasteride, and consult with your doctor if symptoms arise.

Honourable Mention – Pyrilutamide

Pyrilutamide (KX-826)

Pyrilutamide takes a different approach to androgen modulation. Rather than reducing DHT production, it acts as a topical androgen receptor antagonist, blocking DHT and testosterone from binding to their receptors in the follicle. By interfering with receptor activation, pyrilutamide aims to suppress the downstream gene expression that leads to follicular miniaturization.^[36]Koralewicz, M. M., & Szatkowska, O. A. (2024, July). Topical solutions for androgenetic alopecia: evaluating efficacy and safety. Forum Dermatologicum. 10(3). 61-70. Available at: … Continue reading

Clinical data show encouraging signals. Trials conducted in China and the United States suggest that topical formulations applied once or twice daily can produce measurable increases in hair counts over several months. Reported side effects are primarily mild local dermatitis, and systemic exposure appears very low. However, many of these results remain unpublished in peer-reviewed journals and have failed to demonstrate statistical superiority over placebo for some measurements.^[37]Kintor Pharmaceuticals. (2022). Developing Novel Drugs and Commercialization Platform. Available at: … Continue reading,^[38]Kintor Pharmaceutical Limited. (2023, March 28). Kintor Pharma Announces Completion of Subject Enrollment in Phase III Clinical Trial for KX-826 for Treatment of Male Androgenetic Alopecia in China. … Continue reading Because these reports have not been published in peer-reviewed journals, they can only currently be considered pre-releases, rather than academic papers. The absence of published, peer-reviewed, blinded, controlled data means that we can’t draw firm conclusions on pyrilutamide, even in the wake of the many press releases that Kintor has published.

To learn more about the research on Pyrilutamide and when to be cautious of press-release-style publications, read our in-depth article.  

For now, pyrilutamide should be viewed as an experimental therapy. Its mechanism is compelling and localized, offering a theoretical advantage over systemic antiandrogens. Still, robust, peer-reviewed clinical trials confirming efficacy and long-term safety are needed before it can be considered a mainstream treatment. Those interested in exploring it should do so only under medical supervision or within the context of formal clinical research.

Final Thoughts

DHT blockers span a broad spectrum, ranging from gentle, naturally derived modulators like pumpkin seed oil and EGCG to powerful prescription therapies such as finasteride and dutasteride. Natural options may improve scalp health and have a modest influence on hormonal activity, but their effects are typically gradual and limited. In contrast, pharmacological inhibitors act directly on the enzymatic pathways responsible for DHT synthesis, offering stronger and more predictable outcomes. Topical finasteride has emerged as a compelling middle ground, delivering scalp-level efficacy with minimal systemic impact, while dutasteride represents the upper limit of potency for those requiring more aggressive intervention.

Ultimately, the “best” DHT blocker depends on individual tolerance, goals, and the stage of hair loss. A well-balanced regimen typically combines a DHT inhibitor with a growth stimulant, such as minoxidil, alongside scalp care and lifestyle modifications. With consistent use and proper medical guidance, these approaches can collectively slow, halt, or even reverse the progression of AGA, helping individuals maintain fuller, healthier hair over time.

When someone notices a thinning crown, a widening part, or a receding hairline, it is natural to assume that the follicles in those areas are dying. But in androgenic alopecia (AGA), that is not usually what happens, at least not in the way most people mean it. 

AGA is primarily a condition of hair follicle miniaturization. The follicle often remains in the scalp, but it gradually shrinks and produces lower-quality hair fibers. A thick, long, pigmented terminal hair might become a shorter, finer, less pigmented vellus hair that contributes very little to visible coverage.

This, therefore, raises the question: if a follicle has not simply disappeared, could it recover and return to its former state as a terminal hair?

The short answer is sometimes. 

Treatments like finasteride and minoxidil can slow miniaturization and improve visible hair growth in many people. However, they must be used continuously to maintain their effects, and they do not reliably restore every follicle to the size or productivity it had before AGA began. Furthermore, while studies suggest that bald AGA scalps can retain some stem cell populations, this does not mean that all long-bald follicles are merely “asleep” and ready to be reactivated.

To understand why, we first need to look at how AGA affects the normal hair cycle.

What Happens to Hair Follicles in AGA?

A hair follicle is not a permanent, continuously growing structure. It repeatedly moves through a cycle of growth, regression, rest, and renewal. 

The three main phases are:^[1]Kloepper, J.E., Sugawara, K., Al-Nuaimi, Y., Gaspar, E., & Paus, R. (2010). Methods in hair research: How to objectively distinguish between anagen and catagen in human hair follicles. … Continue reading,^[2]Alonso, L., & Fuchs, E. (2006). The hair cycle. Journal of Cell Science. 119(Pt 3). 391-393. Available at: https://doi.org/10.1242/jcs.02793

• Anagen: The active growth phase. The follicle produces a hair shaft, and scalp hairs can remain in anagen for years.

• Catagen: A brief regression phase. Growth stops, the lower part of the follicle shrinks, and the hair-producing bulb moves upward.

• Telogen: The resting phase. The follicle remains relatively inactive before eventually returning to anagen. The old club hair may shed during this period or shortly before the next hair begins to grow.

In healthy scalp hair, anagen is unusually long. That is why terminal scalp hairs can grow to substantial lengths. But in AGA-prone areas of the scalp, the cycle gradually changes. 

Genetically susceptible hair follicles respond to androgen signaling, particularly dihydrotestosterone (DHT), by producing hairs that are progressively smaller with each cyle. The anagen phase shortens, meaning each hair has less time to grow. At the same time, the follicle that is produced is thinner and finer.^[4]Randall, V.A. (2008). Androgens and hair growth. Dermatologic Therapy. 21(5). 314-328. Available at: https://doi.org/10.1111/j.1529-8019.2008.00214.x,^[5]Sawaya, M.E., & Price, V.H. (1997). Different levels of 5-alpha-reductase type I and II, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia. Journal of … Continue reading 

This is called the terminal-to-vellus transition.

Terminal hairs are the thick, pigmented hairs that create most of the scalp’s visible coverage, whereas vellus hairs are much finer, shorter, and less pigmented. In AGA, a follicle may not abruptly become a true vellus follicle. Instead, it gradually moves along a spectrum, producing hairs that become increasingly vellus-like over repeated cycles. 

In practical terms, AGA does not usually mean that a hair follicle simply “falls out”. It means that the follicle becomes smaller and less capable of making a cosmetically useful hair.

Why AGA Does Not Look Uniform

One reason AGA can be difficult to assess in its early stages is that follicles do not miniaturize at the same speed. 

Two adjacent follicles can be at very different stages. One may still produce a thicker terminal hair, while the follicle beside it may produce a short, fine, miniaturized fiber. This produces a mixture of hair diameters within the same scalp area, a feature known as hair-diameter diversity, or anisotrichosis.

That mixture is one of the most useful signs of AGA under trichoscopy. Rather than a uniform reduction across all hairs, clinicians often observe increasing variation. Some hairs remain relatively thick, while others are much thinner and shorter. A 2024 cross-sectional study in men with AGA found that hair-diameter diversity increased with disease severity, while mean hair diameter declined and the proportion of thinner hairs rose.^[6]Kim, M.S., Kim, J., Lee, S.Y., et al. (2024). Quantitative measurement of hair diameter diversity as a diagnostic indicator of androgenetic alopecia in Korean males: A cross-sectional study. JAAD … Continue reading

This is why AGA often looks like reduced density rather than immediate baldness. The hairs may still be present, but an increasing proportion are too fine to provide meaningful coverage.

Are Miniaturized Follicles Dead or Dormant?

The short answer is that neither word is completely accurate.

Calling a miniaturized AGA follicle “dead” suggests that it has been physically destroyed, which is simply not the case.

AGA is classified as a non-scarring alopecia. Even when an area of scalp looks bald, miniaturized follicular structures may still remain. This differs from scarring alopecia, where inflammation can physically destroy follicles and replace them with fibrotic tissue. In those conditions, follicular openings can disappear, and the potential for spontaneous regrowth is much more limited.^[7]Vidal, C.I. (2015). Overview of alopecia: A dermatopathologist’s perspective. Missouri Medicine. 112(4). 308-312. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC6170065/ 

But “dormant” is not quite right either.

A miniaturized AGA follicle may still cycle and produce a hair shaft. The issue is that the produced shaft may be too fine, short, or lightly pigmented to provide noticeable scalp coverage. In other words, it’s not necessarily inactive, but rather functioning at a reduced level.

It should be noted that AGA can still become difficult to reverse, especially in longstanding bald areas. But its biology is not identical to a scarring disorder. A miniaturized follicle and a physically destroyed follicle are not the same thing.

What Stem Cell Studies Actually Show

One influential study compared bald and haired scalps from men with AGA. Researchers found that bald scalp retained KRT15-positive cells associated with the hair follicle’s bulge region, a stem-cell niche located in the permanent portion of the hair follicle. However, they also found marked depletion of several additional activated progenitor-cell populations located near the bulge, including CD200-high/ITGA6-high and CD34-positive cells.^[8]Garza, L.A., Yang, C.C., Zhao, T., et al. (2011). Bald scalp in men with androgenetic alopecia retains hair follicle stem cells but lacks CD200-rich and CD34-positive hair follicle progenitor cells. … Continue reading

At first glance, that might sound like very good news. If stem cells are still there, perhaps the follicles can simply be switched back on.

But that conclusion goes beyond what the study showed.

A more cautious interpretation is that some of the hair follicle’s core machinery persists in the bald AGA scalp, while the processes required to activate those cells or convert them into the progenitor cells needed for robust hair production may be impaired.

Put differently, the issue may not be a total absence of follicular stem cells; it might be a failure of the signaling, activation, or stem-cell-to-progenitor conversion steps required to rebuild a normal terminal hair.

That is an important finding for regenerative hair loss research. It is not proof that every long-bald follicle can currently be restored with conventionally available treatments.

Can AGA Treatments Reverse Miniaturization?

The most accurate answer is: partially, in some follicles, in some people. 

That may sound less exciting than claims of “follicle revival” or “complete regrowth”, but it reflects what the clinical evidence actually supports. 

A positive response to treatment can include:

• A longer anagen phase, allowing hairs to grow for longer before entering regression.
• Increased hair-shaft diameter, making existing hairs more visible.
• A shift from producing very fine, vellus-like hairs toward producing thicker, more cosmetically meaningful hairs.
• Recruitment of follicles that were producing very little visible hair into a more productive growth cycle.
• Slower ongoing miniaturization, which can preserve density that would otherwise have been lost.

These changes can substantially improve scalp coverage. But they are not necessarily equivalent to full anatomical restoration of every affected follicle.

What Finasteride Studies Show

Finasteride reduces the conversion of testosterone to DHT by inhibiting type II 5-alpha-reductase. In men with AGA, this reduces DHT in serum and scalp tissue, thereby lowering one of the key androgenic signals that drives miniaturization in genetically susceptible follicles.^[10]Drake, L., Hordinsky, M., Fiedler, V., et al. (1999). The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia. Journal of the American Academy of … Continue reading

Randomized trials have shown that finasteride can increase hair counts and improve photographic appearance compared with placebo in men with AGA.^[11]Kaufman, K.D., Olsen, E.A., Whiting, D., et al. (1998). Finasteride in the treatment of men with androgenetic alopecia. Journal of the American Academy of Dermatology. 39(4 Pt 1). 578-589. Available … Continue reading 

Long-term evidence is particularly useful here because AGA is progressive. In a five-year multinational study, men taking finasteride 1 mg daily showed durable improvements in hair count, investigator assessments, patient assessments, and clinical photographs, while the placebo group continued to lose hair over time.^[12]Shapiro, J., Kaufman, K.D., Olsen, E.A., Whiting, D., & Savin, R. (2003). Long-term (5-year) multinational experience with finasteride 1 mg in men with androgenetic alopecia. European Journal of … Continue reading

However, “finasteride works” should not be interpreted as “finasteride can restore your original hair density”.

Some men do see visible regrowth, while others maintain what they already have. Some improve in one area, like the crown, but not the frontal hairline. Some have a modest response despite a substantial reduction in DHT, while others do not experience meaningful cosmetic improvement.

This is because DHT reduction is only one part of the chain between drug exposure and visible hair growth. The final outcome depends on disease duration, degree of miniaturization, follicular biology, treatment adherence, age, genetics, and the amount of potentially recoverable hair remaining.

For many people, preventing further decline is not a treatment failure. In a progressive condition such as AGA, stabilizing hair loss can be a meaningful outcome.

What Does Minoxidil Do?

Minoxidil works through a different treatment pathway than finasteride. It does not meaningfully reduce DHT or remove the follicle’s underlying androgen sensitivity.

Instead, minoxidil appears to influence hair cycling and follicular productivity. Its exact mechanism is not fully understood, but research suggests that it can promote anagen activity, influence potassium channels and intracellular signaling, and affect growth-factor pathways within the follicular environment.^[13]Messenger, A.G., & Rundegren, J. (2004). Minoxidil: Mechanisms of action on hair growth. British Journal of Dermatology. 150(2). 186-194. Available at: … Continue reading,^[14]Suchonwanit, P., Thammarucha, S., & Leerunyakul, K. (2019). Minoxidil and its use in hair disorders: A review. Drug Design, Development and Therapy. 13. 2777-2786. Available at: … Continue reading 

Clinically, minoxidil can increase total and non-vellus hair growth compared with a placebo. A systematic review and meta-analysis reported improvements in total and non-vellus hair counts with topical minoxidil.^[15]Fiedler, V.C., Alaitz, M., & Hayden, R.E. (2015). Topical minoxidil: Systematic review and meta-analysis of its efficacy in androgenetic alopecia. Journal of the American Academy of Dermatology. … Continue reading

In a 48-week trial in men with AGA, 5% topical minoxidil outperformed both 2% minoxidil and placebo for non-vellus hair count, investigator-rated scalp coverage, and patient-rated treatment benefit.^[16]Olsen, E.A., Dunlap, F.E., Funicella, T., et al. (2002). A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. … Continue reading 

The important limitation is that minoxidil does not eliminate the underlying androgen sensitivity of AGA. That is why its benefits are generally treatment-dependent. If treatment is stopped, the hair that was being maintained or improved by minoxidil may gradually be lost.

Why Combination Therapy Can Help

Studies and reviews of combination minoxidil and finasteride treatment generally suggest better outcomes than monotherapy, at least for some patients.^[17]Gupta, A.K., Bamimore, M.A., & Foley, K.A. (2020). The efficacy and safety of finasteride combined with topical minoxidil for androgenetic alopecia: A systematic review and meta-analysis. Journal … Continue reading Using both makes biological sense. One treatment can slow the process driving miniaturization, while the other may improve the productivity of the remaining follicles. 

What About Microneedling, PRP, and Experimental Treatments?

Microneedling, platelet-rich plasma (PRP), low-level light therapy (LLLT), topical anti-androgens, and cell-based or regenerative approaches are frequently discussed in the treatment of AGA. 

Some of these interventions have encouraging signals.

For example, systematic reviews of PRP have found that PRP injections can improve hair density compared with control treatments in several small randomized trials. However, PRP preparation, platelet concentration, injection technique, treatment schedule, comparator treatment, and outcome measurement vary substantially between studies.^[18]Zhang, X., Ji, Y., Zhou, M., et al. (2023). Platelet-rich plasma for androgenetic alopecia: A systematic review and meta-analysis of randomized controlled trials. Journal of Cutaneous Medicine and … Continue reading

Microneedling combined with minoxidil has also shown better average hair-count outcomes than minoxidil alone in meta-analyses. But the evidence remains heterogeneous, with studies using different needle depths, devices, treatment intervals, and follow-up periods.^[19]Zhou, Y., Wang, J., Liu, Y., et al. (2025). Evaluating the efficacy and safety of combined microneedling with minoxidil versus minoxidil monotherapy for androgenetic alopecia: A systematic review and … Continue reading

The key issue is not whether these interventions can improve average hair-count measurements. Some certainly do. The question is whether those changes demonstrate anatomical reversal of miniaturization in longstanding follicles.

Right now, the answer is no.

Prolactin-Receptor Inhibitors

While the above treatments can be effective, they aren’t designed specifically to address the possibility that AGA involves defective communication between hair-follicle stem cells and the progenitor cells needed to build a robust terminal hair. 

That is one reason prolactin-receptor inhibitors have attracted attention.

The prolactin receptor is expressed in hair follicles, and experimental work suggests that prolactin signaling can influence hair-cycle regulation. New injectable antibodies, like Absci’s ABS-201, are being developed to block prolactin receptor signaling in people with AGA.

The appeal of this approach is straightforward. If miniaturized follicles retain some stem-cell populations but fail to generate enough active progenitor cells, a treatment that improves the follicle’s regenerative environment could, in theory, help more follicles return to productive growth. 

But “in theory” is the important phrase here.

HMI-115, which we have covered in more detail here, is one of the first PRLR-blocking treatments to reach early-stage clinical testing for AGA. In a company-reported open-label Phase 1b study, 12 male participants with AGA reportedly had a mean increase of 14 non-vellus hairs per cm2 after 24 weeks of treatment.^[20]Hope Medicine. (2024). Positive outcome from a Phase Ib study in Australia treating androgenetic alopecia with HMI-115. Company press release. Available at: … Continue reading This result is promising, but the study was small, lacked a placebo comparison, and has not yet provided the kind of peer-reviewed, full clinical dataset needed to determine how reliably HMI-115 improves hair density, caliber, or long-term outcomes.

ABS-201 is an anti-prolactin receptor antibody in the earlier stages of clinical development. Its ongoing Phase 1/2a HEADLINE trial is randomized, double-blind, and placebo-controlled, with planned measures including target-area hair count, hair width, and pigmentation.^[21]Absci. (2026). Absci announces positive interim Phase 1 data from the HEADLINE trial evaluating ABS-201 in androgenetic alopecia. Company press release. Available at: … Continue reading However, the company’s initial human update focused on safety and pharmacokinetics in the single-ascending-dose portion of the trial, rather than confirmed hair-growth efficacy. 

Absci has also reported ex vivo findings from human scalp tissue suggesting that PRLR blockade may prolong anagen and improve growth-associated follicular activity.^[22]Absci. (2025). Absci reports new human ex vivo data demonstrating that ABS-201 promotes hair follicle growth. Company press release. Available at: … Continue reading 

For now, prolactin-receptor inhibitors are best viewed as an intriguing test of a newer biological hypothesis: that improving the regenerative signaling environment of the follicle may complement conventional DHT-lowering and growth-promoting therapies. Whether this translates into clinically meaningful reversal of advanced miniaturization remains unknown.

Why Earlier Treatment Usually Produces Better Results

Early intervention tends to be more rewarding because, even if follicles are starting to produce finer, shorter hairs, they may still have greater regenerative capacity than follicles further along in the process.

There are two potential benefits to treating earlier:

• Preservation: Slowing miniaturization before thicker terminal hairs become very fine or disappear from view.

• Thickening: Improving the caliber, length, and visibility of hairs produced by follicles that remain viable but are already underperforming. 

This is why preventing further deterioration can be a successful outcome even without dramatic regrowth. 

Someone who began treatment while they still had a dense field of miniaturized hairs may see a substantial cosmetic improvement if enough of those hairs thicken. Someone with a longstanding slick-bald area may have fewer follicles capable of producing visible hair, even if some follicular structures remain in the scalp.

Does Fibrosis Create a Point of No Return?

Perifollicular inflammation and fibrosis have been observed in AGA, particularly around the upper follicle. Histological studies have identified inflammatory cell infiltrates and fibrotic changes in at least some of the affected scalp areas.^[23]Jaworsky, C., Kligman, A.M., Murphy, G.F., & Kennedy, J.W. (1992). Characterization of inflammatory infiltrates in male pattern alopecia: Implications for pathogenesis. British Journal of … Continue reading,^[24]Mahé, Y.F., Michelet, J.F., Billoni, N., et al. (2000). Androgenetic alopecia and microinflammation. International Journal of Dermatology. 39(8). 576-584. Available at: … Continue reading 

This has led to an understandable theory. Perhaps fibrosis gradually locks a follicle into a permanent non-responsive state. 

But the evidence is not strong enough to say that fibrosis is the sole cause of irreversible AGA.

AGA is a complex condition involving several factors, one of which may be fibrosis, but it should not be treated as the sole explanation for why recovery becomes harder. 

The Arrector Pili Muscle Hypothesis

Another proposed explanation involves the arrector pili muscle, the tiny smooth muscle attached to the hair follicle that causes goosebumps.

Research suggests that miniaturized hair follicles in AGA may lose their normal attachment to the arrector pili muscle. This is notable because miniaturized follicles in alopecia areata may preserve this attachment and can often regrow terminal hair when the autoimmune process resolves.^[25]Yazdabadi, A., Whiting, D., Rufaut, N., & Sinclair, R. (2012). Miniaturized hairs maintain contact with the arrector pili muscle in alopecia areata but not in androgenetic alopecia. International … Continue reading 

This has been proposed as one reason why AGA miniaturization may become harder to reverse than miniaturization in alopecia areata. However, this is best understood as a biological model rather than a clinically validated “point-of-no-return” test. No clinician can currently examine a scalp and use arrector pili attachment alone to calculate the chance that a particular follicle will regrow.

How Can You Estimate Whether a Hair Follicle Might Respond?

There is a non-invasive test that can prove whether a specific follicle is recoverable. 

But clinicians can look for clues to help estimate whether an area of the scalp still contains follicles capable of producing more visible hair. 

Visible Miniaturized Hairs

Fine, short hairs in an area of thinning are often more encouraging than completely smooth, long-bald skin. While this does not guarantee regrowth, it suggests that follicles in the area are still producing shafts, even if those shafts are currently too fine to provide useful density.

Hair-Shaft Diameter Diversity

A mixture of thick terminal hairs and fine miniaturized hairs is a hallmark of active AGA miniaturization. Trichoscopy can show this variation more clearly than the naked eye. It can also identify an increased proportion of vellus-like hairs, changes in follicular units, and regional density differences.^[26]Kuczara, A., Waskiel-Burnat, A., Rakowska, A., Olszewska, M., & Rudnicka, L. (2024). Trichoscopy of androgenetic alopecia: A systematic review. Journal of Clinical Medicine. 13(7). 1962. … Continue reading

Density Under Standardized Trichoscopy

A standardized trichoscopic examination or phototrichogram can help document:

• Hair density per square centimeter.
• Average shaft diameter.
• The proportion of terminal versus vellus-like hair.
• Changes in the same scalp area over time.

Duration and Speed of Progression

Duration matters, but it is not a precise predictor. 

An area that has been slick-bald for many years is generally less likely to respond than an area that has recently thinned and still contains visible miniaturized hairs. But there is no scientifically validated rule stating that follicles become irreversibly “dead” after a specific number of years. 

Speed also matters. Rapid recent thinning may warrant evaluation for additional contributors, such as telogen effluvium, inflammatory scalp disease, medication effects, nutritional deficiency, or endocrine conditions.

Duration and Speed of Progression

Duration matters, but it is not a precise predictor. 

An area that has been slick-bald for many years is generally less likely to respond than an area that has recently thinned and still contains visible miniaturized hairs. But there is no scientifically validated rule stating that follicles become irreversibly “dead” after a specific number of years. 

Speed also matters. Rapid recent thinning may warrant evaluation for additional contributors, such as telogen effluvium, inflammatory scalp disease, medication effects, nutritional deficiency, or endocrine conditions.

Response to an Adequate Treatment Trial

Ultimately, an individual’s response after a sufficiently long and consistent treatment trial is often more useful than a baseline prediction.

AGA treatments work slowly because hair cycling is slow. A short trial of a few weeks or a couple of months is generally not enough to judge whether miniaturized hairs are thickening or whether progression has stabilized. 

Photographs can help, but only if they are standardized.

For useful comparisons, take photographs with the same:

• Lighting
• Camera distance
• Camera angle
• Hair length
• Hairstyle or part placement
• Scalp dryness and hair product use
• Head position

Phone photographs alone cannot determine whether follicles are viable. They can show changes in coverage, but they cannot distinguish miniaturization from shedding, breakage, changes in hair length, or lighting changes.

A scalp biopsy is also not normally required solely to predict regrowth in typical AGA. Biopsy is generally reserved for uncertain cases, atypical presentations, or situations where scarring alopecia or another diagnosis needs to be excluded.

Is There a Proven Point of No Return?

No. 

There is currently no validated hair-diameter threshold, duration of baldness, Norwood stage, fibrosis score, or trichoscopic measurement that defines the exact point at which an AGA follicle becomes irreversibly non-responsive. 

Longstanding bald areas are less likely to produce substantial regrowth with existing medical treatments than areas containing numerous fine hairs. But less likely is not the same as impossible, and current evidence does not allow clinicians to calculate a precise individual probability from duration alone. 

This uncertainty can be frustrating. But it is better than false certainty in either direction. 

Final Thoughts

AGA miniaturization is best understood as a continuum rather than an on/off process. Affected follicles do not usually vanish all at once; instead, they gradually become smaller and produce hairs that are shorter, finer, less pigmented, and less able to cover the scalp. Because neighboring follicles can be at different stages of miniaturization, AGA often creates a mixture of thick terminal hairs and fine vellus-like hairs rather than uniform hair loss. This is also why “dead” and “dormant” are imperfect descriptions: a miniaturized follicle may still be present and may still produce a hair shaft, but it may no longer produce hair that contributes meaningfully to cosmetic density. 

Research suggesting that some follicular stem-cell populations persist in bald AGA scalp is biologically important, but it should not be interpreted as proof that long-bald follicles can currently be restored to their original state. The more realistic takeaway is that treatment can sometimes reverse part of miniaturization, particularly in follicles that are still producing fine, visible hairs. Finasteride, minoxidil, and combination approaches may help preserve existing hair, slow further diameter loss, and improve the thickness, length, or visibility of hair that remains responsive. This is why earlier treatment generally offers the greatest opportunity: the goal is not always dramatic regrowth or a return to original density, but preventing further deterioration while improving the follicles that are still capable of producing visible hair.

Oral minoxidil has become one of the most popular treatments for pattern hair loss, and for good reason. In clinical trials, it works just as well or even outperforms 5% topical minoxidil, with investigator assessments rating oral minoxidil as performing better than topical minoxidil. ^[1]Penha, M.A., Miot, H.A., Kasprzak, M., Müller Ramos, P. (2024). Oral Minoxidil vs Topical Minoxidil for Male Androgenetic Alopecia: A Randomized Clinical Trial. JAMA Dermatology. 160(6). 600-605. … Continue reading^[2]Ramos, P.M., Sinclair, R.D., Kasprzak, M., Miot, H.A. (2020). Minoxidil 1 mg oral versus minoxidil 5% topical solution for the treatment of female-pattern hair loss: A randomized clinical trial. … Continue reading

Oral minoxidil is also affordable, convenient, and, with the increasing popularity of telemedicine, as accessible as ever.

But there’s a trade-off.

Oral and topical minoxidil work the same way. Minoxidil is enzymatically activated, converted into minoxidil sulfate (the active form of the drug), interacts with the cells in the hair follicle, and, in turn, enhances hair growth.

With the use of topical minoxidil, this activation process happens in the hair follicle itself. With oral minoxidil, some of this happens in the liver, in a metabolic process called first-pass metabolism.

The minoxidil and active minoxidil sulfate then travel through the blood to the scalp and into the hair follicles themselves, where they support hair growth. But because the blood delivers minoxidil sulfate throughout the whole body, it also results in significant exposure to different parts of the body, like the cardiovascular system.

As a result, oral minoxidil has an increased risk of cardiovascular side effects that we don’t typically see with topical minoxidil. These may include:

• Heart palpitations
• Tachycardia
• Fluid retention
• Dizziness
• Pericardial effusion
• and more

However, these side effects typically only occur once the active minoxidil sulfate reaches cardiovascular tissue via the bloodstream. If we can reduce the blood levels of active minoxidil sulfate, we can, in theory, reduce the risk of side effects with oral minoxidil while (hopefully) still maintaining the directionally better results.

This is the premise of sublingual minoxidil, a form of oral minoxidil that dissolves under the tongue.

This article explains the science behind sublingual minoxidil, why it works, and why, in all likelihood, it could be a better form of minoxidil.

Sublingual Minoxidil From our partners at Ulo

Sublingual Minoxidil

A rapidly-dissolving sublingual tablet with minoxidil. Available in 1.25 mg and 2.5 mg doses. Prescribed 100% online. Choose a multi-month plan and get up to 30% plus a free gift bundle.

Free full-size gifts with 3-month+ plans Prescribed online, shipped to your door

Claim up to 30% off + Free Gifts

Sublingual deliveryDissolves under the tongue

*Only available in the U.S. Prescription requires an online medical consultation at no extra cost. Off-label products are not endorsed by the FDA. Free gifts included with select multi-month plans while supplies last. Ulo is a partner of Perfect Hair Health; we may earn a commission on purchases.

Is Oral Minoxidil Better Than Topical Minoxidil?

Topical minoxidil is one of two FDA-approved treatments for androgenic alopecia (AGA). It’s been studied since the 1980s. Regrowth tends to peak between months four and eight of treatment, and in people who keep using it, the gains hold through at least year five.

The catch is that it only works for about 40 to 60% of people who try it. Surveys of people who quit topical minoxidil find that most of them stopped because they didn’t see results.

The reason for this is twofold:

• Penetration. Only a small fraction of the minoxidil applied to the scalp makes it through the skin to the follicles.
• Activation. Minoxidil is a prodrug (i.e., it’s inactive until the body converts it). The conversion is done by an enzyme called sulfotransferase, which attaches a sulfate group to minoxidil and turns it into minoxidil sulfate. Minoxidil sulfate is the form of minoxidil that opens potassium channels in the follicle and stimulates growth. If the scalp doesn’t have enough sulfotransferase activity, minoxidil sits inactive in the skin and doesn’t produce an effect. And, as it turns out, a large share of people fall into this category: in one study of 120 patients, 40.8% had low sulfotransferase activity in their scalp.^[3]Chitalia, J., Dhurat, R., Goren, A., McCoy, J., Kovacevic, M., Situm, M., Naccarato, T., Lotti, T. (2018). Characterization of follicular minoxidil sulfotransferase activity in a cohort of pattern … Continue reading And the research suggests this likely makes a meaningful difference in the effectiveness of topical minoxidil: around 85% of patients with normal enzyme activity responded to topical minoxidil, compared to just 8.7% of those with low sulfotransferase activity.^[4]Goren, A., Shapiro, J., Roberts, J., Desai, N., Zarrab, Z., Pietrzak, A., Lotti, T. (2015). Clinical utility and validity of minoxidil response testing in androgenetic alopecia. Dermatologic Therapy. … Continue reading

Oral minoxidil, on the other hand, is metabolized differently. Instead, part of the oral minoxidil taken orally is activated by sulfotransferase in the liver. It then travels from the bloodstream to the scalp, where it delivers active minoxidil sulfate to hair follicles and supports growth. It also delivers inactive minoxidil, which is then activated by sulfotransferase enzymes in the scalp.

In other words, oral minoxidil overcomes both critical barriers to efficacy with topical minoxidil. It delivers more inactive minoxidil and supplies minoxidil sulfate to the follicle without having to rely on sulfotransferase enzymes in the scalp alone.

But the bloodstream doesn’t just deliver active minoxidil sulfate to the scalp, it also delivers it systemically, including to sensitive tissues like the cardiovascular system. Because minoxidil sulfate is a potent vasodilator (i.e., it relaxes the smooth muscle in blood vessel walls), it can have a significant effect on the cardiovascular system.

As a result, oral minoxidil carries a risk of cardiovascular side effects that we don’t typically see with topical minoxidil, where only around 1.4% of the applied dose reaches the bloodstream. These side effects are typically very rare, but can include:^[5]Jimenez-Cauhe, J., Lo Sicco, K.I., Shapiro, J., Hermosa-Gelbard, A., Burgos-Blasco, P., Melian-Olivera, A., Ortega-Quijano, D., Pindado-Ortega, C., Buendia-Castaño, D., Asz-Sigall, D., Vaño-Galvan, … Continue reading

• Heart palpitations and tachycardia (0.9 to 4% of patients)
• Fluid retention (1.3 to 10%)
• Dizziness or lightheadedness (1 to 1.7%)
• Pericardial effusion (extremely rare at doses used in hair loss)

But what if there was a way to deliver active minoxidil to the follicles without exposing the rest of the body to minoxidil sulfate? Could there be an opportunity for us to harness the benefits of oral minoxidil while minimizing the side effects?

Sublingual minoxidil might be the answer. Let’s unpack the research.

Oral vs. Sublingual Minoxidil: The Research

When taken sublingually, oral minoxidil bypasses first-pass hepatic metabolism. In other words, it skips metabolic processing in the liver, including by the sulfotransferase enzyme. So instead of minoxidil sulfate being delivered to follicles alongside the inactive minoxidil, sublingual minoxidil means only the inactive minoxidil is transported via the bloodstream to the scalp, not minoxidil sulfate.

With less active minoxidil sulfate in the bloodstream to interact with tissues other than the scalp, you would expect to see a lower rate of side effects.

And that’s exactly what researchers found.

Study #1

In a randomized, double-blind, placebo-controlled phase I trial, published in 2021, researchers tested the effects of three doses of sublingual minoxidil, 0.45 mg, 1.35 mg, and 4.05 mg, in 40 men and women with AGA. ^[6]Bokhari, L., Jones, L.A., Sinclair, R.D. (2022). Sublingual minoxidil for the treatment of male and female pattern hair loss: a randomized, double-blind, placebo-controlled, phase 1B clinical trial. … Continue reading

The sublingual minoxidil was considered effective. At 24 weeks, hair density improved in a dose-dependent way: roughly 45% of patients on 0.45 mg showed improvement in frontal density and 55% at the vertex, rising to nearly 67% in both areas with a 4.05 mg dose.

However, because there was no oral minoxidil group in this study, we don’t know how it compares to oral minoxidil for efficacy or side effects.

Study #2

In a hallmark study, researchers directly compared the efficacy and safety of oral minoxidil with sublingual minoxidil. ^[7]Sanabria, B., Miot, H.A., Sinclair, R., Chaves, C., Müller Ramos, P. (2025). Sublingual Minoxidil 5 mg versus Oral Minoxidil 5 mg for male androgenetic alopecia: A double-blind randomized clinical … Continue reading

110 men with AGA (Norwood-Hamilton 3V, 4V, and 5V) were enrolled. One group took 5 mg of sublingual minoxidil daily plus an oral placebo. The other took 5 mg of oral minoxidil daily plus a sublingual placebo. Total and non-vellus hair density were measured in the vertex by trichoscopy with hair-to-hair matching, and three dermatologists blind to treatment scored global photographs.

After 24 weeks:

• Total hair density rose by 24.5 hairs/cm² in the sublingual group and 21.8 hairs/cm² in the oral group.
• Terminal hair density rose by 7.8 hairs/cm² with sublingual and 7.4 hairs/cm² with oral.
• On global photographs of the crown, 42% of the sublingual group and 40% of the oral group were rated as improved.

While sublingual numbers were directionally a little higher, both sublingual and oral minoxidil were measured as having about the same impact on hair growth.

However, side effects are where the groups separated:

• Heart palpitations occurred in 4 of 43 men (9.3%) on oral minoxidil and 0 of 43 men (0%) on sublingual minoxidil.
• Hypertrichosis was the most common side effect on both routes and was nearly identical at most sites: beard growth in 47.9% vs. 48.8%, chest hair in 43.8% vs. 42.9%. The one exception was the upper back (43.8% sublingual vs. 18.6% oral), which the authors noted as an unusual result.
• Shedding, insomnia, headache, dizziness, and mild swelling were infrequent and similar across groups.

At the end of the study, the authors concluded that sublingual minoxidil and oral minoxidil were about on par in terms of efficacy. Both were well tolerated, with less frequent palpitations in the sublingual group. The authors attribute the absence of palpitations to minoxidil escaping hepatic metabolism.

Sublingual Minoxidil From our partners at Ulo

Sublingual Minoxidil

A rapidly-dissolving sublingual tablet with minoxidil. Available in 1.25 mg and 2.5 mg doses. Prescribed 100% online. Choose a multi-month plan and get up to 30% plus a free gift bundle.

Free full-size gifts with 3-month+ plans Prescribed online, shipped to your door

Claim up to 30% off + Free Gifts

Sublingual deliveryDissolves under the tongue

*Only available in the U.S. Prescription requires an online medical consultation at no extra cost. Off-label products are not endorsed by the FDA. Free gifts included with select multi-month plans while supplies last. Ulo is a partner of Perfect Hair Health; we may earn a commission on purchases.

Study #3

The original publishers of the 2021 study revisited their original data, using hair-to-hair matching software to track the diameter of individual hairs from baseline to week 24.^[8]Sinclair, R., Sicinska, J., Bokhari, L., Kasprzak, M. (2025). Sublingual minoxidil increases fibre diameter in male androgenetic alopecia: a proxy for reversal of hair follicle miniaturization. … Continue reading

There were considerable differences across doses and placebo:

• In the placebo group, average hair fiber diameter fell by 2 µm over 24 weeks.
• At 0.45 mg, it also fell by 2 µm.
• At 1.35 mg, hair fiber diameter rose by 3 µm.
• At 4.05 mg, it rose by 6 µm, the largest gains in the thickest hairs.

Because hair follicle miniaturization and the resultant shrinking of hair diameter are significant drivers of pattern hair loss, thickening of hair diameter suggests sublingual minoxidil may address a significant underlying factor in hair loss.

Notably, this is the first human evidence that a minoxidil treatment thickens existing hairs, consistent with the vellus-to-terminal reconversion seen in a humanized mouse model.^[9]Gilhar, A., Keren, A., Paus, R. (2023). Vellus-to-terminal hair follicle reconversion occurs in male pattern balding and is promoted by minoxidil and platelet-rich plasma: in vivo evidence from a new … Continue reading

However, like the original study, we are limited in our ability to compare this directly to oral minoxidil.

Study #4

In a 2026 randomized, double-blind, placebo-controlled trial, researchers assessed the effect of sublingual minoxidil in transgender people recorded female at birth and taking full-dose testosterone.^[10]Tang, G.T., Leemaqz, S., Bhoyrul, B., Eisman, S., Kasprzak, M., Sicinska, J., Sinclair, R., Cheung, A.S. (2026). Treatment of androgenetic alopecia in transgender people receiving testosterone … Continue reading This group develops AGA at about 2.5 times the rate of cisgender women, and finasteride is generally a poor fit because it can interfere with masculinization.

Participants were randomized to sublingual minoxidil (titrated to 1.35 mg twice daily) or placebo for 24 weeks, then moved to 2.5 mg twice daily in an open-label extension through week 48. Blood pressure, heart rate, and testosterone were measured at every visit.

At 24 weeks, midfrontal total hair count rose by 15.7 hairs/cm² more on minoxidil than on placebo (p=0.03), and non-vellus hair count by 12.7 hairs/cm² more (p=0.04). At 24 weeks, sublingual minoxidil didn’t beat placebo for vertex hair growth but eventually outpaced placebo by week 48. Self-rated vertex improvement was 57% on minoxidil versus 30% on placebo. There was no difference between groups in postural hypotension, hypertrichosis, or any other side effect, and sublingual minoxidil didn’t impact blood pressure, heart rate, or testosterone levels.

Study #5

Andrés-Lencina and colleagues reviewed 87 patients (73 women, 14 men) treated with a compounded sublingual minoxidil spray at their clinic.^[11]Andrés-Lencina, J.J., Brisco, F., Ricart, J.M., Gómez-Zubiaur, A. (2025). Tolerance and Safety Profile of Sublingual Minoxidil in the Treatment of Androgenic Alopecia. Actas Dermo-Sifiliográficas. … Continue reading Median doses were 0.5 mg per day for women and 1 mg per day for men. Three months in, patients were surveyed by phone about side effects.

The authors compared their results against two large oral minoxidil series. Side effects were less frequent with sublingual minoxidil than in a 435-patient oral minoxidil study that used the same phone survey, and about as frequent as in a 1,404-patient oral minoxidil study that relied on medical records rather than patient surveys.^[12]Sanabria, B., de Nardo, V.T., Miot, H.A., Ramos, P.M. (2021). Adverse effects of low-dose Oral Minoxidil for androgenetic alopecia in 435 patients. Journal of the American Academy of Dermatology. … Continue reading^[13]Vañó-Galván, S., Pirmez, R., Hermosa-Gelbard, A., et al. (2021). Safety of low-dose oral minoxidil for hair loss: A multicenter study of 1404 patients. Journal of the American Academy of … Continue reading

Sublingual Minoxidil Studies: Where Do We Stand?

All in, while more research is needed, the existing research suggests sublingual minoxidil seems to perform on par with or directionally better than oral minoxidil. Even better, it seems to do so with a much lower risk of some side effects.

According to these studies, it seems the cardiovascular impact of minoxidil may be, in part, related to the spike of the active drug in the blood. If we can prevent a spike of active minoxidil sulfate in the blood, we can, in theory, reduce the risk of side effects with oral minoxidil while (hopefully) keeping the directionally better regrowth.

However, sublingual delivery doesn’t seem to reduce the risk of other side effects like hypertrichosis, insomnia, headache, dizziness, and fluid retention. However, all but hypertrichosis remained rare.

But What If I Have Low Sulfotransferase Levels In My Scalp?

If you have lower sulfotransferase levels in your scalp, you might be worried that sublingual minoxidil might not be as effective as oral minoxidil. After all, if the advantage of oral minoxidil is that it bypasses the need for minoxidil activation in the scalp, then we would expect that bypassing activation in the liver with sublingual minoxidil could theoretically lead to subpar results (compared to regular oral minoxidil).

Except this doesn’t seem to be true. In research comparing oral and sublingual minoxidil, they generally perform about the same despite the fact that sublingual minoxidil bypasses this essential step.

Why might this be the case? There are two reasons:

• Sublingual minoxidil bypasses sulfation in the liver, but it also bypasses glucuronidation. Glucuronidation is another metabolic process that occurs in the liver after taking oral minoxidil. Except instead of activating minoxidil, this process actually inhibits it. As a result, a portion oral minoxidil may be activated by the liver, but a portion is also be inhibited. In short, sublingual minoxidil might be more bioavailable even if it’s not converted to its active form before reaching the hair follicle. This might mean that sublingual minoxidil, by bypassing glucuronidation, supplies a larger amount of minoxidil to be converted to minoxidil sulfate in the follicle. In turn, more bioavailable amounts of minoxidil may make up for less minoxidil sulfate.
• The liver doesn’t contribute much at all to the efficacy of oral minoxidil. If oral minoxidil arrived at the follicle in its activated sulfate form (in sufficient amount), then the number of sulfotransferase enzymes present in your scalp shouldn’t affect response to oral minoxidil at all. But it, as it turns out, it does. In a 2020 study, researchers studying oral minoxidil found that low follicular sulfotransferase activity predicted weaker regrowth with oral minoxidil.^[14]Ramos, P.M., Goren, A., Sinclair, R., Miot, H.A. (2020). Oral minoxidil bio-activation by hair follicle outer root sheath cell sulfotransferase enzymes predicts clinical efficacy in female pattern … Continue reading In other words, even with oral minoxidil, sulfotransferase activity at the follicle is likely still a main reservoir of the active drug. As such, the reason oral minoxidil has less to do with bypassing scalp enzymes, and more to do with the amount of inactive minoxidil it delivers to the follicle. By delivering more minoxidil to the follicles, it overcomes the reduced absorption of topical minoxidil, producing a greater effect. It doesn’t mean the active minoxidil sulfate delivered to the scalp via the liver is inconsequential in oral minoxidil treatment, but rather that it’s not the most significant factor.

As a result, it doesn’t seem that there is a disadvantage to using sublingual minoxidil when it comes to expected growth potential.

Is There a Best Sublingual Minoxidil Dose?

Sublingual minoxidil has been tested at various doses in the research, as low as 0.45 mg and as high as 5 mg. While doses of 0.45 mg, 1.35 mg, 2.5 mg, 4.05 mg, and 5 mg have all shown favorable results, only 5 mg has data to support its non-inferiority to standard oral minoxidil. 1.35 mg and 2.5 mg were rated as more effective than placebo, but weren’t validated against standard oral minoxidil.

This doesn’t mean doses lower than 5 mg won’t be effective, but it is the most evidence-backed dose when it comes to sublingual minoxidil.

Is Sublingual Minoxidil Available Today?

Ulo just released their Sublingual Minoxidil Rx. It’s an orange-flavored, rapidly dissolving tablet that easily dissolves under the tongue. It’s a convenient, easy way to take oral minoxidil while harnessing the potential of sublingual delivery.

Sublingual Minoxidil From our partners at Ulo

Sublingual Minoxidil

A rapidly-dissolving sublingual tablet with minoxidil. Available in 1.25 mg and 2.5 mg doses. Prescribed 100% online. Choose a multi-month plan and get up to 30% plus a free gift bundle.

Free full-size gifts with 3-month+ plans Prescribed online, shipped to your door

Claim up to 30% off + Free Gifts

Sublingual deliveryDissolves under the tongue

*Only available in the U.S. Prescription requires an online medical consultation at no extra cost. Off-label products are not endorsed by the FDA. Free gifts included with select multi-month plans while supplies last. Ulo is a partner of Perfect Hair Health; we may earn a commission on purchases.

Bottom Line

Sublingual minoxidil made its way into research on the premise that its delivery route might have less of an impact on the cardiovascular system. And in a landmark head-to-head trial, researchers found exactly that. Heart palpitations occurred in 0% of men taking 5 mg of sublingual minoxidil, compared with 9% of men taking 5 mg of standard oral minoxidil. And importantly, it was just as effective: both groups grew the same amount of hair over six months.

Oral minoxidil’s cardiovascular effects are driven by a spike in the active form of minoxidil, minoxidil sulfate, in the blood. That surge in active minoxidil dips blood pressure and contributes to related side effects.

Sublingual minoxidil minimizes the spike in the active form of minoxidil by bypassing the first-pass metabolism responsible for its activation. Instead, minoxidil gets supplied directly to the scalp tissue, and at higher amounts than topical minoxidil.

This is also why sublingual minoxidil performs on par with oral minoxidil: by delivering higher amounts to the hair follicle, more minoxidil can be converted to the active form in the follicles. By providing a higher dose of minoxidil to follicles, both oral and sublingual minoxidil outperform topical minoxidil.

In general, research around sublingual minoxidil is still in its infancy. However, the early clinical data make it a reasonable option for anyone looking to explore other forms of minoxidil that are best suited to their needs and preferences when approaching hair loss.

The hair loss industry is rife with quick-fix solutions, fleeting fads, and ineffective natural supplements. There are, however, tried-and-tested prescription medications that can reliably combat hair loss and promote regrowth. Does this mean we can rely on Rx vendors to always provide safe, dependable, and evidence-based treatments? Unfortunately, the world of prescription hair loss medication can be prone to the same issues that plague over-the-counter solutions. What’s worse, Rx drugs pose a real danger of severe side effects.

Happy Head is a telehealth company specializing in hair-loss medications. For many years, we happily recommended their products: they provided proven treatments and were one of the only places to find effective options like topical dutasteride. Unfortunately, issues have become apparent that are typical of wider problems with the hair loss industry.

If you’ve been using Happy Head and are pleased with the results, there should be nothing to worry about. Their offerings of minoxidil, finasteride, and dutasteride, among others, are powerful tools against hair loss and can drive real, meaningful improvements.

However, their model has critical oversights, some involving consumer safety, and after years of voicing our concerns with no changes, we were inspired to launch Ulo to fix these exact problems. This article will detail the six major reasons why we lost faith in recommending them to our readers.

Interested in Topical Dutasteride?

Hair gains bigger than finasteride? Dutasteride makes this possible, if prescribed*

Take the next step in your hair regrowth journey. Get started today with a provider who can prescribe a topical solution tailored for you.

Click Here For 15% Off

*Only available in the U.S. Prescriptions not guaranteed. Restrictions apply. Off-label products are not endorsed by the FDA.

Concern #1: Genetic Testing for Hair Loss Treatments

In an industry with a limited number of established pharmaceutical options, it can be hard to stand out. Happy Head’s unique selling point is its DNA Kit and Customized Hair Growth Treatment, which, they claim, reveals which treatments will work for your unique DNA. 

The pitch is this: there are certain gene variants that underlie how hair loss develops, and others that can predict how well hair loss drugs will work. For $298, Happy Head provides a home DNA test; you take a swab and send it back for analysis. This enables them to generate reports on your personal genetic makeup and recommend treatments accordingly.

They provide two reports:

• Hair and Scalp Report – This identifies “Genetic predispositions for 33 hair, scalp, and related micronutrient traits.”
• Treatment Insight Report – Identifying “14-16 genetic traits for medication sensitivity and baldness patterns.”

It sounds impressively technical, but what is the science behind this “breakthrough innovation”?

The Genetics of Hair Loss

It’s important to note that genetic factors are heavily involved in our predisposition to hair loss. Androgenic alopecia (AGA) is highly heritable, with family studies suggesting genetics account for around 80% of predisposition in men. It is, however, a polygenic trait, meaning that many genes each contribute small effects rather than a single “baldness gene.”^[1]Heath, A. C., Nyholt, D. R., Gillespie, N. A., & Martin, N. G. (2003). Genetic basis of male pattern baldness. *Journal of Investigative Dermatology.* 121(6). 1561–1564. Available at: … Continue reading

AGA is driven by hormonal activity: as levels of an androgen called dihydrotestosterone (DHT) rise, it can cause miniaturization of hair follicles that progressively shortens the hair growth phase, leading to hairs that are thin, short, and sparse.^[2]Trüeb, R. M. (2002). Molecular mechanisms of androgenetic alopecia. *Experimental Gerontology.* 37(8–9). 981–990. Available at: https://doi.org/10.1016/S0531-5565(02)00093-1 Because of this association with androgen activity, the androgen receptor locus (region of DNA) is most heavily associated with hair loss.^[3]Sadasivam, I. P., Sambandam, R., Kaliyaperumal, D., & Dileep, J. E. (2024). Androgenetic alopecia in men: An update on genetics. *Indian Journal of Dermatology.* 69(3). 282. Available at: … Continue reading

Other genes involved in androgen activity, such as SRD5A2, which plays a role in androgen metabolism, are also associated with susceptibility to hair loss. Genes involved in other pathways important to hair follicle development, such as the WNT pathway, may also play a role.^[4]Gupta, A. K., Dennis, D. J., Economopoulos, V., & Piguet, V. (2026). The genetic landscape of androgenetic alopecia: Current knowledge and future perspectives. *Biology.* 15(2). 192. Available … Continue reading 

This research may tell us how likely someone is to develop AGA as they grow older. Of course, for most people already seeking treatment for AGA, this information isn’t particularly useful. Clinical diagnosis is typically based on the appearance of the hair, scalp examination, and family history, rather than on genetic tests. However, there are some cases where genetic insights might be useful. 

Treatments that target hormonal aspects of AGA, like finasteride and dutasteride, won’t work for other causes of hair loss. Some hair loss is the result of nutrient deficiencies, many of which are caused by genetic variation. For example, biotin deficiency can lead to alopecia because biotin is essential for keratin production, a key component of hair. Mutations in the BTD gene, encoding an enzyme called biotinidase, which is essential for the body to use biotin, can therefore cause hair loss. However, most biotin deficiencies are diagnosed in children, and hair loss is apparent from a young age.^[5]Yang, Y., Yang, J. Y., & Chen, X. J. (2020). Biotinidase deficiency characterized by skin and hair findings. *Clinics in Dermatology.* 38(4). 477–483. Available at: … Continue reading 

The autoimmune condition alopecia areata may also have a genetic basis, and predispositions have been identified in genes involved in the immune system.^[6]Biran, R., Zlotogorski, A., & Ramot, Y. (2015). The genetics of alopecia areata: new approaches, new findings, new treatments. *Journal of Dermatological Science.* 78(1). 11–20. Available at: … Continue reading

The Hair and Scalp Report provided by Happy Head after DNA testing lists genetic predispositions for 33 traits, ranging from autoimmune hair loss (e.g., alopecia areata) to scalp hydration and vitamin deficiencies. If you thought you had AGA, but instead had a different cause of hair loss, some insight into the underlying genetics could prove useful in rare cases. 

However, clinicians typically distinguish among different forms of alopecia by physical examination and, in rare cases, by blood tests. If you want to understand your hair loss, visiting a physician is a far more reliable route. What’s more, the Rx products that Happy Head offers require a diagnosis prior to being prescribed, so you will have to see a healthcare practitioner regardless of your underlying genetics.

Can Genetics Predict Responses to Hair Loss Drugs?

The main promise of Happy Head’s genetic testing is that it can identify “which treatments will work for your unique DNA”. Given the range of options available to people suffering from hair loss and the sometimes unpredictable nature of treatment responses, it’s an enticing prospect. But does the science back up Happy Head’s bold claims?

We’ve investigated the potential of genetic testing for personalized hair loss treatment before, and you can read our in-depth report here.

Happy Head provides a Treatment Insight Report, which highlights “14-16 genetic traits for medication sensitivity and baldness patterns”. Helpfully, the company has detailed these genetic traits, the associated genes, and the studies supporting their use, so we can assess how powerful their predictions might be. You can find the full list here.

What Does the Genetic Test Actually Look At?

The test assesses the presence of a kind of genetic variation called single-nucleotide polymorphisms (SNPs, normally pronounced “snips”). DNA is made up of genes, which in turn are comprised of individual units called nucleotides. When a gene is “read”, the sequence of nucleotides will determine what protein is made, and therefore what effect the gene will have. SNPs are variations in these nucleotides; change the nucleotide, and you might change the impact of the gene.^[7]Nelson, M. R., Marnellos, G., Kammerer, S., Hoyal, C. R., Shi, M. M., Cantor, C. R., & Braun, A. (2004). Large-scale validation of single nucleotide polymorphisms in gene regions. *Genome … Continue reading,^[8]National Human Genome Research Institute. (n.d.). Single nucleotide polymorphisms (SNPs). *Genome.gov.* Available at: https://www.genome.gov/genetics-glossary/Single-Nucleotide-Polymorphisms-SNPs

For example, if we know that a SNP changes the activity of a gene involved in drug metabolism, we might be able to predict how well certain drugs are going to work. 

We’ll take a look at the “genetic traits” identified in the Happy Head test and see if SNPs in the genes they assess might have predictive power. Most of these traits are related to drug efficacy: “Minoxidil Effectiveness”, “ Dutasteride Metabolism”, etc. 

Which SNPs Can Predict Response to Therapy?

First, we’ll take a look at the limited cases where SNPs might actually provide some insight.

Minoxidil is FDA-approved for androgenic alopecia and is a reliable treatment with many years of clinical evidence. However, the efficacy of minoxidil can be unpredictable, and one source of the variation in response has been identified: an enzyme called SULT1A1. For minoxidil to work, it needs to first be converted into minoxidil sulfate in the body. This conversion is performed by sulfotransferases, most notably SULT1A1.

Consequently, the amount of SULT1A1 in the scalp may predict the amount of active minoxidil.^[10]Pietrauszka, K., & Bergler-Czop, B. (2022). Sulfotransferase SULT1A1 activity in hair follicle, a prognostic marker of response to the minoxidil treatment in patients with androgenetic alopecia: … Continue reading Therefore, the gene that produces SULT1A1, also called SULT1A1 (gene names get italicised), could impact minoxidil efficacy.

One study found that a SNP in the SULT1A1 gene can alter the activity of the enzyme.^[11]Yu, X., Dhakal, I. B., Beggs, M., Edavana, V. K., Williams, S., Zhang, X., Mercer, K., et al. (2010). Functional genetic variants in the 3′-untranslated region of sulfotransferase isoform 1A1 … Continue reading However, they also concluded that this genetic variation can’t account for the differences in SULT1A1 activity observed in the total population. 

The key factor in the efficacy of minoxidil is the activity of SULT1A1 in the scalp. Having the gene that makes a certain enzyme doesn’t mean that it’s expressed (turned on) in all the cells and tissues in the body. As such, there are likely to be multiple underlying mechanisms for differences in SULT1A1 activity in the scalp. Still, the evidence suggests that variations in the SULT1A1 gene could predict minoxidil activity. 

There is also limited evidence that certain genes may be linked to responsiveness to dutasteride. A 2019 study looked at SNPs across the whole genomes of men who had taken dutasteride and assessed if specific genes correlated with response.^[12]Rhie, A., Son, H.-Y., Kwak, S. J., Lee, S., Kim, D. Y., Lew, B.-L., Sim, W.-Y., et al. (2019). Genetic variations associated with response to dutasteride in the treatment of male subjects with … Continue reading

From a sample of 42 men, the researchers looked for genes in which SNPs most commonly occurred among the best and worst responders. They identified a handful of genes that may be associated with response to dutasteride.

The sample size is quite small, and the correlation between the presence of SNPs and response to dutasteride isn’t that strong. Importantly, the predictive power of the identified genes is cumulative: the model the researchers used considers multiple genes simultaneously, rather than the predictive power of SNPs in individual genes. 

The Happy Head Treatment Insights include four of the six genes most associated with dutasteride effectiveness in the study. However, these are spread over three different “traits”. The predictive power of their model is therefore likely to be weak. However, the evidence does provide some scientific basis for the insights from the genetic test.

How Strong is the Evidence Overall?

We’ve looked at two examples where elements of Happy Head’s “genetic traits” might have some predictive power. SULT1A1 expression is likely associated with minoxidil efficacy, whereas genetic determinants of dutasteride efficacy would require stronger, more robust models that incorporate multiple genes to have any predictive value. 

So what about the evidence supporting the other traits? Unfortunately, the DNA testing approach for personalized hair loss plans is largely based on over-extrapolation from data with little or no link to hair loss.

For example, Trait #5, Finasteride Effectiveness, lists SRD5A1 and SRD5A2 as genes related to this trait. The literature cited includes research that shows these genes are associated with prostate cancer and benign prostate hyperplasia, and one study that suggests variations in SRD5A2 can be associated with decreased risk of hair loss.^[14]Hayes, V. M., Severi, G., Padilla, E. J. D., Morris, H. A., Tilley, W. D., Southey, M. C., English, D. R., et al. (2007). 5α‐reductase type 2 gene variant associations with prostate cancer risk, … Continue reading,^[15]Li, X., Huang, Y., Fu, X., Chen, C., Zhang, D., Yan, L., Xie, Y., Mao, Y., & Li, Y. (2010). Meta-analysis of three polymorphisms in the steroid-5-alpha-reductase, alpha polypeptide 2 gene … Continue reading  

The implication is that, because SRD5A2 is associated with higher DHT levels, this would increase finasteride efficacy, as finasteride inhibits DHT. However, there is no clinical evidence at all to suggest this is the case. 

Happy Head also cites a review paper that outlines some ways genetic markers could provide personalized AGA medicine. Interestingly, the authors of the paper work for a company called Fagron Genomics, which manufactures genetic tests for personalized AGA medicine.^[16]Vila-Vecilla, L., Russo, V., & Torres de Souza, G. (2024). Genomic markers and personalized medicine in androgenetic alopecia: a comprehensive review. *Cosmetics.* 11(5). 148. Available at: … Continue reading

Trait #9 is Topical Retinoic Acid Effectiveness, which lists associated genes as CRABP2, CYP26B1, and RXRG. Retinoic acid is a common additive in hair loss, especially in the form of tretinoin. However, the research cited by Happy Head to support the use of these genes for prediction has no relation to hair loss or AGA. One paper discusses CRABP2 in skin aging, while another highlights the role of CYP26 in cancer.^[17]Bielli, A., Scioli, M. G., D’Amico, F., Tarquini, C., Agostinelli, S., Costanza, G., Doldo, E., et al. (2019). Cellular retinoic acid binding protein-II expression and its potential role in skin … Continue reading,^[18]Stevison, F., Jing, J., Tripathy, S., & Isoherranen, N. (2015). Role of retinoic acid-metabolizing cytochrome P450s, CYP26, in inflammation and cancer. *Advances in Pharmacology.* 74. 373–412. … Continue reading 

One study shows that changes in CRABP2 expression can increase serum retinoic acid levels in the umbilical cord of newborns. The relevance of the finding to hair loss is unclear.^[19]Manolescu, D. C., El-Kares, R., Lakhal-Chaieb, L., Montpetit, A., Bhat, P. V., & Goodyer, P. (2010). Newborn serum retinoic acid level is associated with variants of genes in the retinol … Continue reading

The story is similar for the rest of the genetic traits: over-extrapolation of limited data from tangentially related studies. While genetic variation may be able to provide meaningful insights into hair loss drug efficacy in the future, there is currently insufficient data to back up Happy Head’s bold claims.

Concern #2: Topical Latanoprost

Latanoprost has become a popular component of topical hair loss treatments since a 2011 study suggested that it could increase hair density in men with AGA.^[20]Blume-Peytavi, U., Lönnfors, S., Hillmann, K., & Garcia Bartels, N. (2012). A randomized double-blind placebo-controlled pilot study to assess the efficacy of a 24-week topical treatment by … Continue reading However, serious concerns have been raised about the drug’s long-term safety and efficacy. 

Originally developed as a medication for glaucoma, latanoprost was tested as a treatment for AGA when users of the drug noted increased hair growth in their eyelashes. The 2011 study demonstrated significant increases in hair counts and hair density for 0.1% topical latanoprost compared to placebo. However, 50% of men in the study didn’t show any improvement at all, or got worse.

Given these results from a small study (16 participants in total), a 2018 follow-up study compared latanoprost with minoxidil and explored combination therapies. Unfortunately, the study design was flawed, with high participant dropout rates and poorly defined study groups and procedures.^[21]Bloch, L. D., Escudeiro, C. C., Sarruf, F. D., & Sakai Valente, N. Y. (2018). Latanoprost and minoxidil: comparative double-blind, placebo-controlled study for the treatment of hair loss. … Continue reading

Other studies investigating latanoprost for alopecia areata have proven inconclusive, with low response rates.^[22]Mehta, J. S., Raman, J., Gupta, N., & Thoung, D. (2003). Cutaneous latanoprost in the treatment of alopecia areata. *Eye.* 17(3). 444–446. Available at: https://doi.org/10.1038/sj.eye.6700354,^[23]Faghihi, G., Andalib, F., & Asilian, A. (2009). The efficacy of latanoprost in the treatment of alopecia areata of eyelashes and eyebrows. *European Journal of Dermatology.* 19(6). 586–587. … Continue reading

As such, the verdict is still out on how effective latanoprost is at treating AGA and other hair loss conditions, with much more research required. Importantly, however, there are significant safety concerns associated with the drug. 

Long-term use of latanoprost in patients with glaucoma can cause changes in iris color. Clinical data suggest this affects around 10% of people after a year of use, though some studies indicate the incidence could be as high as 70%.^[24]Teus, M. A., Arranz-Marquez, E., & Lucea-Suescun, P. (2002). Incidence of iris colour change in latanoprost treated eyes. *British Journal of Ophthalmology.* 86(10). 1085–1088. Available at: … Continue reading Given the potential for systemic absorption of the drug when applied topically, or for the drug to enter the eyes when applied to the head, this could pose a risk for those using it as a hair loss cure. What’s more, hair loss treatments are typically taken consistently for many years, increasing lifetime exposure.

For glaucoma patients, the potential for changes in iris pigmentation is likely weighed against the benefits of a proven treatment for a debilitating condition. For those looking to treat hair loss, this risk is associated with a drug that is, so far, clinically unproven. In this context, the inclusion of latanoprost in hair-loss medications could be seen as irresponsible.

You can read our in-depth article about latanoprost here.

Concern #3: Propylene Glycol

The use of propylene glycol is a widespread problem in the hair growth industry. It’s used as an excipient, meaning it serves as an “inactive” ingredient that helps to stabilize the active drugs or increase their availability. For drugs like minoxidil, which is poorly water-soluble, propylene glycol helps keep the solution uniform and consistent. It can also enhance the penetration of drugs by affecting the barrier of the stratum corneum, the outermost layer of the skin.^[25]Carrer, V., Alonso, C., Pont, M., Zanuy, M., Córdoba, M., Espinosa, S., Barba, C., Oliver, M. A., Martí, M., & Coderch, L. (2020). Effect of propylene glycol on the skin penetration of drugs. … Continue reading,^[26]Lessmann, H., Schnuch, A., Geier, J., Uter, W. (2005). Skin-sensitizing and irritant properties of propylene glycol. Contact Dermatitis. 53(5). 247-259. Available at: … Continue reading

Unfortunately, propylene glycol is also widely recognized as an irritant and a cause of contact dermatitis. This effect will only be compounded by once or twice daily application in topical formulations. One retrospective study found that 6.4% of minoxidil users experience some skin irritation, and many of these reactions will be the result of propylene glycol.^[27]Shadi, Z. (2023). Compliance to Topical Minoxidil and Reasons for Discontinuation among Patients with Androgenetic Alopecia. Dermatology and Therapy (Heidelb). 13(5). 1157-1169. Available at: … Continue reading.

Skin irritation is a common reason for people to discontinue treatment with topical hair loss products. More careful formulation could lead to better adherence and, ultimately, better results. 

Concern #4: Corticosteroids

The use of irritants like propylene glycol leads us to our fourth concern: the use of corticosteroids. Daily application of irritants to the scalp can lead to significant inflammation, which is actively detrimental to hair growth. To combat this, telehealth companies have turned to corticosteroids like hydrocortisone and fluocinolone. These steroids mimic the activity of cortisol to suppress inflammation and local immune response.^[28]Stacey, S. K., & McEleney, M. (2021). Topical corticosteroids: choice and application. *American Family Physician.* 103(6). 337–343. Available at: https://pubmed.ncbi.nlm.nih.gov/33719380/

However, corticosteroids are designed for intermittent use when treating acute inflammation. They are not designed for twice-daily application over the course of many years. The steroids wear down the stratum corneum and epidermis, and can lead to long-term side effects like spider veins.^[29]Torok, H. M., Jones, T., Rich, P., Smith, S., & Tschen, E. (2005). Hydroquinone 4%, tretinoin 0.05%, fluocinolone acetonide 0.01%: a safe and efficacious 12-month treatment for melasma. *Cutis.* … Continue reading

The corticosteroids used in hair growth products are typically low-potency, meaning they can be used for longer periods of time than high- or medium-potency products. Happy Head, for example, uses 1% hydrocortisone in its TopicalRx Finasteride & Minoxidil formulation. However, one study showed that after only 2 weeks, 1% hydrocortisone can lead to a significant reduction in epidermal thickness. Although the skin recovered after multiple weeks of use, , this was only after treatment was ended.^[31]Aschoff, R., Schmitt, J., Knuschke, P., Koch, E., Bräutigam, M., & Meurer, M. (2011). Evaluation of the atrophogenic potential of hydrocortisone 1% cream and pimecrolimus 1% cream in uninvolved … Continue reading

In clinical trials, 1% hydrocortisone can lead to skin atrophy (thinning) after 6 to 12 months in a small percentage of patients.^[32]Guin, J. D. (1981). Complications of topical hydrocortisone. *Journal of the American Academy of Dermatology.* 4(4). 417–422. Available at: https://doi.org/10.1016/S0190-9622(81)70040-9,^[33]Lenane, P., Macarthur, C., Parkin, P. C., Krafchik, B., DeGroot, J., Khambalia, A., & Pope, E. (2014). Clobetasol propionate, 0.05%, vs hydrocortisone, 1%, for alopecia areata in children: a … Continue reading However, as we’ve already noted, hair loss products should be designed for daily application for many years. The unnecessary inclusion of potentially harmful ingredients, with no clear benefit, is a major concern.

Concern #5: Dutasteride Formulation

One of the most important factors for drug producers and telehealth companies to consider when formulating their products is bioavailability: the extent to which the active ingredient is absorbed and used in the body. For common drugs like minoxidil and finasteride, this is fairly straightforward, as they are bioavailable on their own without much chemical modification.

Dutasteride, on the other hand, is poorly soluble in water and needs to be formulated with lipids. This is why it’s typically sold as a soft-gel capsule rather than a pill. 

There are emerging concerns that some telehealth companies may be dispensing oral dutasteride in compounded capsule formulations that differ from the soft-gel, lipid-based versions used in clinical trials. When dutasteride is compounded as a powder and combined with other ingredients (such as oral minoxidil, vitamins, or biotin) into a single capsule, its absorption may be reduced.

To see if compounded dutasteride pills had reduced efficacy, we ran a small test. One participant took 3 pills of 0.5 mg powdered dutasteride (i.e., 1.5 mg total) and then checked changes in their blood DHT levels 12 hours later. Like finasteride, dutasteride works by reducing levels of DHT, and we’d normally expect to see around 80-90% reduction in serum DHT with only 1 mg of dutasteride, based on pharmacology data.^[34]Gisleskog, P. O., Hermann, D., Hammarlund‐Udenaes, M., & Karlsson, M. O. (1998). A model for the turnover of dihydrotestosterone in the presence of the irreversible 5α‐reductase inhibitors … Continue reading

However, we saw a reduction of only 13.6%. It is safe to assume that this level of DHT reduction will lead to substantially lower effectiveness for the drug. While rigorous, peer-reviewed research is needed to confirm the extent of these differences, the findings are enough to raise serious concerns. 

Happy Head compounds its dutasteride with minoxidil and vitamin D3 in a “SuperCapsuleTM”. While these compounded pills are designed to make taking them daily easier, they may be blocking their hair growth capabilities. The lack of evidence for the efficacy of dutasteride when it’s compounded in this way makes it difficult to understand the benefits of combining the drugs rather than providing the tried-and-tested gel-form capsule.

Interested in Oral Dutasteride?

Oral Dutasteride Hair gains bigger than finasteride? Dutasteride makes this possible, if prescribed*

Take the next step in your hair regrowth journey. Get started today with a provider who can prescribe a topical solution tailored for you.

Click Here For 15% Off

*Only available in the U.S. Prescriptions not guaranteed. Restrictions apply. Off-label products are not endorsed by the FDA.

Can Prescription Vendors Do Better?

It is possible to provide personalized hair loss treatment. Rather than using marketing buzzwords and expensive, unproven DNA testing, vendors and telehealth companies can focus on the type and extent of hair loss, the tolerability of side effects, and ongoing management. 

After years of advocating for better standards across the industry and pushing for improved formulations, we saw many telehealth brands move in the opposite direction. That experience ultimately led us to cofound Ulo, a telehealth company dedicated exclusively to hair growth, with the goal of fixing the problems we repeatedly observed and offering consumers treatment plans that are genuinely personalized and grounded in clinical evidence.

Ulo is built around three core principles: evidence, personalization, and consumer safety. Unlike some brands that rely heavily on unproven testing or trend-driven ingredients, Ulo states that it builds treatment plans around established therapies, physician oversight, and independently vetted formulations.

Ulo is committed to addressing several common industry practices highlighted in this article:

• Personalization and Customization: There’s no need for poorly evidenced genetic testing to find the right solution. Conversations with experts and examinations by clinical professionals are the best way to find the treatment regimen and management plan for you.
• Safer Topical Design: Ulo avoids propylene glycol and corticosteroids in its topical products, instead focusing on safe formulations and adjustable ingredient combinations.
• Avoidance of Trend-Driven Ingredients: They don’t include ingredients with limited safety data or unclear benefit unless there is a clear evidence-based rationale.
• Evidence-based Formulations: Rather than using mega-dosed or experimental combinations, Ulo emphasizes clinically supported concentrations and delivery formats. For example, it offers oral dutasteride in soft-gel form consistent with clinical trial formulations.

This model underscores what telehealth hair-loss providers could do differently: prioritize proven drug-delivery systems, avoid unnecessary or potentially harmful additives, provide genuine physician-led personalization, and set realistic expectations for outcomes.

Final Thoughts

The rise of telehealth hair-loss companies has made prescription treatments more accessible than ever, but accessibility does not always guarantee quality. While the concerns with Happy Head we’ve listed here raise serious questions about the brand and its products, they are not isolated to one company. Unfortunately, overstated claims, untested formulations, and unnecessary inclusion of risky components are common.

As this review highlights, differences in formulation, ingredient selection, and evidence standards can impact both safety and results. The takeaway is simple: effective hair-loss treatment is rarely about novelty or trendy new ingredients. Instead, prioritize providers that emphasize proven formulations, transparent evidence, and ongoing medical oversight.

If you are noticing a receding hairline, widening part, reduced density, or progressively finer hairs, a blood DHT test can sound like a logical next step. 

Dihydrotestosterone (DHT) is often described as the hormone responsible for androgenic alopecia (AGA). That framing can make the question seem straightforward. If DHT contributes to follicular miniaturization, wouldn’t a high DHT result show whether DHT is causing your hair loss?

There are other understandable reasons to want the test, too. You may be trying to distinguish AGA from stress-related shedding or a nutritional problem. You may want an objective explanation for a visible change in your hair. Or if you are considering a treatment such as finasteride, you may wonder whether your baseline DHT level could predict whether the medication will work for you. 

A blood test can feel more definitive than looking at the scalp. It provides a number, a laboratory reference range, and apparently clear categories such as “normal” or “high.” But hair follicles do not respond only to the amount of DHT circulating in the bloodstream. They respond to a combination of local DHT production, androgen-receptor signaling, genetic susceptibility, and site-specific biology within the scalp. 

That does not make serum DHT meaningless. It is a real hormonal measurement, and hormone testing can be appropriate when someone has signs of androgen excess or another possible endocrine disorder. However, interpreting a DHT result as a direct test for AGA can be misleading. 

To understand why, it helps to separate two related but different questions:

1. What is the DHT concentration in the blood at the time of testing?
2. Are susceptible scalp follicles undergoing androgen-related miniaturization?

What is DHT?

Dihydrotestosterone, or DHT, is an androgen hormone created from the conversion of testosterone by 5-alpha-reductase.^[1]Kinter KJ, Amraei R, Anekar AA. Biochemistry, Dihydrotestosterone. [Updated 2023 Jul 30]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from: … Continue reading

DHT binds to the androgen receptor, a protein inside certain cells that acts as a molecular receiver for androgen signals. Once DHT binds, the androgen receptor can influence the expression of genes involved in tissue growth, development, and function. 

There are several forms of 5-alpha-reductase. In hair biology, the two most often discussed are: 

• Type I 5-alpha-reductase, which is found in skin and pilosebaceous structures, among other tissues.

• Type II 5-alpha-reductase, which is particularly relevant in androgen-sensitive tissues and is a key therapeutic target of finasteride.

Both enzymes can contribute to the local conversion of testosterone into DHT, but their distribution and relative importance vary by tissue, sex, and scalp location.

DHT is not inherently “bad”. It has important physiological roles, particularly in male sexual development and in androgen-dependent tissues. The apparent contradiction is that DHT can stimulate terminal hair growth in some areas, such as the beard, chest, and other body sites, while contributing to progressive miniaturization of susceptible scalp follicles.

This is not because beard and scalp follicles receive different blood DHT concentrations, but because follicles in different areas of the body interpret androgen signals differently. Their local enzyme activity, androgen-receptor expression, surrounding signaling environment, and genetic programming all differ.^[3]Itami, S., Sonoda, T., Kurata, S., Takayasu, S. (1994). Mechanism of action of androgen in hair follicles. Journal of Dermatological Sciences. S98-103. Available at: … Continue reading,^[4]Rutberg, S.E., Kolpack, M.L., Gourley, J.A., Tan, G., Henry, J.P., Shander, D. (2006). Differences in expression of specific biomarkers distinguish human beard from scalp dermal papilla cells. … Continue reading

How DHT contributes to AGA

AGA is best understood as an interaction among several factors:

• Androgen exposure, including testosterone and DHT
• Local production and metabolism of androgens within the scalp
• Activity of 5-alpha-reductase enzymes in and around the follicle
• Androgen receptor amount and responsiveness
• Genetic susceptibility
• Follicle-specific signaling pathways that influence hair-cycle duration, inflammation, growth factors, and miniaturization

In other words, AGA is not simply “high DHT”. It is a condition in which particular scalp follicles are susceptible to androgen-mediated change. 

Human hair follicle research illustrates this point. In a study of frontal and occipital scalp follicles from men and women with AGA, Sawaya and Price found site- and sex-specific differences in levels of androgen receptors, type I and type II 5-alpha-reductase, and aromatase.^[5]Sawaya, M.E., Price, V.H. (1997). Different levels of 5-alpha-reductase type I and II, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia. Journal of … Continue reading Frontal follicles had higher androgen-receptor and 5-alpha-reductase levels, while occipital follicles had higher aromatase levels. The differences were also quantitatively distinct between women and men.

This helps explain why hair loss often follows a pattern. In many men, the frontal scalp, temples, and vertex are more vulnerable than the occipital scalp. In many women, thinning is more apparent over the central scalp or widening part line, while the frontal hairline may be relatively preserved.

It also explains why balding and non-balding follicles can behave differently within the same person. Two follicles may be exposed to the same circulating DHT concentration, yet one remains stable while the other progressively miniaturizes.

Why the same DHT level can mean different things

Consider two people with the same serum DHT results:

• One may have follicles with relatively low local 5-alpha-reductase activity, lower androgen receptor signaling, or low genetic susceptibility to AGA.
• The other may have genetically susceptible frontal or vertex follicles with greater local androgen signaling and a stronger miniaturizing response

The blood test may look similar. The clinical hair outcome may be completely different.

That is why a serum result cannot substitute for assessment of the scalp itself.

What a blood DHT test measures

A blood DHT test measures the concentration of DHT in serum at one particular point in time. It does not directly measure what is occurring inside your scalp follicles.

A reported result can also be influenced by several factors:

• The laboratory method used to measure DHT
• The laboratory’s reference range
• Normal biological variation over time
• Timing of sampling
• Sex, age, and hormonal status
• Use of oral contraceptives, hormone therapy, anabolic-androgenic steroids, or anti-androgen medications
• Use of 5-alpha-reductase inhibitors such as finasteride or dutasteride
• Other medical conditions that influence androgen production, metabolism, or binding proteins

DHT measurement can be technically challenging, especially at the relatively low concentrations often found in women. Where hormone testing is clinically necessary, assay quality matters. For example, endocrine guidance commonly emphasizes high-quality testosterone measurement and assessment of related markers such as sex hormone-binding globulin (SHBG), rather than treating DHT as a standalone diagnostic marker.^[6]Elhassan, Y.S., Hawley, J.M., Cussen, L., Abbara, A., Clarke, S.A., Kempegowda, P., Dhillon-Smith, R.K., Thadani, P., Busby, M., Owusu-Darkwah, L., Marrington, R., Duncan, C.W., Semple, R.K., … Continue reading 

A blood DHT result does not tell you:

• The DHT concentration inside an individual scalp follicle
• Local 5-alpha-reductase activity in the balding scalp
• Androgen receptor density or sensitivity
• Genetic susceptibility to AGA
• Whether miniaturization is occurring
• How advanced miniaturization is
• Whether another type of hair loss is present instead

Serum and scalp DHT are related pharmacodynamic measures: medications that reduce DHT systemically can also reduce it in the scalp. But they are not interchangeable measures. A serum concentration is not a direct readout of follicular androgen signaling or a diagnostic marker of scalp miniaturization.

Do people with AGA have higher serum DHT?

The evidence is mixed. Some studies report group-level differences in circulating androgen markers between people with AGA and control participants. However, group differences do not automatically create a useful diagnostic test for an individual patient.

Research finding	What it means clinically
A group with AGA has a higher average DHT value than a control group	DHT may be associated with AGA biology in that study population
Individual values overlap substantially between groups	A single DHT result cannot reliably distinguish who does and does not have AGA
DHT is not associated with hair-loss severity	A higher result does not necessarily mean more severe miniaturization
No validated diagnostic cutoff exists	A clinician cannot diagnose AGA solely from a serum DHT number

For example, Urysiak-Czubatka and colleagues found elevated serum DHT levels in some participants with AGA and in controls. Mean differences were not significant across alopecia types and controls, and DHT elevation was not correlated with the degrees of hair loss progression.^[7]Urysiak-Czubatka, I., Kmiec, M, L., Broniarczyk-Dyla, G. (2014). Assessment of the usefulness of dihydrotestosterone in the diagnostics of patients with androgenetic alopecia. Advances in Dermatology … Continue reading The authors concluded that the diagnostic usefulness of serum DHT was questionable, particularly for women.

Similarly, a retrospective study in men reported higher average serum DHT and free testosterone in AGA cases than in controls, but found no significant differences in DHT or free testosterone across different clinical severity grades of AGA.^[8]Zhang, Y., Xu, J., Jing, J., Wu, X., Lv, Z. (2018). Serum Levels of Androgen-Associated Hormones Are Correlated with Curative Effect in Androgenic Alopecia in Young Men. Medical Science Monitor. 24. … Continue reading  

These findings can coexist. DHT may be biologically relevant to AGA, yet remain a poor standalone diagnostic test. It stands to reason, therefore, that there is currently no validated serum DHT cutoff for diagnosing AGA.

Can normal DHT levels rule out AGA?

No. A normal blood DHT level does not rule out AGA. A person can have normal circulating testosterone and DHT concentrations while genetically susceptible scalp follicles still respond to local androgen signaling with progressive miniaturization. The relevant issue is not only how much androgen is present in the blood, but how a particular follicle processes and responds to that androgen exposure. 

This is particularly relevant to female pattern hair loss. Many women with a typical frontal-central or diffuse pattern of thinning have normal circulating androgen concentrations and no other obvious signs of androgen excess. 

That does not mean androgens are irrelevant. It actually means that normal systemic hormone values do not rule out local androgen-mediated effects in susceptible follicles.

Hormone results should therefore be interpreted in context:

• Normal DHT does not “clear” someone of AGA
• High DHT does not prove that AGA caused their hair loss
• A normal androgen panel does not mean a person’s hair loss is imaginary, trivial, or untreatable
• A hormone result should not replace a scalp examination, trichoscopy, and differential diagnosis

Can DHT testing predict whether finasteride will work?

Not reliably. 

Finasteride can substantially reduce DHT in both the blood and scalp at relatively low doses.^[9]Drake, L., Hordinsky, M., Fiedler, V., Swinehart, J., Unger, W.P., Cotterill, P.C., Thiboutot, D.M., Lowe, N., Jacobson, C., Whiting, D., Stieglitz, S., Kraus, S.J., Griffin, E.I., Weiss, D., … Continue reading But the relationship between DHT suppression and visible hair improvement is not linear: in clinical dose-ranging studies, 1 mg and 5 mg daily delivered similar hair-growth benefits.^[10]Roberts, J.L., Fiedler, V., Imperato-McGinley, J., Whiting, D., Olsen, E., Shupack, J., Stough, D., DeVillez, R., Rietschel, R., Savin, R., Bergfeld, W., Swinehart, J., Funicella, T., Hordinsky, M., … Continue reading

These findings support the pharmacology of finasteride. It reduces DHT systemically and within the scalp. But they do not establish that a baseline serum DHT test predicts an individual’s clinical response.

Why a “good” DHT reduction is not the same as hair regrowth

The chain from medication to visible hair outcome includes several steps:

• Finasteride reduces conversion of testosterone to DHT
• Serum and scalp DHT decline
• Susceptible follicles may experience less androgen-mediated miniaturizing pressure
• Some follicles may stabilize, enlarge, cycle differently, or produce thicker hairs
• Visible change depends on baseline disease duration, follicle viability, age, genetic factors, adherence, dose, and time on treatment

A post-treatment DHT result can show that the drug is exerting an expected hormonal effect, but it cannot tell you with certainty whether hair density, hair caliber, shedding, or progression will improve. 

Baseline serum DHT has not been validated as a “finasteride responder test.” Nor does greater serum DHT suppression automatically mean proportionally greater regrowth. 

Treatment response is better assessed through standardized clinical measures, such as:

• Consistent global photographs taken with the same lighting, angle, hair length, and part placement.
• Trichoscopy or phototrichogram measurements where available
• Hair-caliber and density assessment
• Documented change in shedding and scalp visibility 
• Clinical evaluation of adverse effects and overall safety

For many people, stabilization rather than dramatic regrowth is still a meaningful treatment outcome.

When hormone testing can be useful

Hormone testing can be appropriate when hair loss occurs alongside signs suggesting androgen excess or a broader endocrine condition. In that setting, testing should be used to investigate the clinical picture rather than as an AGA home-screening panel.

In women, clinicians might consider endocrine evaluation when there is:

• Hirsutism, meaning excess terminal hair growth in an androgen-dependent pattern
• Irregular menstrual cycles or ovulatory dysfunction
• Severe or persistent acne
• Infertility
• Central weight gain, acanthosis nigiricans, or other features that may suggest polyendocrine metabolic ovarian syndrome (PMOS – formerly PCOS)
• Rapid onset of androgenic symptoms
• Rapidly progressing or atypical hair loss
• Clinical features suggesting thyroid, adrenal, pituitary, or ovarian disease

Depending on the history and examination, a clinician may order tests such as total testosterone, a calculated or high-quality free-testosterone measurement, SHBG, DHEAS, 17-hydroxyprogesterone, prolactin, thyroid testing, or other targeted investigations.^[11]Elhassan, Y.S., Hawley, J.M., Cussen, L., Abbara, A., Clarke, S.A., Kempegowda, P., Dhillon-Smith, R.K., Thadani, P., Busby, M., Owusu-Darkwah, L., Marrington, R., Duncan, W.C., Semple, R.K., … Continue reading,^[12]Vujovic, A., Del Marmol, V. (2014). The Female Pattern Hair Loss: Review of Etiopathogenesis and Diagnosis. Biomed Research International. 767628. Available at: https://doi.org/10.1155/2014/767628 DHT is not generally recommended as the central test in a biochemical work-up for androgen excess.

The practical question is usually not “Is my DHT high enough to cause AGA?” It is, “Do my symptoms and examination suggest an endocrine disorder that needs investigation alongside my hair loss?”

How AGA is actually diagnosed

AGA is primarily a clinical diagnosis. A dermatologist or hair-loss clinician evaluates the pattern of hair loss and looks for evidence of follicular miniaturization.

Assessment typically involves:^[13]Kuczara, A., Waskiel-Burnat, A., Rakowska, A., Olsewska, M., Rudnicka, L. (2024). Trichoscopy of Androgenetic Alopecia: A Systematic Review. Journal of Clinical Medicine. 13(7). 1962. Available at: … Continue reading 

• History: When the shedding or thinning began, how it has progressed, family history, medications, illness, nutritional risks, hormonal symptoms, and prior treatments. 

• Distribution: Recession at the temples, frontal or vertex thinning in many men, or central thinning and widening of the midline part in many women.

• Hair caliber variation: The coexistence of thick terminal hairs and finer, shorter miniaturized hairs in affected scalp areas.

• Trichoscopy: Magnified scalp examination that can reveal hair-shaft diameter diversity, increased vellus-like hairs, and other features of miniaturization.

• Differential diagnosis: Consideration of telogen effluvium, alopecia areata, traction alopecia, inflammatory or scarring alopecias, nutritional deficiency, medication-related loss, and other causes where clinically indicated.

• Biopsy: Usually reserved for uncertain, atypical, or potentially scarring cases rather than routine diagnosis.

Hair shaft diameter variability is one of the most useful trichoscopic features of AGA. Reviews identify hair-diameter diversity, vellus hairs, and the peripilar sign among valuable diagnostic indicators. A diagnostic guideline also recommends comparing density and hair caliber across scalp areas and notes that biopsy is generally reserved for cases of uncertainty or when alternative diagnoses, such as scarring alopecia or diffuse alopecia areata, must be considered. 

The key diagnostic evidence is therefore found in the scalp, rather than in a single DHT concentration.

Final Thoughts

A serum DHT test is a biological measurement that can be relevant in certain endocrine contexts, and can also reflect the systemic hormonal effects of drugs like finasteride. But it does not measure follicular DHT exposure, androgen receptor sensitivity, local enzyme activity, genetic susceptibility, or the degree of scalp hair miniaturization. 

Normal DHT cannot rule out AGA. High DHT cannot establish that AGA is the cause of hair loss. The most useful diagnostic question is “what is happening to the follicles on my scalp?” For suspected AGA, diagnosis and treatment monitoring should prioritize clinical pattern, standardized photographs, hair-caliber changes, trichoscopy where available, exclusion of competing diagnoses, and medication safety.

For decades, the medical treatment of androgenic alopecia (AGA), or male and female pattern hair loss, has largely centered on two strategies:

• Stimulating follicles with minoxidil 
• Reducing the activity of dihydrotestosterone (DHT) with drugs such as finasteride

Those approaches can help many people, but neither works for everyone. It’s also clear that some miniaturized follicles stop producing cosmetically meaningful hairs, even when androgen signaling is reduced. This has created demand for treatments that target other aspects of the hair-loss process: inflammation, fibrosis, growth-factor signaling, stem-cell activity, and hair-cycle regulation.

ABS-201 represents one of the more unusual attempts. Rather than targeting DHT, 5-alpha-reductase, or the androgen receptor directly, ABS-201 is designed to block the prolactin receptor (PRLR). ABS-201 is a monoclonal antibody. It is a laboratory-made protein designed to bind to a specific target (in this case, the prolactin receptor). By binding to that receptor, ABS-201 aims to prevent prolactin from activating it.

That target may initially sound surprising. Prolactin is best known for its role in lactation, but it is also active in the skin and hair follicles. Laboratory research suggests that prolactin signaling can promote the transition of follicles into catagen, the regressive phase of the hair cycle, and can inhibit hair shaft growth under experimental conditions.^[1]Jin, S-E., Kim, J., Sung, J-H. (2024). Recent approaches of antibody therapeutics in androgenetic alopecia. Frontiers in Pharmacology. 15(1434961). Available at: … Continue reading

The question is whether blocking this pathway can meaningfully reverse hair follicle miniaturization in humans with AGA. At present, the answer is not known. ABS-201 is in an early Phase 1/2a trial, and the publicly available human data so far are primarily preliminary safety and pharmacokinetic data rather than proof of hair regrowth.^[2]absci. (no date). Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR). Absci. Available at: … Continue reading

To understand the rationale and its limitations, we interviewed Absci’s founder (we made a video you can watch here). He shared the company’s interpretation of earlier anti-PRLR research, preliminary experiments using human scalp tissue, and its expectations for the ongoing ABS-201 trial. In this article, we examine those claims alongside the published evidence and the questions that remain unanswered.

The basic idea: block the receptor, not the hormone

Hormones and signaling proteins influence cells by binding to receptors, molecular “docking stations”, on or within cells. When prolactin binds the prolactin receptor, it activates downstream signaling pathways that can alter cell behavior.

ABS-201 is a monoclonal antibody designed to bind the prolactin receptor (PRLR). In principle, an antibody that occupies the receptor and prevents productive prolactin signaling could dampen prolactin-related activity in tissues that express PRLR, including the hair follicle. Human scalp follicles have been shown to express both prolactin and PRLR, supporting the idea that local prolactin signaling may influence follicle biology.^[3]Foitzik, K., Krause, K., Conrad, F., Nakamura, M., Funk, W., Paus, R. (2006). Human Scalp Hair Follicles Are Both a Target and a Source of Prolactin, which Serves as an Autocrine and/or Paracrine … Continue reading 

ABS-201 is not designed to lower circulating prolactin concentrations in the way dopamine agonists can be used to treat certain forms of hyperprolactinemia. Instead, it is intended to interfere with signaling at the prolactin receptor itself.

That makes the proposed hair-loss mechanism distinct from that of finasteride or dutasteride. Those drugs reduce conversion of testosterone to DHT, thereby addressing an established driver of follicular miniaturization in genetically susceptible scalp regions. ABS-201 instead aims to alter a separate signaling pathway that may affect hair-cycle regulation. In cultured human scalp follicles, prolactin exposure has been associated with reduced hair shaft elongation, reduced keratinocyte proliferation, increased apoptosis, and earlier entry into catagen, the regressive phase of the hair cycle.^[4]Foitzik, K., Krause, K., Conrad, F., Nakamura, M., Funk, W., Paus, R. (2006). Human Scalp Hair Follicles Are Both a Target and a Source of Prolactin, which Serves as an Autocrine and/or Paracrine … Continue reading,^[5]Grymowicz, M., Rudnicka, E., Podfigurna, A., Napierala, P., Smolarczyk, R., Smolarczyk, K., Meczekalski, B. (2020). Hormonal Effects on Hair Follicles. International Journal of Molecular Sciences. … Continue reading 

It is important not to overstate this distinction. AGA remains, by definition and by extensive evidence, an androgen-responsive condition. A prolactin-receptor antibody should not yet be framed as proving that prolactin is “upstream of DHT”, or as replacing the central role of androgen signaling in pattern hair loss. That proposed hierarchy remains a hypothesis, not a settled conclusion.

Absci’s founder did not reject the role of androgens when we spoke. Instead, he proposed that prolactin might interact with androgen signaling in the hair follicle. 

“Androgens are a part of it, but from what we’re seeing, prolactin actually sits potentially upstream of the androgen receptor.”

In other words, Absci thinks prolactin may influence how hair follicles respond to androgens. The company says its laboratory findings support that possibility, but it has not been shown that prolactin drives androgen signaling in people with AGA, or that blocking prolactin could replace the need to target DHT.

Why prolactin is relevant to hair follicles

The case for studying PRLR in hair loss did not begin with ABS-201. Human scalp follicles can both express prolactin and respond to it, meaning that the follicle may be both a source and a target of local prolactin signaling. In organ-culture experiments, prolactin and its receptor were more strongly expressed during catagen, the phase in which a follicle regresses after active growth.^[6]Jin, S-E., Kim, J., Sung, J-H. (2024). Recent approaches of antibody therapeutics in androgenetic alopecia. Frontiers in Pharmacology. 15(1434961). Available at: … Continue reading

In the same line of research, exposure of isolated human scalp follicles to relatively high concentrations of prolactin reduced hair-shaft elongation, reduced proliferation of hair-matrix keratinocytes, increased markers of apoptosis (programmed cell death), and promoted premature entry into catagen.^[7]Foitzik, K., Krause, K., Conrad, F., Nakamura, M., Funk, W., Paus, R. (2006). Human scalp hair follicles are both a target and a source of prolactin, which serves as an autocrine and/or paracrine … Continue reading 

That does not mean that every person with AGA has elevated serum prolactin, nor does it establish that prolactin is the dominant cause of pattern hair loss. In fact, clinical literature on hyperprolactinemia and diffuse hair loss is mixed; moderately elevated circulating prolactin does not appear to be a universal explanation for hair shedding.^[8]Lutz, G. (2012). Hair loss and hyperprolactinemia in women. Dermato Endocrinology. 4(1). 65-71. Available at: https://doi.org/10.4161/derm.19472

One argument for investigating PRLR in AGA concerns local rather than systemic signaling. A person may not need dramatically abnormal blood prolactin for local PRLR signaling to influence hair follicle biology.

In our interview, Absci’s founder emphasized the distinction between prolactin circulating in the blood and prolactin produced locally in tissues. As he put it:

“You could have normal systemic levels of prolactin that come from the pituitary, but an increased level of prolactin within the scalp”

This could help explain why a normal blood test would not necessarily rule out local PRLR signaling. It does not, however, demonstrate that excess local prolactin causes AGA or identify which patients might benefit from blocking its receptor.

In a small ex vivo study using scalp tissue from two healthy women, estrogen increased prolactin and prolactin receptor expression in selected regions of the skin and hair follicles. The researchers also found increased expression of both genes in cultured outer root sheath cells. But the study did not test whether these changes affected hair growth or whether blocking PRLR would alter estrogen’s effects. It therefore complicates a simple “more PRLR means more hair loss” explanation without telling us whether a PRLR-blocking antibody would help or harm people with AGA.^[9]Langan, E.A., Ramot, Y., Hanning, A., et al. (2010). Thyrotropin-releasing hormone and oestrogen differentially regulate prolactin and prolactin receptor expression in female human skin and hair … Continue reading

The animal data that sparked interest

Much of the excitement around prolactin-receptor blockade in hair loss stems from preclinical work on a related anti-PRLR antibody, originally developed within Bayer’s research program and subsequently licensed for development as HMI-115. The treatment has been reported to produce unusually striking regrowth in stump-tailed macaques, a primate species often used in AGA research because some animals develop patterned scalp hair loss that resembles aspects of human male- and female-pattern hair loss.^[10]Ekkehard, M., Joachim, S., Jorn, K., Christiane, O. (2017). Prolactin receptor antibody for male and female pattern hair loss. World Intellectual Property Organization. Available at: … Continue reading Reports describe an increase in terminal hair growth and persistent changes after treatment withdrawal. 

The macaque findings are genuinely intriguing for two reasons. First, primate data are more relevant to human hair biology than standard mouse studies. Mouse hair follicles cycle in synchronized waves across large areas of skin; human scalp follicles cycle asynchronously. A drug that generates a dramatic result in mice can therefore fail to translate to human pattern hair loss. 

Second, the reported durability of the macaque response, if confirmed in fully published data, would be particularly notable. AGA is chronic and progressive, and most established treatments require continued use to preserve their benefits. A therapy that triggered durable restoration of follicular growth capacity after dosing stopped would challenge the usual treatment model. 

However, animal findings, no matter how dramatic, are not clinical proof. Differences in species, dosing, disease biology, hair-cycle timing, study design, and measurement methods can all affect translation. Until robust human trial data are available, the primate studies should be treated as a reason for cautious interest, not a prediction of equivalent results in people.

From HMI-115 to ABS-201

HMI-115 is another anti-PRLR monoclonal antibody currently being developed by Hope Medicine. In a small open-label Phase 1b study, the company reported that 12 male participants experienced a mean increase of 14 non-vellus hairs per cm2 after 24 weeks of treatment.^[11]Hope Medicine. (2024). Positive Outcome from a Phase Ib Study in Australia Treating Patients with Androgenic Alopecia. Hope Medicine. Available at: https://www.hopemedinc.com/company-release-37 … Continue reading

The result was encouraging enough to justify further research, but it cannot establish efficacy on its own. The study was small, open-label, and lacked a placebo control. Hair counts can be affected by photography, hair-clipping technique, image analysis, the definition of “non-vellus” hair, natural cycling variation, and regression toward the mean. Without randomization and a placebo comparison, it is impossible to know how much of the observed change was due to the drug.

HMI-115 nonetheless helped validate PRLR as a clinically testable hair-loss target and advanced to a larger randomized Phase 2 evaluation.

ABS-201 targets the same receptor, but is a different antibody developed by Absci, not a new name for HMI-115. The company says it used generative AI and experimental validation to engineer ABS-201 with properties intended to support infrequent dosing. In its interim Phase 1 update, Absci estimated a half-life of at least 65 days following a single intravenous dose, suggesting the possibility of two or three injections over six months if future studies confirm the pharmacology and clinical benefit.^[12]Absci. (2026).  Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR). Absci. Available at: … Continue reading

That is a potentially attractive practical profile. Pattern hair loss treatments often struggle with adherence: topical therapies can be burdensome, and daily tablets may be unacceptable to some patients. An intermittently administered antibody could be convenient, but convenience only matters if the therapy ultimately proves safe, effective, and appropriately priced.

Absci’s central argument is pharmacological rather than simply practical. Its founder told us the company modeled receptor occupancy (the proportion of prolactin receptors bound by the drug at a given dose and time point) using publicly disclosed pharmacokinetic data for HMI-115 and estimated that occupancy in the earlier human study rose to roughly 70-73% before fluctuating. 

Absci contrasts this with its prediction that ABS-201 can maintain PRLR occupancy above 90% for approximately six months. It proposes that insufficiently sustained blockage could help explain why HMI-115’s early human hair-count findings were more modest than the macaque results. These are company-generated estimates and an explanation to be tested, not proof that HMI-115 participants were underdosed.

Why receptor occupancy may matter

A central part of Absci’s rationale for ABS-201 is receptor occupancy. 

In our interview, Absci described a hypothesis that anti-PRLR treatment may need to maintain very high receptor occupancy, reportedly above 90%, to reduce prolactin signaling sufficiently to produce meaningful hair-growth effects. The company has publicly described its ABS-201 dose selection as targeting predicted PRLR occupancy above 90% and has contrasted this with the lower estimated occupancy for HMI-115.^[13]Absci. (no date). ABS-201™ for Androgenetic Alopecia. Absci. Available at: https://www.absci.com/abs-201-case-study/ (Accessed: September 2026) The founder’s concern is that partial blockade might leave substantial signaling intact.

“Even if you’re at 60, 70, even 80% receptor occupancy, you could still have full activity of the actual pathway until you block it substantially.” 

Whether this degree of signaling reserve operates in human AGA-affected follicles, and whether 90% is the relevant threshold, remains to be established.

The general pharmacology is plausible. Drug binding and biological effect do not always move in a simple, one-to-one fashion. Some biological systems have what pharmacologists call receptor reserve or signaling reserve, meaning that activating a fraction of the available receptors can still generate a substantial downstream response because cellular signaling pathways amplify the original signal.^[14]Berg, K.A., Clarke, W.P. (2018). Making Sense of Pharmacology: Inverse Agonism and Functional Selectivity. International Journal of Neuropsychopharmacology. 21(10). 962-977. Available at: … Continue reading  In such a system, partially blocking a receptor may reduce signaling without being sufficient to produce a clinically visible effect.

Think of it like a faucet rather than a light switch. Turning the tap halfway off reduces water flow, but it may still leave enough water running to fill a container. If prolactin-receptor signaling in a miniaturizing follicle has a similar degree of biological reserve, a treatment may need to block a large number of receptors before downstream signals involved in follicle regression are meaningfully reduced.

However, the key uncertainty is the number itself. Public academic literature does not currently establish that human scalp follicles require 90% PRLR occupancy for hair regrowth, nor does it establish that 60-70% occupancy is inadequate. The proposed threshold appears to be a company-specific, model-informed development assumption rather than a clinically validated cutoff for AGA.

This also means the suggestion that earlier HMI-115 studies were “underdosed” should be treated with caution. It is one possible explanation for the modest, uncontrolled Phase 1b signal reported with HMI-115, but it is not a proven conclusion. Small sample size, absence of a placebo group, dose exposure, treatment duration, participant selection, hair-counting methodology, and intrinsic differences between antibodies could all contribute to the results.

For ABS-201, the most informative future analysis would connect four pieces of evidence:

• Drug exposure over time
• Estimated or measured PRLR engagement
• Evidence that downstream PRLR signaling is being altered
• Placebo-adjusted changes in hair count, width, and standardized photography

The stem cell link

If high and sustained PRLR blockade does matter, the next question is which biological process it might alter within the follicle. Absci’s leading explanation centers on follicular stem and progenitor cells.

Hair follicles contain epithelial stem-cell populations, including cells in the bulge region. During normal cycling, stem cells and their progeny participate in rebuilding the lower follicle and initiating a new anagen (growth) phase. In AGA, researchers have suggested that stem cells may be retained while their conversion into downstream progenitor populations becomes impaired. In other words, the follicle may retain some regenerative “hardware” but struggle to activate it effectively.

This concept has scientific support. Experimental studies have linked androgen signaling and altered Wnt/beta catenin signaling to impaired hair-follicle stem cell differentiation in AGA.^[15]Kretzschmar, K., Cottle, D.L., Schweiger, P.J., Watt, F.M. (2015). The Androgen Receptor Antagonizes Wnt/β-Catenin Signaling in Epidermal Stem Cells. Journal of Investigative Dermatology. 135(11). … Continue reading

Absci’s proposed model is that PRLR blockade may help sustain anagen, reduce catagen-associated signaling, and restore a more growth-permissive environment for follicular stem and progenitor cells. In our interview, Absci presented preliminary experiments using cultured human scalp tissue. In samples from three men with AGA, the company compared untreated tissue with tissue exposed to prolactin, ABS-201, or both. It reported greater hair-shaft growth and more follicles remaining in the growth phase after exposure to ABS-201 over a three-day period. Added prolactin had the opposite effect, while the combined treatment appeared to counteract it. 

Absci also described ex vivo findings involving K15-positive stem-cell markers, CD34-positive progenitor-cell markers, and collagen XVII. The company interprets these observations as suggesting that PRLR blockade could protect or improve the follicular stem cell environment. But marker changes over several days cannot establish that an injection restores that environment, reverses miniaturization, or produces durable regrowth in a patient.

We asked whether Absci had tested non-balding scalp tissue alongside the AGA-affected samples. Its founder confirmed that it had not. 

Without that comparator, these experiments cannot tell us whether the response is distinctive to balding follicles.

Terms such as “stem-cell activation,” “follicle regeneration,” and “reversal of miniaturization” can sound more definitive than the current evidence warrants. Ex vivo human scalp experiments are useful because they use human tissue, but they do not replicate the full biology of chronic pattern hair loss in a living person. They cannot, on their own, establish that a treatment will produce durable cosmetic improvement in a large, diverse patient population.

What the ABS-201 trial is testing

The ongoing HEADLINE study, registered as NCT07317544, is a randomized, double-blind, placebo-controlled Phase 1/2a trial of ABS-201 in healthy adults with and without AGA. The study is designed to enroll up to 227 participants across single- and multiple-ascending-dose cohorts.^[16]National Library of Medicine. (2026). Study of ABS-201 Evaluating Single and Multiple Ascending Doses in Adults With and Without Androgenetic Alopecia. National Library of Medicine. Available at: … Continue reading   

The early single-ascending-dose portion tested intravenous doses of 150 mg, 450 mg, 900 mg, and 1,800 mg. In Absci’s June 2026 update, 32 healthy adults had been enrolled across four cohorts. The company reported no serious adverse events at the data cutoff. Treatment-related adverse events were described as mild, with headache the most commonly reported event overall.

These findings are preliminary and blinded, which means they cannot yet tell us whether ABS-201 is more effective than, or even meaningfully different from, placebo for hair regrowth. 

The multiple-ascending dose component is evaluating subcutaneous doses of 300 mg, 600 mg, and 1,200 mg in participants with AGA. The trial includes the following objective endpoints:

• Target area hair count
• Target area hair width
• Hair darkness or pigmentation assessed with central image analysis
• Participant self-assessment
• Investigator global assessment
• Pharmacokinetic, pharmacodynamic, and immunogenicity measures

These measures matter because hair count alone does not tell the complete cosmetic story. A person may grow more hair, but if that hair remains very thin or lightly pigmented, the visual benefit may be limited. Conversely, increases in shaft diameter and pigmentation can materially contribute to perceived density.

Absci plans to report an exploratory 13-week readout in December 2026. In our recent interview, its founder described this as a “directional” assessment rather than a definitive efficacy test. He said the company had not set a firm hair-count target for that readout, but hoped it would show a path toward an increase of more than 30 hairs/cm2 at 26 weeks. Participants will also be followed for a year after treatment to assess how any changes evolve over time. 

Trial-design questions worth watching

The presence of placebo control, blinding, objective imaging, and multiple hair endpoints makes the HEADLINE trial substantially more informative than an uncontrolled before-and-after study. Still, early trials can be difficult to interpret, especially in the context of hair loss.

One issue is prior treatment washout. The trial excludes topical minoxidil use within 3 months of screening; oral minoxidil and other stimulators within 6 months; finasteride within 6 months; and dutasteride within 12 months. 

These washout periods are not inherently inappropriate. They are common attempts to reduce confounding. But they leave interpretive questions. People who discontinue minoxidil may experience delayed shedding and subsequent changes in the hair cycle. People stopping anti-androgen therapy may also continue to change for months after discontinuation. If these dynamics are unevenly distributed between the treatment and placebo groups, particularly in a modestly sized trial, they can complicate hair-count results.

A second issue is the definition of hairs counted by imaging systems. In AGA trials, the threshold chosen to classify a hair as non-vellus or terminal can materially influence apparent efficacy. Readers should look not only for the headline change in hairs/cm2 but also for the pre-specified diameter threshold, baseline hair characteristics, changes in width, standardized photography methods, and placebo-adjusted results.

A third issue is the ascertainment of safety. PRLR is not a scalp-exclusive target, and systematic anti-PRLR therapy may affect tissues beyond the hair follicle. A credible program needs more than a low count of voluntarily reported adverse events. It should transparently describe how adverse events were elicited, categorized, adjudicated, and followed up, as well as how laboratory and hormonal parameters were monitored and how pregnancy-related risks were managed.

During our interview, we asked specifically how adverse events would be elicited and whether outcomes relevant to reproductive health would be actively assessed. The founder discussed the rigor of the clinical team and the blinded, placebo-controlled design, but did not provide details on adverse-event collection methods or a list of reproductive endpoints in his answer. That does not imply that the trial lacks appropriate monitoring, but it does mean that we should be on the lookout for them in the protocol and, when available, in the results.

We also asked how Absci intends to present its interim results, given how difficult hair-loss trial announcements can be to interpret when they emphasize selective subgroups or changes from baseline without a clear placebo comparison. The founder responded:

“I can promise you that we will have a non-controversial data cut. It’s going to be clear-cut data that will be easy to interpret.” 

That is a useful commitment, but its value will depend on the actual release of interpretable treatment-versus-placebo results, endpoint definitions, sample sizes, missing-data information, and safety findings.

What could success look like for Absci?

The best outcome for ABS-201 would not simply be “more hairs than baseline”. A convincing Phase 2 signal would include several converging features:

• A clear placebo-adjusted improvement in target area hair count
• Supporting improvements in hair width and clinically meaningful photography
• Consistent benefit across relevant subgroups, including male and female participants where adequately powered
• A plausible dose-response relationship
• Evidence of durable benefit even after stopping
• A safety profile that remains acceptable at doses needed to produce efficacy 
• Reporting of missing data, withdrawals, prior-treatment exposure, adverse events, and predefined analysis methods.

Final Thoughts

ABS-201 is one of the more scientifically interesting drugs in the current AGA pipeline because it targets a pathway outside the conventional DHT/minoxidil framework. Research in human hair follicles, mice, and primates supports the idea that PRLR signaling can influence hair cycling and regression.

But plausibility is not the same as proof. The early ABS-201 safety data are reassuring, in a limited sense, in that a small, blinded, single-dose study had not identified any serious safety signals as of the company’s June 2026 update. However, they do not yet demonstrate that the drug regrows hair.

Our interview made Absci’s hypothesis more specific: the company believes that sustained, high-level PRLR blockade could affect hair cycling and the follicular stem-cell environment in ways earlier anti-PRLR treatment may not have achieved. It also clarified what we still cannot know, from the absence of non-balding comparator tissue in the ex vivo experiments to the unvalidated human receptor-occupancy threshold. The placebo-controlled ABS-201 results will be far more informative than either a compelling mechanism or striking macaque photographs. Until then, ABS-201 remains a promising research question, not a proven hair-loss treatment.

Finding the right hair loss treatment can feel overwhelming, and expert guidance is essential to identify the best formula for your needs. The PhD-led team at Perfect Hair Health leverages emerging research and close collaborations with top innovators to provide readers with the most accurate and actionable reviews of hair restoration offerings. Topical finasteride is one of the most sought-after treatments on the market, boasting clinical support, targeted results, and easy application. 

This comprehensive guide to the top-rated topical finasteride products is based on extensive research, expert recommendations, and the latest consumer feedback. Whether you’re just beginning your hair health journey or searching for better hair loss solutions, this article provides valuable information on safe and effective treatment options. Our recent partnership with Ulo enhances this guide with privileged insights on clinical findings and state-of-the-art protocols.  

Read on for specialized guidance, insightful reviews, and proven recommendations of topical finasteride preparations from today’s leading brands. 

Topical Finasteride From our partners at Ulo

Get Personalized Topical Finasteride

Compounded finasteride for DHT control targeted at the follicle. Get prescribed 100% online. Choose a multi-month plan and get up to 30% plus a free gift bundle.

Free full-size gifts with 3-month+ plans Prescribed online, shipped to your door

Claim up to 30% off + Free Gifts

Topical finasterideTargets DHT at the scalp

*Only available in the U.S. Prescription requires an online medical consultation at no extra cost. Off-label products are not endorsed by the FDA. Free gifts included with select multi-month plans while supplies last. Ulo is a partner of Perfect Hair Health; we may earn a commission on purchases.

Quick Look: 5 Best Topical Finasteride Products

Here’s a side-by-side comparison of our top recommended topical finasteride treatments. Read on for more details on each of these excellent products. 

Product	Price	Finasteride %	Customization	Application
Ulo	$64+/month	0.005% – 0.2%	High	Solution
Strut Health	$59	0.1-0.25%	Medium	Solution/Gel
Happy Head	$59-99/month	0.3%	Medium	Liposomal Gel
Roman	$50/month	0.3%	Low	Spray
Hims	$35+/month	0.3%	Low	Spray

Topical Finasteride: What It Is & Why It’s Better 

First, we will briefly explore the science behind topical finasteride, including its mechanism of action in treating hair loss and the advantages of topical formulations. 

What Is Topical Finasteride?

Topical finasteride is a clinically proven treatment for androgenic alopecia (AGA), a type of hair loss that affects more than 50% of men by the age of 50.^[1]Jang, W.S., Son, I.P., Yeo, I.K., Park, K.Y., Li, K., Kim, B.J., Seo, S.J., Kim, M.N., Hong, C.K. (2013). The Annual Changes of Clinical Manifestation of Androgenetic Alopecia Clinic in Korean Males … Continue reading AGA is caused by dihydrotestosterone (DHT), a testosterone-derived hormone that damages hair follicles, causing them to shrink and produce thinner hair. Finasteride reduces DHT levels by inhibiting the enzyme 5-alpha-reductase, protecting the hair follicles to stop hair loss and encourage new growth.^[2]Duran, R, C-D., Martinez-Ledesma, E., Garcia-Garcia, M., Gauzin, D.B., Sarro-Ramirez, A., Gonzalez-Carillo, C., Rodriguez-Sardin, D., Fuentes, A., Cardenas-Lopez. (2024). The Biology and Genomics of … Continue reading 

While orally administered finasteride has been in use since 1997, topical formulations are a relatively new development. When applied to the scalp, finasteride provides targeted treatment with a reduced risk of systemic side effects associated with oral preparations. Topical finasteride is shown to reduce DHT levels on the scalp for greater hair count and density with comparable effectiveness to oral finasteride.^[3]Lee, S.W, Juhasz, M., Mobasher, P., Ekelem, C., Mesinkovska, N.A. (2018).  A Systematic Review of Topical Finasteride in the Treatment of Androgenetic Alopecia in Men and Women. Journal of Drugs in … Continue reading

Numerous studies confirm that topical finasteride slows and reverses hair loss by boosting hair thickness, density, and growth cycles. These results are enhanced when combined with other topical treatments like minoxidil. Due to minimal systemic absorption and attendant side effects, topical formulas are considered a safer choice for prolonged use. Overall, topical finasteride is prized among clinicians and patients as a safe, effective, and convenient solution to pattern hair loss.^[4]Lee, S.W, Juhasz, M., Mobasher, P., Ekelem, C., Mesinkovska, N.A. (2018).  A Systematic Review of Topical Finasteride in the Treatment of Androgenetic Alopecia in Men and Women. Journal of Drugs in … Continue reading,^[5]Piraccini, B.M., Blume-Peytavi, U., Scarci, F., Jansat, J.M., Falques, M., Otero, R., Tamarit, M.L., Galvan, J., Tebbs, V., Massana, E. (2021). Efficacy and safety of topical finasteride spray … Continue reading

Why Choose Topical Over Oral?

Because topical finasteride is applied directly to the scalp, it offers localized therapy and avoids the side effects associated with oral finasteride’s systemic exposure. Here is a brief overview of this and other primary advantages of topical formulas:

• Better Safety Profile: Oral finasteride is absorbed into the bloodstream and can have global side effects like sexual dysfunction, hormone disruption, and mood swings. In contrast, topical formulas target the scalp directly and minimally affect plasma levels. Topicals are consistently shown to have fewer systemic side effects. If present, side effects tend to be mild and temporary, such as scalp irritation.

• Individualized Dosing: While the oral finasteride dose is a standardized 1 mg, topical formulas enable tailored dosages and greater precision through potency titration. This is especially important given the dose-dependent outcomes of finasteride treatment. The finasteride concentration in topicals can range from a maintenance dose of 0.005% to a more aggressive protocol of 2.5%.

• Greater Customization: Topical formulas often combine other proven treatments, such as tretinoin, minoxidil, and caffeine. Studies demonstrate that finasteride-minoxidil combinations deliver superior results compared to single-agent treatments. Plus, the range of available delivery methods (e.g., solutions, sprays, gels) can improve convenience, satisfaction, and adherence. 

• Long-Term Use: With a better safety profile and lower systemic impact, topical finasteride is more suitable for prolonged use, which is often necessary to maintain the benefits of hair loss treatment. 

In short, research data indicate that topical finasteride yields comparable results with a more favorable safety profile than oral finasteride, making it a better option for long-term treatment. Further benefits of topical formulations include greater dose precision, synergistic adjuvants like minoxidil, and a range of delivery methods to support compliance.^[6]Lee, S.W, Juhasz, M., Mobasher, P., Ekelem, C., Mesinkovska, N.A. (2018).  A Systematic Review of Topical Finasteride in the Treatment of Androgenetic Alopecia in Men and Women. Journal of Drugs in … Continue reading,^[7]Piraccini, B.M., Blume-Peytavi, U., Scarci, F., Jansat, J.M., Falques, M., Otero, R., Tamarit, M.L., Galvan, J., Tebbs, V., Massana, E. (2021). Efficacy and safety of topical finasteride spray … Continue reading

Evaluation Criteria: What Makes the Best?

When selecting the best topical finasteride products, we adhered to the following evaluation criteria, which are thoroughly supported by clinical findings and customer feedback.^[8]Piraccini, B.M., Blume-Peytavi, U., Scarci, F., Jansat, J.M., Falques, M., Otero, R., Tamarit, M.L., Galvan, J., Tebbs, V., Massana, E. (2021). Efficacy and safety of topical finasteride spray … Continue reading,^[9]Suchonwanit, P., Iamsumang, W., Leerunyakul, K. (2020). Topical finasteride for the treatment of male androgenetic alopecia and female pattern hair loss: a review of the current literature. Journal … Continue reading

✓ Effectiveness

We assessed scientific data, DHT decrease rates, and real-world testimonies of hair count increases. The top products deliver measurable results in 3-6 months with continuous improvements in hair density throughout the first year and beyond.

✓ Safety

Because finasteride is a prescription-only treatment, we verified that providers adhere to all safety regulations, including proper prescribing and monitoring protocols. Leading suppliers also provide full ingredient transparency to help assess potential side effects.

✓ Customization

Premium brands offer treatment customization options tailored to patients’ needs and preferences, maximizing outcomes beyond those achieved with traditional, standardized approaches. These include concentration adjustments, synergistic add-on ingredients such as minoxidil, and various delivery methods. 

✓ Convenience

Successful treatment outcomes depend on long-term compliance and a positive user experience. Factors such as ease of application, clear instructions, manageable dose frequency, and responsive support help ensure uninterrupted treatment.

✓ Value

The best providers balance superior quality with transparent and affordable pricing models that cover doctor consultations, prescriptions, and follow-up care. These are especially important concerns in the telehealth landscape, where many subpar platforms employ opaque billing practices to stack on hidden fees and unexpected charges.  

How to Choose the Right Product for Your Needs 

When choosing the product that best meets your hair loss treatment needs, consider the extent of your hair loss and treatment aims, such as basic upkeep or intensive restoration. Also account for your preferred delivery method (i.e., gel, solution, or spray), desired add-ons, medical support requirements, and budget. 

Reviewing the Best Topical Finasteride Products

With the above key factors in mind, let’s turn now to our top recommended options that each offer unique advantages sure to satisfy. 

#1: Ulo Finasteride + Minoxidil Plus Rx

Pros:	Cons:
✓ Clinically-proven combination therapy	✗ Prescription products are only available in the USA
✓ True personalization with custom concentrations and medical consultations
✓ PhD-scientist formulated
✓ Ongoing medical monitoring and a user-friendly platform
✓ Quality-tested ingredients free of irritants

Ulo’s combination formula of high-strength finasteride with prescription-grade minoxidil takes the top spot, reflecting the platform’s commitment to providing safe, scientifically proven hair loss treatments tailored to meet individual needs. Every Ulo product is developed by a team of PhD scientists who deliver innovative interventions in hair restoration.

Their advanced finasteride and minoxidil solution blocks DHT and stimulates new growth in a targeted dual treatment that is proven superior to monotherapies in clinical trials. Ulo’s finasteride formulas are uniquely customizable and available in different concentrations (0.005% for maintenance and 0.2% for stronger protocols), with a series of synergistic add-ons like caffeine to boost circulation, tretinoin for better absorption, and melatonin for antioxidant protection.

The deluxe treatment begins at $64 per month, which includes an onboarding medical consultation to assess each client’s needs, a physician-crafted treatment plan, and continued dermatologist oversight. All Ulo products are strictly sourced from pharmacies that adhere to safety and quality regulations. The clinic’s licensed dermatologists provide customized treatment regimens with free home prescription deliveries and ongoing support.

Bottom Line: Ulo’s individualized hybrid treatment is the ultimate in advanced hair restoration technology. With precise formulation and continuous medical supervision, this tailored solution delivers exceptional results for a low monthly subscription fee starting at $64. Ulo’s guiding dedication to safety and efficacy makes this full-service platform the best option for those who are serious about combating hair loss.

#2 Strut Finasteride Hair Loss Formula

Pros:	Cons:
✓ Custom-compounded topical finasteride formulas (with optional add-ons)	✗ Not available internationally, and currently cannot ship to Arkansas
✓ Online consult and prescriptions from U.S. board-certified physicians	✗ Auto-refills by default; some reviews report difficulty canceling and customer service gaps
✓ Multiple formulation options (gel or solution; adjustable finasteride strength)
✓ Convenient telehealth model with free, discreet shipping in most U.S. states.

Strut Health is a U.S.-based telehealth provider offering customized topical finasteride for AGA. After an online questionnaire and photo-based evaluation, a board-certified clinician designs a compounded formula that may contain finasteride alone or in combination with other actives like minoxidil, tretinoin, fluocinolone, or biotin. The company’s finasteride hair-loss formulas typically use 0.1-0.25% topical finasteride, with optional minoxidil concentrations up to 7.5% and tretinoin in a gel or solution base, giving flexibility to tailor potency and tolerability.

Our in-house lab testing showed that Strut Health’s finasteride product contained the correct concentrations of ingredients (finasteride, minoxidil, and tretinoin), indicating that they can be trusted to provide a quality product.

However, there are trade-offs. Strut does not accept insurance, and pricing for topical finasteride (often around the mid-range of the telehealth market) may add up for long-term use. The company currently ships to nearly all U.S. states but cannot ship to Arkansas, and there is no international service. Public reviews highlight convenience for many users but also recurring concerns about auto-refills and difficulty canceling, as well as frustration with customer support responsiveness and refund policies. 

Bottom Line: Strut Health’s topical finasteride offers a flexible, telehealth-delivered alternative for patients who want DHT-targeted treatment without taking a daily pill, with customizable formulas that can include or exclude minoxidil and other actives. Its convenience, physician oversight, and compounding flexibility are strong advantages, but subscription-based pricing and mixed customer service reviews may give more budget-conscious patients pause.

#3 Happy Head Topical Super Solution: Finasteride, Minoxidil & Liposomal

Pros:	Cons:
✓ Medical oversight by board-certified dermatologists	✗ Price rises from $59 to $99 after the first six months
✓ Higher concentrations of 0.3% finasteride + 8% minoxidil	✗ Higher concentrations may increase side effect risk
✓ Made with a delayed-release liposomal base	✗ Gel formula cannot be customized
✓ User-friendly platform and follow-up care	✗ May irritate sensitive skin
✓ Affiliate programs available	✗ Possible shipping and customer service concerns

Our next selection is from Happy Head, known for unique formulations and dermatologist oversight. The Topical Super Solution features a more concentrated combination of 0.3% finasteride with 8% minoxidil for targeted hair restoration. 

Available in a mess-free pump dispenser, this gel is made with the brand’s proprietary liposomal delivery base that boosts scalp penetration with timed medication release and once-daily application. This helps minimize bloodstream absorption, reducing potential side effects, and is a notable safety feature for higher finasteride doses. That said, some ingredients in the carrier base should not be used on sensitive skin. Other products from the brand are more customizable and can be adapted to sensitive skin.

The starting price of Happy Head’s treatment is competitive at $59 for a monthly subscription that covers dermatologist oversight and prescription deliveries. However, the price increases to $99 after the first six months. Some reviews cite a lack of transparency regarding potential side effects, as well as intermittent shipping delays and inconsistent customer service. 

Bottom Line: Happy Head’s potent dual therapy is a useful option for patients with intermediate to severe hair loss and normal skin. The delayed-release gel base increases medication absorption for more targeted treatment while decreasing systemic side effects and requires application only once a day. Advantages include dermatologist support and attractive pricing, but patients should be aware of reviews citing shipping and customer service issues. 

#4: Roman (Ro) Hair Solution Rx

Pros:	Cons:
✓ Transparent and competitive price of $50 per month	✗ Contains potential irritants not suitable for sensitive skin
✓ High finasteride concentration (0.3%) for aggressive treatment	✗ High fixed concentration with a greater risk of side effects
✓ Includes minoxidil and tretinoin for synergistic effects	✗ Limited customization options
✓  Convenient once-daily application	✗ Standard delivery system lacks advanced features
✓ Established telehealth provider with medical supervision

Roman offers a simple topical finasteride formula designed for convenient, once-daily use and focused intervention. The spray contains three active ingredients: high-dose 0.3% finasteride with 6% minoxidil and tretinoin to enhance absorption. This product delivers a potent dose of finasteride on par with premium rivals through a no-frills spray system.

While tretinoin may improve minoxidil absorption, Roman’s spray has some drawbacks for users with sensitive skin or systemic side effect concerns. The 0.3% finasteride concentration cannot be tailored to individual response, and the standard delivery system does not have delayed-release technology to offset the risk of systemic absorption as seen in Happy Head’s liposomal gel. Inactive ingredients like ethyl alcohol and propylene glycol are also known irritants.

Roman is an accessible option for many users. The transparent and fixed monthly fee of $50 covers doctor consultations, prescription deliveries, and unlimited follow-ups. However, users with sensitive skin or more complex treatment needs may find Roman’s standardized and less gentle formulation to be unsuitable for long-term compliance.

Bottom Line: Roman offers a potent and affordable dual finasteride therapy with telehealth support features. Although it is not customizable like leading alternatives, this spray is a convenient choice for individuals with moderate to severe hair loss who can tolerate high dosages and potential irritants.

#5: Hims Topical Finasteride & Minoxidil Spray

Pros:	Cons:
✓ Lowest starting rate of $35+/month	✗ Standardized approach that lacks customization
✓ Well-known brand with recognized platform	✗ Minimal ongoing medical support
✓ Simple ordering process and rapid shipping	✗ Contains irritants not suitable for sensitive skin and fixed high dose
✓ No lengthy consultations required	✗ Basic telehealth features without specialist care
✓ High-dose dual treatment	✗ Concerns about the price transparency of subscription tiers

Hims is a well-known brand that offers topical finasteride through its streamlined telemedicine platform. Their fixed-dose spray of 0.3% finasteride and 6% minoxidil is a convenient and affordable option without the customization features of premium competitors, appealing to those who value simplicity over tailored care. 

Like similar high-dose sprays, this standardized formula from Hims is not suitable for patients with sensitive skin, complex treatment needs, or those requiring a lower maintenance dose.

This provider’s appeal is its wide accessibility. With low prices starting at just $35 per month, quick doctor consultations, and shipping in all 50 states, Hims is a gateway brand for many new hair loss patients. However, this entry-level approach lacks the treatment personalization and close medical supervision of established specialty providers. 

Bottom Line: Hims’ topical finasteride spray is an affordable and easily accessible option backed by a recognized brand name. Although Hims fails to offer the precision treatment and close medical oversight of premium alternatives, it is a mainstay for patients who prioritize low costs and convenience.

Final Verdict: Our Topical Finasteride Picks

After a comprehensive evaluation, Ulo emerges as our top choice for topical finasteride in 2026. Their genuine customization, science-backed formulations, and ongoing dermatologist supervision set the gold standard for personalized hair restoration.

While competitors offer standardized protocols or unproven technologies, Ulo delivers verified results through precision medicine tailored to individual needs. For patients seeking the highest quality care, Ulo’s scientific rigor and safety-first approach make it the clear winner.

What to Expect: Timeline and Results 

Realistic treatment expectations facilitate long-term compliance and successful outcomes. Medical research has established the following evidence-based benchmarks of expected improvements with topical finasteride use as prescribed to treat androgenetic alopecia.

Clinical Timeline for Topical Finasteride Results

Timeframe	What to Expect	Clinical Evidence
3 Months	Terminal hair count starts to improve; increases in total hair count may not yet be observable	[10]​​B. Piraccini et al. (2021). Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial. Journal of the European … Continue reading,[11]Cheng Zhou et al. (2025). Efficacy and safety of topical finasteride spray solution in the treatment of Chinese men with androgenetic alopecia: A phase III, multicenter, randomized, double-blind, … Continue reading
6 Months	Noteworthy increases in hair counts (total and terminal); visible increase in vertex hair growth	[12]​​B. Piraccini et al. (2021). Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial. Journal of the European … Continue reading,[13]Cheng Zhou et al. (2025). Efficacy and safety of topical finasteride spray solution in the treatment of Chinese men with androgenetic alopecia: A phase III, multicenter, randomized, double-blind, … Continue reading,[14]A. Rossi et al.  (2020). Efficacy of Topical Finasteride 0.5% vs 17α-Estradiol 0.05% in the Treatment of Postmenopausal Female Pattern Hair Loss: A Retrospective, Single-Blind Study of 119 … Continue reading
12-18 Months	Maximum improvement is typically observed; continuous improvements in hair coverage and density	[15]A. Rossi et al.  (2020). Efficacy of Topical Finasteride 0.5% vs 17α-Estradiol 0.05% in the Treatment of Postmenopausal Female Pattern Hair Loss: A Retrospective, Single-Blind Study of 119 … Continue reading

• Early Treatment Phase (Months 1-3): During early treatment, visible changes are minimal, which may be disappointing for new patients. The therapy begins to suppress scalp DHT levels, creating shifts that are not yet cosmetically evident. Studies show that improvements in terminal hair count begin around 3 months, though total hair count is not yet typically impacted. 

In the first 6-8 weeks, some experience a temporary increase in shedding as finasteride prompts new growth cycles to start. This is expected and is an encouraging indication that the treatment is taking effect. 

• Visible Improvement Phase (Months 3-6): Visible results begin to appear during this period. Studies show notable increases in hair counts and density by 6 months. Patients tend to note particular improvements in the crown or vertex region.
  
• Optimization Phase (Months 6-18): The most significant benefits occur during this phase. Research indicates that maximum improvements arise around 12 months of continued treatment, as hair density and new growth quality increase.
  
• Long-Term Maintenance: According to clinical data, benefits stabilize around 18-24 months, and treatment transitions from active regrowth to maintenance. Because treatment cessation can lead to the gradual return of hair loss within 6-12 months, continued daily compliance is essential to maintain long-term therapeutic outcomes. 

Topical Delivery Formats

There are several different topical finasteride delivery formats that each offer unique advantages to suit individual needs and preferences, as follows:

• Solutions are liquid formulas typically applied using a dropper for targeted administration on desired scalp areas. These lightweight preparations are valued for their excellent absorption and residue-free finish. Because solutions may contain irritating excipients such as propylene glycol, sensitive patients should opt for gentle blends like Ulo’s prescription topicals. 
• Sprays are a lighter, more fluid type of solution applied using an aerosol or pump. This form enables misting over larger or difficult-to-reach scalp areas. However, sprays are not as precise as droppers, as the liquid may run off and fail to effectively reach the hair follicles.
• Gels offer a more controlled application with a thicker consistency than solutions. They often include advanced delivery bases such as liposome carriers with delayed-release technology, designed to enhance penetration and reduce systemic absorption. However, customization options are typically limited due to compounding practices. Additionally, gel formulas can leave a sticky residue that some users find undesirable.
• Foams may be beneficial for patients with sensitive skin, as they dry quickly and generally lack harsh additives. However, their capacity for targeted application is limited compared to other formulations. 
• Creams and lotions are appropriate for sensitive or dry scalps, featuring thick, emollient-laden bases with moisturizing benefits. Lotions are generally faster-absorbing, more spreadable, and lighter than creams.

The best formulation choice depends on hair and skin type, lifestyle, and personal preferences. Patients are encouraged to consult a doctor to determine the ideal format for their individual needs. 

Safety and Side Effects 

Topical finasteride is noted for its favorable safety profile, especially in contrast to oral formulations; however, understanding potential risks and proper monitoring practices is recommended.

• Common Mild Side Effects: The most common side effects are transient and mild scalp irritation or dryness. Though these reactions often resolve on their own, they also respond well to dose adjustment or calming adjunctive treatments. Patients with sensitive skin should avoid formulas containing irritants like propylene glycol or parabens.^[16]Lee, S.W, Juhasz, M., Mobasher, P., Ekelem, C., Mesinkovska, N.A. (2018).  A Systematic Review of Topical Finasteride in the Treatment of Androgenetic Alopecia in Men and Women. Journal of Drugs in … Continue reading,^[17]Piraccini, B.M., Blume-Peytavi, U., Scarci, F., Jansat, J.M., Falques, M., Otero, R., Tamarit, M.L., Galvan, J., Tebbs, V., Massana, E. (2021). Efficacy and safety of topical finasteride spray … Continue reading 
• When to Contact Your Doctor: More serious side effects or reactions are rare but possible and require prompt medical intervention. These include severe scalp irritation, allergic reactions (blistering, swelling, and redness), and systemic effects like mood changes, sexual dysfunction, or gynecomastia.^[18]Suchonwanit, P., Iamsumang, W., Leerunyakul, K. (2020). Topical finasteride for the treatment of male androgenetic alopecia and female pattern hair loss: a review of the current literature. Journal … Continue reading,^[19]Cheng Zhou et al. (2025). Efficacy and safety of topical finasteride spray solution in the treatment of Chinese men with androgenetic alopecia: A phase III, multicenter, randomized, double-blind, … Continue reading
  
• Topical vs. Oral Finasteride Safety: Clinical data show that topical finasteride has a significantly lower risk of sexual side effects, typically less than 2% compared to 8-15% with oral formulations. This is attributed to the targeted delivery of topical preparations that limit systemic exposure while providing localized scalp treatment.^[20]Mysore, V. (2012). Finasteride and sexual side effects. Indian Dermatology Online Journal, 3(1), 62. https://doi.org/10.4103/2229-5178.93496.
  
• Who Should Avoid Topical Finasteride: Topical finasteride is not suitable for women who are pregnant or nursing due to the risk of birth defects or infant harm. Additionally, individuals with known sensitivity, scalp infections, or certain autoimmune diseases may be ineligible for use. Consult with a doctor before beginning treatment. 

Closing Thoughts 

Topical finasteride is an important development in hair loss therapeutics, providing comparable results with a superior safety profile to oral medications. In today’s market, Ulo’s individualized, clinically rigorous approach sets a benchmark for comprehensive care, outperforming competitors primarily focused on budget or convenience factors.

Successful treatment with topical finasteride requires patience and persistence. Advances in hair restoration technology suggest that tailored medicine, rather than standardized approaches, represents the future. Ready to begin your own journey toward hair restoration? 

Visit Ulo today to see how customized topical finasteride can enhance your results.

Frequently Asked Questions

Do I need a prescription for topical finasteride?

Yes, topical finasteride is a prescription-only medication in the USA. This ensures proper diagnosis, medical supervision, dosage, and quality control. Reputable telehealth providers like Ulo make the prescription process quick and easy via video consultations with licensed doctors specialized in hair restoration therapies. These elite platforms also offer ongoing medical supervision to monitor side effects and adjust treatment for optimization.

Avoid online platforms that market finasteride products without a prescription or those that fail to perform a proper medical consultation before prescribing treatment. Reputable platforms employ board-certified doctors licensed to practice in your state of residence with credentials clearly displayed or offered upon request. Sourcing topical finasteride products from unauthorized vendors without a prescription risks hazardous side effects and ineffectiveness.

Can topical finasteride be used with other hair loss treatments?

Yes, topical finasteride can be beneficially combined with treatments like minoxidil, a popular additive in many available products. These formulas often pair finasteride with additional synergistic ingredients such as antioxidants, vasodilators, antifungals, and absorption enhancers. 

Topical finasteride can also be safely used in conjunction with most non-prescription hair products, hair transplants, and low-level laser treatments. However, it should not be combined with oral DHT blockers (i.e., oral finasteride or dutasteride) due to the risk of systemic side effects. Medical approval is necessary before starting new treatments. 

When will I see results with topical finasteride?

Most patients report stabilization of hair loss after 3-4 months, with notable regrowth in 6-12 months. Shedding within the first 6-8 weeks of starting treatment is considered normal and indicative of the treatment’s efficacy. Because DHT suppression takes time to significantly impact hair growth cycles, consistency and patience are essential for optimal treatment outcomes.

Treatment outcomes can vary between individuals. Consult a doctor to discuss influencing factors and form realistic treatment expectations. This grounded approach facilitates better long-term adherence and more desirable results.  

Is topical finasteride suitable for women?

Although the FDA has not yet authorized topical finasteride to treat AGA in women, it is occasionally prescribed for off-label use in postmenopausal patients with female pattern hair loss (FPHL). Because topical finasteride risks fewer hormonal adverse effects than oral finasteride, it is considered a safer option in these cases. 

However, women of reproductive age are often recommended to completely avoid finasteride due to the risk of severe birth defects from exposure while pregnant. Non-pregnant women who may plan for pregnancy in the future should abstain from finasteride use unless under strict medical supervision with suitable contraception established. Newer low-dose formulations designed for women show promise, although more study is needed to verify long-term viability.

Ultimately, women considering finasteride therapy should speak with an experienced clinician to go over their medical history, weigh the benefits and risks, and review alternative treatment options, such as FDA-approved topical minoxidil.

What is the cost of topical finasteride without insurance? 

The average monthly cost of topical finasteride without insurance can vary from $35 to $90, depending on the source, formulation, and services rendered. Direct-pay telehealth providers tend to offer lower rates than conventional in-person dermatology clinics with combined pharmacy fees. Bespoke formulas with advanced excipients can command higher prices. Patients should account for continued costs to budget for long-term treatment, which is often required for beneficial outcomes. 

What will happen if I stop using topical finasteride? 

If regular topical finasteride treatment is discontinued, hair loss is expected to return gradually within 2-3 months of cessation. Most patients report a rebound to their baseline hair loss level within 6-12 months. Because this regression is gradual, patients have some flexibility regarding therapy breaks or medication transitions if needed. 

Does topical finasteride have any drug interactions?

Compared to oral finasteride, topical formulations have few contraindications due to lower systemic absorption rates. For your safety, inform your prescribing doctor of all current medications, especially blood thinners and other hormonal drugs. While topical finasteride is often safely combined with common medications, there may be exclusions. 

How do I store topical finasteride? 

Topical finasteride should be kept at room temperature out of direct light, moisture, and heat. With proper storage, most products maintain stability for 12-24 months. While refrigeration isn’t required, it may boost shelf life in temperate climates. Be sure to check expiration dates and safely dispose of expired products. 

Can I travel while on topical finasteride? 

Yes, prescribed topical finasteride may be stored in carry-on luggage during domestic travel. When traveling internationally, it is recommended to bring the original prescription and label. Be mindful of TSA restrictions on liquid volumes over 3.4 oz.

How is topical finasteride applied?

Topical finasteride is applied directly to a clean and dry scalp with the product applicator. While specific instructions vary with delivery method, in general, the hair should be parted to expose the scalp and allow targeted application to the desired areas. Patients should consult product instructions for precise indications and dosing protocols. Avoid wetting hair for several hours after application, and thoroughly wash hands after use.

Millions worldwide experience hair loss, with androgenic alopecia (AGA) as the leading cause. Also known as male- or female-pattern hair loss, AGA becomes more prevalent with age. It affects a majority of men over the age of 50 and a substantial number of postmenopausal women. Hair thinning and balding due to AGA is not just a cosmetic concern but can significantly detract from self-esteem and overall quality of life. 

Among popular hair restoration treatments, topical dutasteride is a breakthrough solution to the serious side effects and plateaued results many experience. This potent DHT blocker offers more targeted therapeutic benefits with minimal systemic exposure and reduced risk. However, not all topical dutasteride products meet quality standards, so specialized guidance is key to selecting the right formula. 

The PhD-directed board of experts at Perfect Hair Health draws from the latest clinical data and verified customer feedback to deliver this comprehensive guide to the best topical dutasteride products available in 2026. Through our research collaboration with leading innovators in the field, including our partnership with Ulo, we provide unique insights into the most advanced hair restoration protocols.

Read on for our detailed analysis and evidence-based product recommendations. 

Topical Dutasteride From our partners at Ulo

Get Personalized Topical Dutasteride

Get maximum DHT control in a targeted topical solution. Customize your formula to you and get prescribed 100% online. Choose a multi-month plan and get up to 30% plus a free gift bundle.

Free full-size gifts with 3-month+ plans Prescribed online, shipped to your door

Claim up to 30% off + Free Gifts

Dual 5-AR inhibitionMax DHT control

*Only available in the U.S. Prescription requires an online medical consultation at no extra cost. Off-label products are not endorsed by the FDA. Free gifts included with select multi-month plans while supplies last. Ulo is a partner of Perfect Hair Health; we may earn a commission on purchases.

Quick View: 8 Best Topical Dutasteride Products

Here’s a brief comparison of our most highly recommended topical dutasteride products. Continue reading for in-depth reviews. 

Product	Price	Dutasteride %	Delivery Method	Key Feature
Ulo	$84+/month	0.02%-0.2%	Solution	PhD-developed extensive customization
XYON Health	$129+/month	2%	Gel	Patented controlled-release technology
Strut Health	$69/month	Up to 0.1%	Gel	Alcohol-free and customizable
Blends	~$45/month (90-day supply)	0.3%	Gel	Proprietary hydrating formula
Happy Head	$59-89+/month	Up to 0.3%	Solution	Potency and customization
Maximus	$54.99	0.1%	Gel	Customizability, including the addition of antihistamines
Miiskin	$30-59 + Rx cost	Variable, custom	Solution	No subscription required
Musely	$33/month	0.3%	Solution	Lowest cost option

Science and Benefits of Topical Dutasteride

To begin, we will briefly explore the scientific background of topical dutasteride, including how it works to treat AGA and the distinct benefits of topical preparations.

Mechanism of Action 

Topical dutasteride is valued as a breakthrough treatment for AGA due to its powerful and targeted effects on the molecular levels of hair loss. The root cause of AGA is the testosterone-derived hormone dihydrotestosterone (DHT), which adheres to hair follicles and leads to follicular degeneration and hair loss over time. Dutasteride is classified as a DHT blocker, reducing DHT levels on the scalp to combat hair loss.^[1]R. Cuevas-Díaz Durán., Martinez-Ledesma, E., Garcia-Garcia, M., Gauzin, D.B., Sarro-Ramirez, A., Gonzalez-Carrillo, C., Rodriguez-Sardin, D., Fuentes, A., Cardenas-Lopez, A. (2024) The Biology and … Continue reading,^[2]Dhurat, R., Sharma, A., Rudnicka, L., Kroumpouzos, G., Kassir, M., Galadari, H., Wollina, U., Lotti, T., Golubović, M., Binic, I., Grabbe, S., & Goldust, M. (2020). 5‐Alpha reductase … Continue reading

Among DHT-blocking treatments, dutasteride is considered the most potent due to its dual enzyme activity. Testosterone is converted into DHT through two forms of 5α-reductase enzymes: Type I is located in the skin and sebaceous glands, and Type II is in the hair follicles. Finasteride inhibits only Type II for about 70% DHT reduction, while dutasteride inhibits both types to elicit greater DHT suppression (up to 93% in the skin and 99% in the follicles).^[3]Arif, T., Dorjay, K., Adil, M., & Sami, M. (2017). Dutasteride in Androgenetic Alopecia: An Update.. Current clinical pharmacology, 12 1, 31-35. Available at: … Continue reading

Dutasteride’s powerful DHT inhibition leads to greater therapeutic outcomes in hair restoration. Clinical findings indicate dutasteride’s superior effects on hair count and mass in comparison to finasteride in terms of both quantitative and temporal metrics. While finasteride’s benefits tend to plateau after about 12 months of treatment, dutasteride demonstrates continued improvements up to 12 months and beyond.^[4]Harcha, W., Martínez, J., Tsai, T., Katsuoka, K., Kawashima, M., Tsuboi, R., Barnes, A., Ferron-Brady, G., & Chetty, D. (2014). A randomized, active- and placebo-controlled study of the efficacy … Continue reading

Topical vs. Oral Advantages 

Studies show that topical dutasteride is a safer option than oral with comparable and often better treatment outcomes. When applied locally to the scalp, dutasteride delivers targeted treatment with limited systemic exposure and a reduced risk of serious side effects. If present, adverse reactions to topical dutasteride tend to be transient and mild, in contrast to oral dutasteride’s potential systemic side effects like sexual dysfunction and mood disorders.^[5]Obeid, M., Fattah, N., Elfangary, M., & Husseni, R. (2024). Comparison between Topical Minoxidil 5% Alone versus Combined with Dutasteride (Topical 0.02% through Microneedling or Oral 0.5 mg) in … Continue reading,^[6]Ding, Y., Wang, C., Bi, L., Du, Y., Lu, C., Zhao, M., & Fan, W. (2024). Dutasteride for the Treatment of Androgenetic Alopecia: An Updated Review. Dermatology, 240, 833 – 843. Available at: … Continue reading 

This and other clinically proposed advantages of topical dutasteride are briefly summarized as follows: 

• Safe and Targeted Treatment: Oral dutasteride has systemic exposure through the bloodstream and therefore runs the risk of more serious side effects. Meanwhile, topical treatment targets only the scalp, lowering the risk of severe adverse reactions. Minor irritation at the site of application may occur and tends to resolve quickly. 
• Flexible Dosing: Topical formulations offer greater dose flexibility through modified concentrations, in contrast to the usually fixed doses of oral preparations. Common topical offerings range from a maintenance dose of 0.02% dutasteride to advanced therapies of 2%, allowing dose-dependent customization. 
• Increased Personalization: Topicals can easily integrate synergistic treatments like vasodilators (minoxidil), absorption enhancers (tretinoin), and anti-inflammatories (melatonin) for combination therapies that outperform dutasteride alone. These add-ons are prescribed based on patients’ individual needs and treatment goals.

Plus, patients have a choice of different delivery methods (e.g., sprays, gels, solutions), which can offer greater convenience and adherence.

• Long-term Outlook: Topical use is considered safer for long-term treatment due to its reduced systemic effects. Because hair restoration treatments’ benefits build with time, their suitability for prolonged use is paramount. 

Combined, these factors locate topical dutasteride as a more effective and flexible hair restoration intervention with a greater safety profile than its oral counterpart.^[7]Obeid, M., Fattah, N., Elfangary, M., & Husseni, R. (2024). Comparison between Topical Minoxidil 5% Alone versus Combined with Dutasteride (Topical 0.02% through Microneedling or Oral 0.5 mg) in … Continue reading,^[8]Ding, Y., Wang, C., Bi, L., Du, Y., Lu, C., Zhao, M., & Fan, W. (2024). Dutasteride for the Treatment of Androgenetic Alopecia: An Updated Review. Dermatology, 240, 833 – 843. Available at: … Continue reading,^[9]Radhakrishnan, P., Mariyappan, G., Karthi, J., & Jaisumi, K. (2024). Formulating, Optimizing and Evaluation of Dutasteride Loaded Insitu-Emulgel for Androgenetic Alopecia. International Journal … Continue reading

Choosing the Best: What We Looked For

To help navigate the topical dutasteride market, we developed these quality benchmarks grounded in clinical expertise, scientific evidence, and patient feedback.

Clinical Efficacy

Quality dutasteride products demonstrate notable DHT reduction and improved hair growth within 3-6 months, with these effects continuing over 12 months or longer. The products recommended in this article were assessed based on documented DHT reductions, verified patient feedback, and peer-reviewed studies.

Safety Profile and Medical Oversight

Given the prescription status of topical dutasteride, we verified each telehealth provider’s legitimacy in terms of physician supervision, adherence to legal requirements, and adherence to sound safety protocols. These include proper diagnostic procedures before prescribing, as well as close follow-up care to monitor for side effects and adjust the treatment as needed for optimal outcomes. Trustworthy providers exclusively partner with licensed physicians specialized in hair restoration. 

When it comes to quality assurance, suppliers must partner only with authorized domestic pharmacies to source their compounded medications. Complete ingredient transparency and labeling of allergens establishes acceptable safety profiles.

Personalization Options

Varied patient needs call for customizable treatments that exceed standard one-size-fits-all protocols. Outstanding brands provide a personalized approach through extensive customization options, including variable concentrations, adjuvant blends (e.g., minoxidil), and various delivery formats (e.g., solutions and controlled-release gels). These tailored therapies are physician-crafted to safely elicit the best results. 

User Experience

Prolonged, uninterrupted treatment is necessary to achieve positive results, highlighting the importance of user comfort and satisfaction. Practical considerations, such as application convenience, precise instructions, manageable dose routines, and excellent customer support, all influence treatment adherence.

Cost Transparency

Because treatment sustainability also depends on affordability, we also examined billing models and price transparency. Premium suppliers have honest and reasonable pricing that covers primary treatment costs (prescriptions, consultations, deliveries, and monitoring), free of hidden fees that are common among telehealth providers. 

Selecting Your Ideal Treatment

Begin by assessing your hair loss level and treatment objectives, determining whether moderate maintenance or intensive regrowth protocols are needed. Further considerations include application method preferences (gels, solutions, sprays, etc.), helpful adjuvants, and skin sensitivities. Budgetary limitations and your required level of physician involvement also come into play. 

With these factors in mind, let’s dive into the following product reviews that highlight distinct approaches.

Our Top 8 Topical Dutasteride Products

#1: Ulo Dutasteride + Minoxidil Plus Rx

Pros:	Cons:
✓ PhD-scientist developed with thorough customization	✗ USA-only service for prescription treatments
✓ Customizable concentrations with adjuvant ingredients
✓ Board-certified physician oversight, monitoring, and tailored treatment protocols
✓ Verified quality and safety
✓ Full price transparency and free shipping

The top position goes to Ulo, a leader in clinical rigor and precision hair loss medicine. Known for their highly individualized treatments, cutting-edge protocols, and PhD oversight, Ulo’s offerings are among the most comprehensive and patient-centered available. Their dual topical dutasteride solution with minoxidil delivers potent DHT suppression and new growth stimulation, proven to be more effective than either therapy alone. 

Ulo’s topical systems feature customization across the spectrum, from dutasteride concentration (0.02% for lighter therapy to 0.2% for more aggressive intervention) to adjuvants like absorption enhancers, antioxidants, and vasodilators. Premium services include licensed dermatologist consultations, tailored treatment plans, and continued medical oversight, with a starting monthly subscription price of $84 and no added fees. 

All Ulo safety and medication sourcing practices adhere to the highest regulatory standards, including partnerships with certified domestic pharmacies and strict follow-up protocols. Full ingredient transparency and irritant-free formulations establish excellent safety profiles. Patients enjoy free prescription deliveries and responsive support through Ulo’s sleek telehealth platform.

Our Verdict: Ulo’s advanced dual formula harnesses the power of customized topical dutasteride to deliver the gold standard of hair loss therapy. With PhD-developed formulas, genuine customization, and complete medical oversight, this platform offers proven benefits through a transparent monthly subscription that starts at $84. Their dedication to upholding the highest standards of safe and effective care positions Ulo as the best choice for your hair restoration needs. 

#2 XYON Topical Dutasteride

Pros:	Cons:
✓ Proprietary SiloxysSystem™ Gel for timed release	✗ Premium pricing at $129/month
✓ Highest concentration (2% dutasteride) for aggressive protocols	✗ Limited customization options
✓ Physician oversight	✗ Not recommended for sensitive skin
✓ Service area includes the US and Canada

XYON stands out for its innovative, technology-driven approach, exemplified by its proprietary SiloxysSystem Gel delivery base, which contains delayed-release topical dutasteride at a high concentration of 2%. This controlled-release method allows for a higher dutasteride concentration and more targeted treatment, protecting against systemic exposure and potentially serious side effects. 

While this treatment is a strong option for advanced hair loss cases due to its potency, XYON emphasizes its advanced and proven delivery method over treatment customization features. Monotherapy involves a fixed dose of 2% dutasteride, which may be too strong for some patients. Excipients include ingredients like silicone that are not recommended for sensitive skin. 

XYON’s premium price point reflects not only its forward-looking strategy but also its high medical standards, as the platform offers qualified physician support throughout the process. 

Our Verdict: XYON’s topical dutasteride formulation delivers maximum treatment with minimal systemic risk through its unique delayed-release carrier gel. It is recommended for advanced hair loss patients who can tolerate higher doses and potential irritants, particularly those who don’t mind paying a premium for its advanced technology development. 

#3: Strut Health Topical Dutasteride Gel

Pros:	Cons:
✓ Good value at $69/month with full customization	✗ Lower maximum dutasteride concentration (0.1%)
✓ Alcohol-free, preservative-free options available	✗ Moderate doses may be insufficient for advanced hair loss cases
✓ Extensive customization of adjuvant ingredients	✗ Occasional gaps in customer service are cited
✓ Licensed medical oversight with hair loss specialization	✗ Service area excludes Arkansas

Strut Health is a solid mid-tier option that balances accessible pricing with medically guided customization, emphasizing cost-effectiveness over potency. The preservative- and alcohol-free dutasteride gel contains a moderate 0.1% dutasteride, with tailored add-on options including minoxidil, biotin, and tretinoin at varying concentrations. Capped at such a middling dose, this gentle gel formula is best for mild to moderate hair loss patients with sensitive or dry skin.

Fluocinolone, a corticosteroid, is also available as an adjuvant. While leading providers like Ulo avoid such ingredients due to potential safety concerns, Strut provides appropriate safety disclaimers and maintains an overall emphasis on ingredient transparency, backed by medical oversight.

Strut’s subscription fee of $69 per month for topical dutasteride treatment is a competitive offering, covering consultations, follow-ups, and prescription shipping. Patients cite flexible cancellation policies and rapid home deliveries as notable benefits. We detected some mixed reviews regarding delayed customer service responses and logistical issues.

Our Verdict: Strut Health offers a compelling value proposition with its topical dutasteride gel, priced at only $69 per month, and features that rival those of more expensive providers. The gentle formula with a limited 0.1% dutasteride concentration suits patients with moderate treatment needs who are seeking a budget-friendly option with flexible add-ons and legitimate medical oversight. 

#4: Blends Growth PRO Topical

Pros:	Cons:
✓ Doctor-founded with hair restoration specialization	✗ 90-day supply requirement may not suit all patients
✓ Competitive pricing at ~$45/month (90-day supply)	✗ Fixed formula despite “personalized” marketing claims
✓ Preservative-free, alcohol-free formula with 5 active ingredients	✗ Includes latanoprost with limited long-term safety data for scalp use
✓ 0.3% dutasteride and 7.5% minoxidil offer powerful DHT inhibition	✗ Lacks true customization compared to leading competitors
✓ Proprietary hydrating gel base with advanced formulation

Blends is a physician-founded company with a heavy focus on cutting-edge manufacturing methods and sophisticated formulations. Their small but specialized catalog includes this topical dutasteride treatment made with a proprietary gel base for timed medication release and scalp hydration. Free of alcohol and preservatives, the concentrated 0.3% dutasteride and 7.5% minoxidil formula offers powerful therapeutic effects.

Although Blends asserts the “personalized” and “customized” nature of its products, its Growth Pro Topical gel is actually a comprehensive fixed formula with three adjuvant ingredients in addition to dutasteride and minoxidil: tretinoin, latanoprost, and ketoconazole. Competitively priced at about $45/month (sold in 90-day batches), this offering stands out for its full ingredient transparency and high concentrations suited to aggressive treatment protocols.

However, the use of latanoprost poses concerns due to the lack of long-term studies confirming its safety and efficacy as a topical hair loss treatment. Despite marketing claims of customized protocols, Blends does not allow formulation adjustments to this fixed gel product. Although the monthly cost is lower than that of most leading brands of comparable quality, the minimum purchase requirement of a 90-day supply (~$135) may not suit all patients. 

Our Verdict: This physician-crafted gel formula from Blends is competitively priced, featuring high concentrations of synergistic ingredients for advanced hair loss treatment. Its positioning as a mid-level selection rather than a top choice is due to its false personalization claims and unproven add-on ingredient. 

#5: Happy Head Topical Rx Dutasteride & Minoxidil

Pros:	Cons:
✓ Dermatologist oversight with ongoing support	✗ Limited dutasteride concentration options
✓ 0.3% dutasteride and 8% minoxidil  formula with customizable add-ons, including ketoconazole	✗ Pricing increases after the initial months and can reach ~$109
✓ Established brand with a 6-month money-back guarantee	✗  Some formulations contain potential irritants
✓ User-friendly platform and free consultation	✗ Shipping and customer service inconsistencies

Happy Head represents a dependable option for targeted hair restoration, recognized for its dermatologist-backed and customizable treatments. This hybrid dutasteride-minoxidil solution offers a strong dose of 0.3% dutasteride with up to 8% minoxidil for effective DHT reduction. Elective adjuvants include retinoic acid and hydrocortisone. Anti-dandruff agent ketoconazole can be added for an additional fee. 

While some clinicians warn against the use of topical corticosteroids like hydrocortisone, Happy Head seems to follow established medical safety protocols with appropriate disclaimers. Inactive ingredients like alcohol and propylene glycol can irritate and should be approached with caution. Highly concentrated DHT blockers with harsh excipients require close medical oversight, and patients with sensitive skin may want to seek other options. 

Although transparent about costs, Happy Head’s variable pricing can grow quickly with treatment duration and formulation. Their topical dutasteride solution starts at $59 per month and shifts to $89 after the first six months. The anti-dandruff adjuvant can be added for $20, bringing the total to $109 per month, which exceeds the cost of some comparable providers. Mixed patient reviews cite issues with deliveries and logistical support.

Our Verdict: This combination treatment from Happy Head is a solid choice for patients in need of more aggressive treatment and concentrated formulas. Continued dermatologist oversight, personalization options, and potent formulations can help patients whose results may have stalled on other treatments. However, highly active ingredients and variable pricing may deter those seeking gentler therapies and fixed costs.

#6 Maximus Dutasteride+ Gel

Pros:	Cons:
✓ High level of personalization with physician-driven telehealth oversight	✗ Limited long-term safety data for some ingredient combinations
✓ Competitive monthly pricing	✗ Availability restricted to the U.S.
✓ Physician-guided treatment plans and ongoing clinical support	✗ No subscription flexibility (all via 90-day supply)
✓ Proprietary gel base designed for scalp absorption and minimal mess
✓ Evidence-informed protocols supported by board-certified physicians

 

Maximus Tribe’s Max-Absorb Gel is a highly customizable, prescription-only hair loss solution leveraging physician-driven telehealth and evidence-based formulation. At $54.99 for a 90-day supply, it offers a lot of value for those looking for efficacy and clinical support. The core formulation includes dutasteride (0.1%) with optional minoxidil, tretinoin, and fexofenadine, delivered in a proprietary gel base that is designed to minimize mess and maximize scalp coverage. 

Maximus prioritizes convenience and targeted care: onboarding and ongoing support are managed by board-certified doctors, and the medication is shipped directly to the patient for easy home application. While ingredient customization and clinical guidance are strengths, choices remain limited in comparison to other telehealth options (like Ulo). 

Our Verdict: Maximus offers a well-priced topical dutasteride gel that balances multi-ingredient efficacy with convenient home use and physician oversight. 

#7: Miiskin Dutasteride + Minoxidil

Pros:	Cons:
✓ Direct board-certified dermatologist consultations	✗ Total cost varies with third-party pharmacy fees
✓ Custom-compounded formulations with up to 3 active ingredients	✗ Basic compounding without advanced delivery systems
✓ No automatic subscriptions—pay per order	✗ Less specialized in hair loss compared to dedicated platforms
✓ Legitimate medical oversight with prescription flexibility
✓ Serves both the USA and Mexico

Miiskin differs from the subscription-based providers on this list, as it facilitates direct medical consultations between patients and qualified dermatologists. The pay-as-you-go model allows legitimate medical access without subscription requirements. Miiskin charges $59 for initial consultations and $30 for returning visits. Medication fees vary and are charged separately at the pharmacy where the medication is filled.

While the dermatologist-direct platform increases access to qualified care and prescription hair loss treatments, its simple compounded formulas lack the customization and specialization of leading brands. Ingredient disclosure is limited beyond general mentions of three-active-ingredient formulations and the listing of a combination of dutasteride and minoxidil therapy.

The model does not permit total cost calculation until third-party pharmacy checkout, separate from Miiskin’s billing process, which only covers prescribing dermatologist consultation fees.

Our Verdict: Although Miiskin offers medical legitimacy, the dermatology consultation platform lacks the treatment specialization and transparency of top dutasteride therapy sources. It may be a valuable tool for patients with hair loss to connect with qualified providers and access basic compounded formulas. 

#8 Musely The Hair Topical Solution – Classic

Pros:	Cons:
✓ Lowest cost option at $33/month	✗ Minimal medical oversight compared to competitors
✓ 0.3% dutasteride concentration in a customizable formula	✗ Limited customization options
✓ Aesthetic medicine platform with dermatologist involvement	✗ Medical rigor lacking
✓ Multi-ingredient formulations	✗ Less specialized hair loss expertise
	✗ Some ingredients are not recommended for sensitive skin

Musely’s topical dutasteride solution occupies the final slot on our list as the lowest-priced option at just $33 per month (plus a one-time $20 consultation fee at onboarding). The lower price point reflects less extensive offerings that are well-suited for patients who prefer a more self-directed approach. This tailored prescription formulation combines up to 0.3% dutasteride and 8% minoxidil with optional add-ons of ketoconazole to fight dandruff and hydrocortisone to reduce inflammation. 

It is less customizable than other options, characteristic of Musely’s simplified strategy. Excipients like propylene glycol and alcohol may deter ingredient-conscious consumers due to irritant potential. While such potent formulas and highly active ingredients offer more powerful treatment, they also carry a greater risk of adverse reactions and call for qualified medical supervision. 

However, unlike premium providers, Musely is not known for close medical oversight. In fact, the aesthetic medicine platform has a markedly superficial onboarding and assessment process that falls short of the thorough medical evaluations offered by top providers. Although clinicians are involved in the platform, follow-up care and specialized hair restoration knowledge are lacking, according to customer reviews. 

Our Verdict: Musely is included as a purely budget-friendly option for cost-conscious patients who understand the importance of self-monitoring and supplement with appropriate medical consultation. 

Bottom Line on Buying Topical Dutasteride Online

According to our thorough analysis, Ulo is the best choice for topical dutasteride therapy in 2026. This platform stands out for its rigorous scientific foundation, highly tailored treatments, and commitment to close medical oversight, outperforming the fixed protocols and misleading marketing claims of its peers. 

 

Rather than standardized approaches, Ulo’s PhD-designed therapies with built-in customization features meet the individual needs of each patient, representing the pinnacle of evidence-based precision care in the rapidly evolving field of hair restoration medicine.

Expectations and Timeline

Clinical findings support the following timeline of expected treatment outcomes in topical dutasteride therapy. Familiarity with these will ground your therapy in a realistic outlook, encouraging patience and prolonged adherence.^[10]Obeid, M., Fattah, N., Elfangary, M., & Husseni, R. (2024). Comparison between Topical Minoxidil 5% Alone versus Combined with Dutasteride (Topical 0.02% through Microneedling or Oral 0.5 mg) in … Continue reading,^[11]Ding, Y., Wang, C., Bi, L., Du, Y., Lu, C., Zhao, M., & Fan, W. (2024). Dutasteride for the Treatment of Androgenetic Alopecia: An Updated Review. Dermatology, 240, 833 – 843. Available at: … Continue reading,^[12]Radhakrishnan, P., Mariyappan, G., Karthi, J., & Jaisumi, K. (2024). Formulating, Optimizing and Evaluation of Dutasteride Loaded Insitu-Emulgel for Androgenetic Alopecia. International Journal … Continue reading

• Early Stage (Months 1-3): Within days of beginning treatment, scalp DHT levels start to decline, although cosmetic improvements take longer to show as existing hair cycles complete. Some patients may experience temporary hair shedding in the first 2-8 weeks, which is considered a positive sign that the treatment is working by triggering new growth cycles. 

• Emergence Stage (Months 3-6): After about 3 months of continued therapy, subtle visible improvements typically begin to emerge. Existing strands become thicker, and previously inert hair follicles are reactivated to produce new shafts for measurable increases in hair count metrics.

• Maximization Stage (Months 6-18): This phase sees the most considerable improvements, as hair count and diameter continue to increase for a thicker, healthier appearance. The majority of patients reach optimal results within a year. 

• Maintenance Stage (Long-Term): After reaching peak outcomes, continuous daily application is necessary to sustain benefits. Studies show that indefinite treatment can maintain positive results, although occasional adjustments may be needed over time to account for typical signs of aging.

Risk Profile and Safety

Topical dutasteride is considered a safe hair loss intervention, particularly when weighed against oral formulas that can carry substantial risk due to systemic exposure. Nonetheless, informed risk assessment and familiarity with safety protocols are recommended before beginning any new treatment. Here is a brief overview of medical data on the safety and side effects of topical dutasteride.^[13]Ding, Y., Wang, C., Bi, L., Du, Y., Lu, C., Zhao, M., & Fan, W. (2024). Dutasteride for the Treatment of Androgenetic Alopecia: An Updated Review. Dermatology, 240, 833 – 843. Available at: … Continue reading

Common Side Effects

Adverse patient reactions to topical dutasteride are rare and typically limited to mild, localized scalp irritation that resolves in 2-4 weeks, occurring in only about 5-10% of new users. Depending on individual sensitivities and irritating formulation additives like alcohol, scalp dryness, flaking, and contact dermatitis are possible, though the latter is less common. Mild systemic side effects are extremely rare, documented in under 2% of patients. 

Serious Considerations

Also rare are severe allergic reactions and pronounced systemic side effects, which can include sexual dysfunction, mood disorders, and gynecomastia. These all warrant prompt medical intervention. Topical dutasteride is not recommended in patients with active scalp infections and hormonal disorders.

Topical dutasteride is strongly contraindicated in pregnant or nursing women and in those planning future pregnancies due to the risk of birth defects. Patients with known hypersensitivity to DHT blockers should also avoid use.

Safety and optimal treatment outcomes depend on regular medical follow-up evaluations, typically at three-month intervals in the first year. This enables early identification of problems and treatment response evaluation.

Conclusion: Best Topical Dustaride Products

Cutting-edge topical dutasteride formulations bridge the gap between pharmacological precision and patient satisfaction in hair restoration therapy. Available products represent a spectrum of targeted, proven treatments that are considered safer and more customizable than previous-generation modalities.

Our thorough review of the evolving market identified clear leaders, with Ulo setting itself apart as an exemplary provider of topical dutasteride. Its scientifically optimized protocols are tailored to meet the individual needs of each patient, with qualified medical supervision to ensure a safe and transformative treatment experience.

As hair restoration technology advances, leading topical dutasteride formulations, such as Ulo’s, are at the forefront, empowering users with convenient and clinically proven solutions that not only enhance appearance but also improve quality of life.

Explore Ulo’s advanced topical dutasteride treatments today.

Frequently Asked Questions 

Do I need a prescription for topical dutasteride? Yes, topical dutasteride is a prescription-only treatment in the United States. This ensures proper candidate screening and legitimate medical supervision throughout treatment.

When can I expect results? Initial DHT suppression on the scalp occurs within the first few days, but visible changes in hair growth typically emerge within 3-4 months.  Benefits generally reach their peak after 12-18 months of consistent application.

How do I apply topical dutasteride? Use the product applicator to deposit the treatment directly onto clean, dry scalp areas where you are experiencing hair loss. Allow it to absorb fully before using other hair products. Following application, avoid wetting the hair for several hours and wash your hands thoroughly.

Can I combine topical dutasteride with other treatments? Yes, the benefits of topical dutasteride can be enhanced through combination therapies, such as minoxidil. Consult your prescribing doctor to learn about safe and effective hybrid treatments.

What will happen if I stop treatment? When treatment is halted, scalp DHT levels gradually return to starting levels, which typically leads to resumed hair loss after several months.

How much does topical dutasteride cost? Pricing varies from about $30 to $135+ for a monthly supply, depending on concentration, formulation, brand, and telehealth services included. Leading brands provide comprehensive medical oversight and customization, offering transparent and flat-rate monthly subscription fees. 

Dutasteride is used off-label for androgenetic alopecia due to its ability to lower dihydrotestosterone (DHT), a major hormonal driver of pattern hair loss. At 0.5 mg daily, it suppresses circulating DHT more than finasteride and shows significantly more hair regrowth across multiple clinical trials. So what happens when the dose is increased fivefold, to 2.5 mg?

In a 24-week study, the higher dose produced the greatest numerical increase in hair counts and the greatest investigator-assessed photographic improvement. It reduced scalp DHT by 150% more than that of 0.5 mg, even though it suppressed blood DHT levels about the same. But there are important limitations:

• 2.5 mg dutasteride has only been studied for hair loss in one controlled trial.
• The study only lasted six months, so it was not designed to establish long-term safety

Several anecdotes from users of 2.5 mg dutasteride have also been published online. Before reviewing those cases, we’ll look at what the clinical evidence reveals about 2.5 mg dutasteride.

But first, a primer on oral dutasteride.

Oral Dutasteride From our partners at Ulo

Interested in 2.5 mg Dutasteride?

2.5 mg is the most powerful dose of dutasteride and lowers DHT by inhibiting both type 1 and 2 5a-reductase. Studies show it may lower scalp DHT by more than 0.5 mg dutasteride. Available through a licensed Ulo provider. Choose a multi-month plan and get free full-size gifts.

Free full-size gifts with 3-month+ plans Prescribed online, shipped to your door

Claim up to 30% off + Free Gifts

Dual 5-AR inhibitionType 1 and type 2

*Only available in the U.S. Online medical consultation required. Restrictions apply. Off-label products are not endorsed by the FDA. Free gifts included with select multi-month plans while supplies last. Ulo is a partner of Perfect Hair Health; we may earn a commission on purchases.

What is Dutasteride?

Dutasteride is an oral medication originally approved to treat benign prostatic hyperplasia (BPH). It inhibits the type I and type II forms of 5-alpha-reductase, the enzyme responsible for converting testosterone into DHT. As we’ve already established, DHT is a primary driver of hair loss.

Finasteride, the gold standard for AGA treatment, primarily inhibits type II. At 1 mg, it lowers DHT levels by about 70%. In contrast, dutasteride acts on both, and consequently can reduce circulating DHT by more than 90% at the standard 0.5 mg dose.

Comparatively, 0.5 mg dutasteride generally outperforms 1 mg finasteride for hair regrowth, likely due to greater DHT suppression. ^[1]Harcha et al. (2014). Journal of the American Academy of Dermatology. https://doi.org/10.1016/j.jaad.2013.10.049

For hair loss, the relevant daily doses are:

• 0.1–0.2 mg: lower doses investigated in clinical trials.
• 0.5 mg: the standard, best-studied dose for AGA and the FDA-approved dose for BPH.
• 2.5 mg: a high, off-label dose tested in one clinical trial.

Potential adverse effects include decreased libido, erectile or ejaculatory changes, and, less commonly, breast tenderness or enlargement. Dutasteride is not FDA-approved for hair loss in the United States currently, however, 0.5 mg and 2.5 mg dutasteride are frequently prescribed off-label by a physician.

The Research on 2.5 mg Dutasteride

Studies on 2.5 mg dutasteride are limited. However, one dose-ranging trial compared various doses of oral dutasteride, including 0.5 mg and 2.5 mg. It measured more than just hair counts: the researchers also assessed standardized photographs, investigator and patient ratings, and DHT concentrations in both blood and scalp tissue.

The study: 0.05–2.5 mg dutasteride

Olsen et al. randomized 416 men aged between 21 and 45 with male pattern hair loss to placebo or various treatment arms: finasteride 5 mg, or dutasteride 0.05, 0.1, 0.5, or 2.5 mg daily for 24 weeks. Hair counts were taken from the same area near the crown at repeated visits, using a small tattoo to ensure accurate tracking. The investigators also evaluated standardized photographs of the frontal scalp and vertex.^[2]Olsen et al. (2006). Journal of the American Academy of Dermatology. 55(6):1014–1023. https://doi.org/10.1016/j.jaad.2006.05.007

At 24 weeks, the study reported the following changes in hair counts:

• Placebo: approximately 32 fewer hairs.
• Finasteride 5 mg: approximately 76 additional hairs.
• Dutasteride 0.5 mg: approximately 95 additional hairs.
• Dutasteride 2.5 mg: approximately 110 additional hairs.

Dutasteride showed a dose-dependent increase in target area hair counts, with the largest gain in hair counts in the 2.5 mg group. The trial established that 2.5 mg outperformed dutasteride 0.5 mg for increasing hair density.

Do More Hairs Mean More Visible Growth?

Not necessarily. In AGA, hair follicles can produce very fine, miniaturized hairs that contribute little to visible scalp coverage. When a study counts those hairs alongside thicker terminal hairs, the increase in its reported hair count may look more impressive than the cosmetic result. This is why the minimum hair shaft diameter used to define a countable, non-vellus hair is important when comparing trials.

This is where other measurements, like photographic assessments and patient satisfaction come into play. And in this case, the other measurements also corroborate the hair count findings: the 2.5 mg group also had the greatest investigator-rated improvement in standardized frontal and vertex photographs, with patient assessments following a broadly similar pattern. These findings make it less likely that the numerical hair count difference was driven by fine hairs that are largely cosmetically insignificant.

Why Did the Higher Dose Produce a Better Response?

In the Olsen trial, 0.5 mg dutas rteedridueced serum DHT by approximately 92% compared with 2.5 mg dutasteride. Judging by blood levels alone, increasing from 0.5 mg to 2.5 mg appears to add very little suppression.

In the scalp itself, however, the reductions were 51% with dutasteride 0.5 mg and 79% with dutasteride 2.5 mg – a much larger reduction. Because reducing DHT locally in the scalp is arguably the most important factor in addressing DHT-driven follicle miniaturization, this may explain why 2.5 mg dutasteride produced a better result.

An Important Note: Oral Dutasteride Formulation Matters

One important consideration when choosing oral dutasteride is its formulation. Unlike finasteride and minoxidil, dutasteride has extremely low water solubility, meaning that how the medication is formulated can significantly affect its absorption.

The Original Format: Softgel

This is why the original FDA-approved dutasteride medication, Avodart, was developed as a soft gelatin capsule. Rather than containing dutasteride as a dry powder, each capsule contains the drug pre-dissolved in a mixture of lipids (oils), emulsified with mono- and diglycerides. This lipid-based formulation helps overcome dutasteride’s poor water solubility, allowing it to be absorbed through the gastrointestinal tract.

And the superiority of this formulation is backed up by research.

Oral Dutasteride From our partners at Ulo

Interested in 2.5 mg Dutasteride?

2.5 mg is the most powerful dose of dutasteride and lowers DHT by inhibiting both type 1 and 2 5a-reductase. Studies show it may lower scalp DHT by more than 0.5 mg dutasteride. Available through a licensed Ulo provider. Choose a multi-month plan and get free full-size gifts.

Free full-size gifts with 3-month+ plans Prescribed online, shipped to your door

Claim up to 30% off + Free Gifts

Dual 5-AR inhibitionType 1 and type 2

*Only available in the U.S. Online medical consultation required. Restrictions apply. Off-label products are not endorsed by the FDA. Free gifts included with select multi-month plans while supplies last. Ulo is a partner of Perfect Hair Health; we may earn a commission on purchases.

The GSK Dutasteride Bioequivalence Study

There is clinical evidence that these formulation differences matter. In 2016, Fossler et al. compared GSK’s marketed 0.5 mg dutasteride softgel with experimental 0.5 mg tablets and hard gelatin capsules in a randomized crossover study. Compared with the softgel, total drug exposure was approximately 76% with the tablet and 73% with the hard capsule. Peak drug concentrations were also lower. Neither experimental formulation met the criteria for bioequivalence, and neither was advanced for further development.^[3]Fossler, M., Zhu, J., Roehrborn, C., McAleese, P., Manyak, M. (2016). Impact of Formulation on the Pharmacokinetics of Dutasteride: Results from Two Phase I Studies. Clinical Drug Investigation. … Continue reading

Would lower absorption also mean less DHT suppression? The study measured dutasteride exposure, not DHT levels or hair regrowth, so it cannot establish that directly. However, the researchers noted that earlier dose-finding data suggested lower drug exposure would likely result in less effective serum DHT suppression.

The Problem With Compounded Combination Capsules

Unfortunately, not all oral dutasteride products use this approach.

As dutasteride has become increasingly popular for hair loss, many compounding pharmacies have begun offering combination capsules containing dutasteride, minoxidil, and other ingredients. While these formulations offer the convenience of taking multiple medications in a single pill, some contain powdered dutasteride without an established solubilization system.

This begs the question: are patients actually absorbing the amount of dutasteride they have been prescribed?

While we don’t have direct data to answer that question, one of our own PerfectHairHealth members did test this hypothesis. To do so, this male member took 1.5 mg of powdered dutasteride supplied by a compounding pharmacy, tested his DHT, and, despite the relatively high dose, his serum DHT levels fell by only approximately 13% in 12 hours.

While this doesn’t prove the powdered dutasteride doesn’t work, it does add evidence to GSK’s findings that subpar formulations may lead to subpar efficacy.

How to Check Your Dutasteride

Fortunately, there is a straightforward way to identify oral dutasteride products with established bioequivalence.

The FDA maintains a database called the Orange Book, which identifies approved medications and their therapeutic equivalence ratings. Products with an AB rating have satisfied the FDA’s requirements for bioequivalence to an appropriate reference product. For approved generic dutasteride, this means comparable absorption to the reference formulation at the same dose.

Ulo’s dutasteride softgels are a verified bioequivalent formulation.

This distinction is particularly important for patients considering 2.5 mg dutasteride daily. The hair regrowth reported in clinical trials depends on adequate drug exposure. A compounded capsule containing 2.5 mg of dutasteride powder cannot be assumed to provide the same exposure as an equivalent dose of a proven formulation.

For patients using oral dutasteride, particularly those switching from finasteride or increasing their dose, verifying the formulation with their pharmacist is an important part of evaluating their treatment.

2.5 mg Dutasteride Before and After Photos

Now that we’ve covered the clinical evidence, let’s look at eight anecdotal accounts from Reddit users who reported taking 2.5 mg dutasteride.

Case 1: Male (25), oral dutasteride and oral minoxidil (2 months; 2.5 mg and 5 mg daily)

This Redditor increased oral dutasteride from 0.5 mg to 2.5 mg daily and started 5 mg oral minoxidil at the same time, after about eight months of continued hair loss. He experienced heavy shedding early on, followed by visibly greater density by month two. He noted increased body hair but did not report any other significant side effects.

Case 2: Male (20), oral dutasteride and oral minoxidil (6 months; 2.5 mg each daily)

This poster began 2.5 mg oral dutasteride and 2.5 mg oral minoxidil daily after several years of severe diffuse thinning. He reported noticeable improvement over the course of treatment, with greater scalp coverage by about the six-month mark.

Case 3: Male (49), oral dutasteride and oral minoxidil (6 months; 2.5 mg and 5 mg daily)

This user switched from 1 mg finasteride to 2.5 mg dutasteride after years of continued hair loss on 5 mg oral minoxidil. He reported shedding stopped after the first month, with new growth at the crown and top of the scalp by month two and near-complete coverage in those areas by month six. He noted temporary sexual and urinary symptoms that resolved during treatment. Spontaneous resolution of side effects with DHT-reducing medication occurs often, with the original 2.5 mg dutasteride clinical trial demonstrating that the majority of sexual side effects resolved during treatment.

Case 4: Male, oral dutasteride and oral minoxidil (4 months; 2.5 mg and up to 5 mg daily)

This Redditor took 2.5 mg oral dutasteride alongside oral minoxidil, which he increased from 2.5 mg to 5 mg daily, for four months. He experienced heavy shedding in the first six weeks, then faster growth from around month two, and was satisfied with his progress by month four. He did not report libido or blood pressure-related side effects.

Case 5: Male (26), oral dutasteride and oral minoxidil (5 years total; approximately 18 months at 2.5 mg dutasteride)

This poster used 0.5 mg oral dutasteride for three and a half years before increasing to 2.5 mg under his dermatologist’s supervision, alongside 5 mg oral minoxidil. Over five years of treatment, he reported improved density and greater satisfaction with his hair, with no additional side effects after the dose increase.

Case 6: Male (19), oral dutasteride, minoxidil and RU58841 (approximately 1 year; 2.5 mg dutasteride daily)

This user used 2.5 mg oral dutasteride, 5% topical minoxidil, and 2% topical RU58841 for about a year, adding 2.5 mg oral minoxidil shortly before posting. With several treatments in use at once, the results demonstrated in these photos can’t be attributed to 2.5 mg dutasteride alone.

Case 7: Male (57), multiple treatments (1 year total; approximately 2 months at 2.5 mg dutasteride)

This Redditor used 0.5 mg dutasteride for most of a year before increasing to 2.5 mg for the final two months, alongside finasteride, topical and oral minoxidil, topical antiandrogens, and light therapy. The short time at the higher dose and the number of concurrent treatments limit what can be attributed to 2.5 mg dutasteride.

Strategies to Optimize Dutasteride Response

To optimize your response to 2.5 mg dutasteride, consistency is key. Consistent use of medications and patience are your friends during treatment, as cosmetically significant regrowth can sometimes take 6-12 months to manifest.

Secondly, combination treatments may prove to be more effective than standalone therapies. Dutasteride suppresses DHT and can be combined with other treatments, like those that address additional mechanisms beyond DHT. Minoxidil acts as a hair growth stimulant, while treatments such as ketoconazole may help address inflammatory scalp conditions when indicated. Some patients also consider microneedling or other adjuncts.

Probable Regrowth Timeline

There is no well-established long-term regrowth timeline specific to 2.5 mg dutasteride. However, 2.5 mg dutasteride likely follows the same timeline as other DHT inhibitors. The stages below are therefore a broad guide, not a perfect prediction:

• Months 0–3: Some people experience an initial shed, or see little visible change. Early photographs may be difficult to interpret.
• Months 3–6: In the Olsen trial, changes in hair counts and photographic ratings were measurable by 24 weeks. Some users start to notice less shedding or more coverage in this window.
• Months 6 to 12: Further gains are possible with continued treatment.
• After 12 months: While this is where gains usually plateau, increases in hair density may continue to be realized beyond the 12-month mark.

Safety and Side Effects

Like 0.5 mg dutasteride, there is a risk of side effects when taking 2.5 mg dutasteride.

Studies show that dutasteride at a 0.5 mg dose typically has a low rate of side effects, comparable to, if not lower than, finasteride. However, at a 5x dose, there may be a higher risk of side effects when using 2.5 mg

According to the Olsen trial, overall adverse events were similar between 0.5 mg and 2.5 g, except there was a higher rate of decreased libido with the 2.5 mg dose.

However, no patients discontinued treatment for that reason; four reported resolution while continuing dutasteride, and two more reported resolution after stopping. This suggests that some symptoms were temporary and likely mild, given no participants dropped out due to the side effects.

Prostate studies using higher doses of dutasteride, like 2.5 mg, in prostate studies have also failed to find any significantly increased risks.

However, every risk profile is individual. If your goal is to use a higher dose of dutasteride, start with 0.5 mg, assess your tolerance, and titrate upwards if necessary.

Oral Dutasteride From our partners at Ulo

Interested in 2.5 mg Dutasteride?

2.5 mg is the most powerful dose of dutasteride and lowers DHT by inhibiting both type 1 and 2 5a-reductase. Studies show it may lower scalp DHT by more than 0.5 mg dutasteride. Available through a licensed Ulo provider. Choose a multi-month plan and get free full-size gifts.

Free full-size gifts with 3-month+ plans Prescribed online, shipped to your door

Claim up to 30% off + Free Gifts

Dual 5-AR inhibitionType 1 and type 2

*Only available in the U.S. Online medical consultation required. Restrictions apply. Off-label products are not endorsed by the FDA. Free gifts included with select multi-month plans while supplies last. Ulo is a partner of Perfect Hair Health; we may earn a commission on purchases.

Practical Takeaways

• Dutasteride has an established AGA evidence base at 0.5 mg. A controlled AGA trial compared 2.5 mg to 0.5 mg and other smaller doses of dutasteride.
• In that 24-week hallmark trial, 2.5 mg produced the most dramatic increases to hair count and the strongest photographic rating.
• Scalp DHT suppression differed substantially between 0.5 mg and 2.5 mg (approximately 51% vs. 79%), even though serum DHT suppression was already near its maximum at 0.5 mg.
• Decreased libido was reported more often in the 2.5 mg group of the AGA trial. However, no participants dropped out due to side effects, and most side effects resolved during treatment. Additional studies in prostate research dose up to 5 mg daily.

Final Thoughts

Dutasteride is an off-label treatment for androgenetic alopecia, with growing popularity. It’s most commonly used at the 0.5 mg dose. However, 2.5 mg has also been explored as an escalated dose, demonstrating better improvements to hair density, steeper reductions to scalp DHT, and better overall hair growth compared to 0.5 mg. While it does come with an increased risk of decreased libido, studies suggest these effects are mild and often resolve with treatment. Given its profile, it represents a suitable option for escalating a hair loss protocol that ideally already includes 0.5 mg dutasteride or another DHT-reducing medication prior to switching.

Female hair loss remains a widely misunderstood and often under-treated condition, affecting nearly one-third of all women at some point in their lives and up to two-thirds after menopause. Unlike male pattern hair loss, research and treatment options for women have historically lagged, resulting in limited specialized solutions and significant emotional distress for those afflicted.

Minoxidil stands as the only FDA-approved medication for female pattern hair loss. Its efficacy is supported by robust data, particularly at the 2 and 5% concentrations for women. In this guide, we will showcase the six best minoxidil products for women, including the best overall, best value, and top specialized choices. 

Quick Look: Top 7 Minoxidil Brands for Women 2026

Product	Strength	Format	Customization	Price	Best
Ulo Women’s Rx Minoxidil	7%	Solution	High	$41.65	Overall Topical
Ulo Sublingual Minoxidil	1.25 mg or 2.25 mg	Orange-flavored sublingual tablet	High	From $39	Overall Oral
Musely	8%	Solution	High	$99	Strength
Rogaine Women’s Foam	5%	Foam	None	$49.97	Sensitivity
Hers	2%-5%	Solution/Foam	None	$30	Value
Happy Head (Women’s Formula)	6%	Solution	High	$79	Alternative
Winona	7%	Solution	None	$150	Woman-centered care

Before we get into our list, let’s first take a look at what female pattern hair loss is and how minoxidil works for women.

Topical Minoxidil From our partners at Ulo

Get Personalized Topical Minoxidil

Rx-strength topical minoxidil, formulated without propylene glycol. Prescribed 100% online. Choose a multi-month plan and get up to 30% plus a free gift bundle.

Free full-size gifts with 3-month+ plans Prescribed online, shipped to your door

Claim up to 30% off + Free Gifts

Rx-strengthHigh strength growth support

*Only available in the U.S. Prescription requires an online medical consultation at no extra cost. Off-label products are not endorsed by the FDA. Free gifts included with select multi-month plans while supplies last. Ulo is a partner of Perfect Hair Health; we may earn a commission on purchases.

What is Female Pattern Hair Loss?

Female pattern hair loss (FPHL) is a chronic, non-scarring alopecia where genetically susceptible follicles on the central scalp progressively minaturize, leading to reduced hair density over time. Clinically, women usually show diffuse thinning over the crown and midline part with relative preservation of the frontal hairline rather than “bald patches”.^[1]Bhat, Y.J., Saqib, N-U., Latif, I., Hassan, I. (2020). Female Pattern Hair Loss – An Update. Indian Dermatology Online Journal. 11(4). 493-501. Available at: … Continue reading 

The Ludwig scale grades this pattern from I-III: mild central thinning (I), moderate widening of the part and density loss (II), and advanced, see-through vertex thinning (III). Trichoscopy and histology show increased hair shaft diameter variability and replacement of terminal hairs by finer, vellus-like hairs.^[2]Kothari, C.R., Shivakumar, P. (2024). Trichoscopic Features in Female Pattern Hair Loss: 1-Year Hospital-Based Cross-Sectional Study. Clinical Dermatology Review. 8(2). 95-101. Available at: … Continue reading 

FPHL arises from a mix of genetics, hormones, low-grade inflammation, oxidative stress, and microvascular and aging-related changes around the follicle. Unlike classic male pattern hair loss, many women have normal serum androgens, suggesting that local androgen sensitivity and non-androgen mechanisms both contribute.^[3]Ramos, P.M., Miot, H.A. (2015). Female Pattern Hair Loss: a clinical and pathophysiological review. Anais Brasileiros de Dermatologia. 90(4). 529-543. Available at: … Continue reading 

How Minoxidil Works

Minoxidil functions as a potassium channel opener that promotes vasodilation, increasing blood flow and improving microcirculation around hair follicles.^[4]Hussein, R.S., Dayel, S.B., Abahussein, O., El-Sherbiny, A.A. (2024). Applications and efficacy of minoxidil in dermatology. Skin Health and Disease. 4(6). E472. Available at: … Continue reading

 It is also a prodrug that must be converted by the sulfotransferase enzyme into its active form, minoxidil sulfate. This conversion helps extend the anagen (growth) phase while shortening the telogen (resting) phase, thereby shifting a greater number of follicles into active growth cycles.^[5]Pietrauszka, K., Bergler-Czop, B. (2020). Sulfotransferase SULT1A1 activity in hair follicle, a prognostic marker of response to the minoxidil treatment in patients with androgenetic alopecia: a … Continue reading

Additional evidence indicates that minoxidil stimulates the expression of growth-promoting factors, such as vascular endothelial growth factor (VEGF), and activates the Wnt/β-catenin signaling pathway, both of which further support hair regrowth.^[6]Gupta, A.K., Talukder, M., Shemer, A., Piraccini, B.M., Tosti, A. (2023). Low-Dose Oral Minoxidil for Alopecia: A Comprehensive Review. Skin Appendage Disorders. 9(6). 423-437. Available at: … Continue reading

While minoxidil does not directly address dihydrotestosterone (DHT), it can enhance the effectiveness of other therapies by targeting different biological pathways involved in hair loss. When used alongside anti-DHT treatments such as finasteride, which reduces the underlying hormonal driver of androgenic alopecia, minoxidil offers a complementary, non-hormonal mechanism of action. Clinical research demonstrates that the combined use of topical finasteride and minoxidil produces greater improvements in hair density in men compared to minoxidil alone.^[7]Asad, N., Naseer, M., Ghafoor, R. (2024). Efficacy of Topical Finasteride 0.25% with Minoxidil 5% versus Topical Minoxidil 5% Alone in Treatment of Male Pattern Androgenic Alopecia. Journal of Drugs … Continue reading

Why Women Respond Differently

In women, pattern hair loss is generally less strictly DHT-driven than in men, so microcirculation, oxidative stress, and local inflammatory pathways play a proportionately greater role.^[8]Fabbrocini, G., Cantelli, M., Masara, A., Annunziata, M.C., Marasca, C., Cacciapuoti, S. (2018). Female pattern hair loss: A clinical, pathophysiologic, and therapeutic review. International Journal … Continue reading This helps explain why a vasodilatory, pro-anagen agent like minoxidil is often effective even when anti-androgens alone are insufficient.

Hormonal transitions like perimenopause/menopause, thyroid dysfunction, and polycystic ovary syndrome (PCOS) commonly unmask or accelerate FPHL by altering estrogen-androgen balance and cycling dynamics.^[9]Aksenenko, M., Palkina, N., Komina, A., Ruksha, T. (2019). MiR-92a-1-5p and miR-328-3p Are Up-Regulated in Skin of Female Pattern Hair Loss Patients. Annals of Dermatology. 31(2). 256-259. Available … Continue reading 

OTC vs Prescription Minoxidil for Women

Over-the-counter (OTC) minoxidil for women typically comes at 2-5% concentrations, while prescription or compounded products may use 5-8% or higher strengths in customized products.

2% minoxidil is the classic, label-approved strength for women, with clear evidence of a benefit versus placebo.^[10]van Zuuren, E.J., Fedorowicz, Z., Schoones, J. (2016). Interventions for female pattern hair loss. Cochrane Database of Systematic Reviews. 2016(5). CD007628. Available at: … Continue reading 

Compounded “high-strength” minoxidil (5-8%+) is prescription only and relies in part on carrier agent formulation.^[11]Sattur, S.S., Sattur, I.S. (2021). Pharmacological Management of Pattern Hair Loss. Indian Journal of Plastic Surgery. 54(4). 422-434. Available at: https://doi.org/10.1055/s-0041-1739254 Simply raising the percentage does not guarantee better results and may raise the risk of irritation, hypertrichosis, or systemic absorption of the drug.^[12]Ghonemy, S., Alarawi, A., Bessar, H. (2021). Efficacy and safety of a new 10% topical minoxidil versus 5% topical minoxidil and placebo in the treatment of male androgenetic alopecia: a trichoscopic … Continue reading

So, with that in mind, let’s take a look at our top seven minoxidil brands of 2026.

Best Minoxidil Brands for Women

#1 Best Overall: Ulo Women’s Rx Minoxidil (7%)

Pros:	Cons:
✓ Prescription-only 7% minoxidil, higher than standard OTC strengths	✗Prescription products are only available in the USA
✓ Optional evidence-based add-ons
✓ Quality-tested ingredients free of irritants
✓ Includes medical consultation and ongoing monitoring

Ulo Women’s Rx Minoxidil+ is our go-to product for topical minoxidil treatment. It is designed for those who want more than “pink-labeled” 2-5% solutions and are comfortable with a prescription approach guided by specialists. The 7% concentrated and layered actives (including cetirizine 1%, tretinoin 0.01%, melatonin 0.01%, and caffeine 0.2%) target multiple facets of hair loss with a level of customization that goes beyond typical off-the-shelf products.

Bottom Line: Ulo offers the most precise, clinically guided minoxidil-based treatment for women in 2026, combining higher-strength therapy with thoughtful formulation and ongoing medical oversight.

#2 Best for Overall Oral: Ulo Sublingual Minoxidil

Pros:	Cons:
✓ Convenient, sublingual oral minoxidil	✗ Premium pricing
✓ Orange-flavored sublingual tablet	✗ Only available in the USA
✓ Available in 1.25 mg and 2.25 mg minoxidil strengths
✓ No scalp application or disruption to hair styling
✓ Online medical consultation and ongoing provider support

Ulo’s Sublingual Minoxidil tablets offer a minoxidil alternative for women who are interested in oral minoxidil but prefer the sublingual delivery format. Researchers believe bypassing the liver’s first-pass metabolism through sublingual delivery may reduce the effect of minoxidil on the cardiovascular system. In one study, heart palpitations were reported in approximately 9% the conventional oral minoxidil group versus none of the sublingual oral minoxidil group.^[13]Sanabria, B., Miot, H.A., Sinclair, R., Chaves, C. and Müller Ramos, P. (2025), Sublingual Minoxidil 5 mg versus Oral Minoxidil 5 mg for male androgenetic alopecia: A double-blind randomized … Continue reading

The orange-flavored sublingual tablets dissolve rapidly in the mouth, allowing users a convenient (and delicious) way to deliver minoxidil sublingually.

This may be particularly beneficial for women with longer hair, sensitive scalps, or styling routines that make topical minoxidil difficult to apply consistently. The two available minoxidil strengths, 1.25 mg and 2.25 mg, also provide ample flexibility when selecting an appropriate dose.

Bottom Line: Ulo Sublingual Minoxidil offers a convenient, pill-free way to take prescription oral minoxidil sublingually, particularly for women who find topical treatments difficult to incorporate into their daily hair care routine.

Sublingual Minoxidil From our partners at Ulo

Sublingual Minoxidil

A rapidly-dissolving sublingual tablet with minoxidil. Available in 1.25 mg and 2.5 mg doses. Prescribed 100% online. Choose a multi-month plan and get up to 30% plus a free gift bundle.

Free full-size gifts with 3-month+ plans Prescribed online, shipped to your door

Claim up to 30% off + Free Gifts

Sublingual deliveryDissolves under the tongue

*Only available in the U.S. Prescription requires an online medical consultation at no extra cost. Off-label products are not endorsed by the FDA. Free gifts included with select multi-month plans while supplies last. Ulo is a partner of Perfect Hair Health; we may earn a commission on purchases.

#3 Best for Strength: Musely The Hair Topical Solution-Classic

Pros:	Cons:
✓ High-strength 8% prescription minoxidil.	✗ Use of corticosteroids increases the risk of skin thinning.
✓ Optional evidence-based add-ons like dutasteride and spironolactone for hormonal control.	✗ Propylene glycol and ethyl alcohol base, which can sting or dry out sensitive scalps.
✓ Additional scalp-supporting actives like tretinoin, ketoconazole, caffeine, and melatonin.	✗ More expensive than simpler OTC or lower-strength prescription options.
✓ Includes periodic medical follow-up.

Musely’s 8% “Classic” Hair Topical is designed for women with advanced thinning or those who have plateaued on conventional strengths, combining high-dose minoxidil with potent anti-androgens and supportive ingredients in a single solution, including optional add-ons such as dutasteride 0.3%, spironolactone 0.075%, tretinoin 0.01%, ketoconazole 2%, hydrocortisone 1%, plus adjuncts like caffeine and melatonin. 

It functions more as an intensive, prescription-only protocol than a starter product, and is best reserved for users willing to tolerate a stronger propylene glycol/ethyl alcohol vehicle, and possible skin thinning if using long-term due to the addition of corticosteroids.

Bottom line: For women with stubborn, progressive hair loss who have outgrown basic 5% formulas, Musely’s high-strength, multi-active topical offers one of the most powerful at-home options, provided they are comfortable with higher cost and higher irritation risk.

#4 Best for Sensitivity: Rogaine Women’s Foam

Pros:	Cons:
✓ Propylene-glycol-free foam vehicle, often better tolerated on sensitive or irritated scalps.	✗No medical consultation or follow-up after buying
✓ Widely available OTC	✗ No customization.

Rogaine Women’s Foam is a classic choice for those looking for a gentle-on-the-scalp option of minoxidil. The propylene-glycol-free foam base, robust clinical evidence, and once-daily 5% option make it a gentle yet effective starting point for treating female pattern thinning. It should be noted that if you wanted to try the lower dose option (2%), you need to buy the solution, which contains propylene glycol, and so may not be as beneficial for those with sensitive skin. 

Bottom Line: Get the foam if you have a sensitive scalp or are a beginner, wanting a low-irritant minoxidil option. 

#5 Best Value: Hers Minoxidil Foam and Solution

Pros:	Cons:
✓ Budget-friendly option at around $30 for a 2-month supply.	✗No advanced customization available.
✓ Offers both 2% and 5% strengths at the same price.
✓ Available in solution and foam formats.

Hers Minoxidil is designed for women who want a clinically supported minoxidil treatment without paying premium prices for branding or heavy telehealth layering. With standard 2 and 5% options in familiar vehicles, it delivers an approachable, budget-conscious package for those comfortable managing a simple daily routine themselves.

Bottom Line: For cost-conscious women who want an easy, no-frills entry into proven minoxidil therapy, Hers Minoxidil offers standard concentrations with good value.

#6 Best Alternative: Happy Head Minoxidil and Spironolactone for Women

Pros:	Cons:
✓ Prescription-strength 6% minoxidil, higher than standard OTC options but below ultra-high-dose protocols.	✗ Uses a propylene glycol-containing vehicle, which can increase irritation, dryness, or stinging on sensitive scalps.
✓  Customizable blends that include spironolactone, tretinoin, and hydrocortisone	✗ Inclusion of topical corticosteroids carries a risk of skin thinning and barrier damage if used long-term.
✓ Strong telehealth model with online prescribing and adjustments to treatments over time.	✗ More expensive than generic 5% minoxidil and some standard telehealth offerings.
✓ Good fit for women who need more than basic 2-5% formulas but do not want to jump straight to 8%+ multi-drug cocktails.

Happy Head’s 6% formulas are aimed at women who want a personalized, prescription-only topical that goes beyond standard strengths while still staying below the most aggressive high-dose regimens. By combining minoxidil with spironolactone, retinoic acid, and short-term hydrocortisone in a single bottle, it offers a modular approach that can be tuned to individual tolerance and response rather than a one-size-fits-all solution. It should be noted that Happy Head uses corticosteroids in their topicals to offset the potential irritation from propylene glycol usage. However, this can cause skin thinning with long-term use.

Bottom line: For women who need a tailored, mid-high-strength minoxidil blend with added anti-androgens and supportive ingredients, but prefer not to escalate to ultra-high-dose, steroid-heavy cocktails, Happy Head provides a strong option.

#7 Best for Woman-Centered Care: Winona 7% Minoxidil

Pros:	Cons:
✓ Women-focused clinic model that addresses broader menopausal health alongside hair loss.	✗ Uses a propylene glycol-containing vehicle, which can increase irritation, dryness, or stinging on sensitive scalps.
✓  Prescription-strength 7% minoxidil specifically targeted to menopausal and perimenopausal thinning.	✗ No customization
✓ Guided supportive care pathway, with structured programs, check-ins, and follow-up.	✗ Premium pricing at around $150 for a 3-month supply.
✓ Treatment plans that can integrate other menopause therapies where appropriate

Winona’s 7% minoxidil is designed for women who want more than a stand-alone bottle and value a structured, woman-centered approach that fits into a broader menopause-care framework. The higher-strength prescription formula, combined with clear guidance, follow-up, and attention to hormonal context, makes it particularly suited to postmenopausal and perimenopausal hair loss rather than general early thinning. However, it should be noted that its carrier agent, propylene glycol, may be irritating for sensitive scalps.

Bottom line: For women seeking a guided, menopause-focused program built around prescription-strength minoxidil, Winona offers a structured, woman-centered care pathway, albeit at a higher price and with a more irritant-prone vehicle.

Regrowth Timeline

Setting realistic expectations is essential when beginning topical minoxidil for female pattern hair loss. Unlike quick cosmetic fixes, minoxidil works by gradually altering the hair growth cycle, and visible changes take time to develop.

Timeframe	What to Expect	Clinical Evidence
Months 0-3	An initial increase in shedding may occur as follicles shift out of the resting (telogen) phase and re-enter growth. This temporary “dread shed” phase typically improves within 4–8 weeks and is considered a normal response to treatment initiation.	[14]Nohria, A., Desai, D., Sikora, M., Mandal, S., Shapiro, J., Lo Sicco, K. (2024). Combating “dread shed”: The impact of overlapping topical and oral minoxidil on temporary hair shedding during … Continue reading
Months 3-6	Early visible signs of improvement may appear, including reduced shedding and the emergence of fine, new hairs (vellus to terminal transformation), particularly along the part line and crown.	[15]Amit, K., Mansukh, G., Satyaprakash, M., Dhiraj, D., Hanmant, B. (2023). Real-World Effectiveness, Safety, and Tolerability of Cetosomal Minoxidil 5% Alone and a Fixed Drug Combination of Cetosomal … Continue reading
Months 6-12	More noticeable cosmetic improvements are typically seen, including increased overall density, thickening of existing strands, and improved scalp coverage in areas of diffuse thinning. For many women, this is the point at which changes become easily visible in the mirror and in photos.	[16]Katz, H.I., Hien, N.T., Prawer, S.E., Goldman, S.J. (1987). Long-term efficacy of topical minoxidil in male pattern baldness. Journal of the American Academy of Dermatology. 16(3). 711-718. Available … Continue reading
Months 12+	Hair density gains typically plateau. At this point, continued use is required to maintain results and prevent gradual regression back toward baseline. Stopping treatment may allow thinning to resume over time.	[17]Katz, H.I., Hien, N.T., Prawer, S.E., Goldman, S.J. (1987). Long-term efficacy of topical minoxidil in male pattern baldness. Journal of the American Academy of Dermatology. 16(3). 711-718. Available … Continue reading

Why Do I Need to Stay Consistent When Using Minoxidil?

Topical minoxidil works by extending the anagen (growth) phase of the hair cycle and shortening the telogen (resting) phase, thereby increasing the amount of time that follicles spend actively producing hair. Maintaining this effect requires regular, consistent application. When doses are frequently missed, follicles spend less cumulative time in a growth-biased state, which reduces the likelihood of noticeable improvement.^[18]Messenger, A.G., Rundegren, J. (2004). Minoxidil: mechanisms of action on hair growth. British Journal of Dermatology. 2(1). 186-194. Available at: … Continue reading

This principle is especially important in women, whose hair loss is often more diffuse and gradual, making subtle changes harder to notice in the early months. Because the human scalp hair cycle progresses slowly, with the anagen phase potentially lasting several years, many follicles need prolonged, uninterrupted exposure to minoxidil before visible gains in density and coverage can be achieved.^[19]Hoover E, Alhajj M, Flores JL. Physiology, Hair. [Updated 2023 Jul 30]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: … Continue reading

For this reason, most clinical guidance advises committing to at least six months of daily, consistent use before evaluating the effectiveness of treatment, with continued use required to sustain and build upon results.

What Minoxidil Formulations Are Available?

You can find topical minoxidil in several different delivery vehicles, each with its own advantages in terms of scalp tolerability, ease of use, and fit for a woman’s lifestyle and hair type. In most cases, the “best” option is not defined by pure strength alone, but by how well the formula matches skin sensitivity, styling habits, and consistency of application.

Foam – Best for Sensitive Skin

Propylene glycol–free foam formulations were developed to reduce the risk of contact dermatitis, itching, and dryness that can occur with traditional liquid solutions. Clinical observations suggest that foam is generally better tolerated and faster-drying, making it a strong choice for women with sensitive scalps or those who wash and style their hair frequently.^[20]Purnak, T., Senel, E., Sahin, C. (2011). Liquid formulation of minoxidil versus its foam formulation. Indian Journal of Dermatology. 56(4). 462. Available at: https://doi.org/10.4103/0019-5154.84714

Liquid – Best for Cost and Precision

Classic liquid solutions, usually formulated with alcohol and propylene glycol, remain widely available and affordable. While effective, they may cause itching, dryness, or flaking in some women. These solutions can work well for individuals without scalp sensitivity who prefer a more targeted, dropper-based application, especially along the part line.

Spray – Best for Quick, Even Coverage

Spray or mist-style applicators make it easier to cover larger areas of diffuse thinning, such as along the crown or upper scalp. However, they can be less precise, with some product landing on the hair shafts or surrounding skin rather than directly on the scalp.

Gel – Best for Targeted Areas

Gel or cream-gel formulations tend to stay in place, minimizing runoff and improving control. These are helpful for women treating specific areas of thinning, such as the temples, frontal hairline, or post-partum thinning zones.

Liposomal Delivery

Some prescription and premium products use liposomal or phospholipid-based carriers that are designed to improve follicular penetration while reducing irritation and systemic absorption. These advanced bases may be especially attractive for women who need stronger formulations but have experienced irritation with traditional vehicles.

How Safe is Minoxidil?

Topical minoxidil is generally well tolerated by women, but like any active medication, it can produce local scalp irritation, a brief increase in shedding during the early treatment phase, and, in very rare cases, systemic side effects, particularly in individuals with underlying skin or cardiovascular conditions.

Common local reactions may include:

• Mild itching
• Flaking or dryness
• Redness
• Burning or stinging
• Temporary increase in shedding

These symptoms are typically mild, tend to improve as the scalp adapts, and can often be reduced by switching to a foam-based formula, lowering concentration, or using a gentler vehicle.

Systemic and heart-related reactions are extremely uncommon with proper topical use. However, isolated case reports and safety data recommend seeking medical attention if symptoms such as chest tightness, heart palpitations, lightheadedness, dizziness, or unexplained swelling develop, as these could indicate increased systemic absorption or accidental ingestion. The risk of cardiovascular effects is significantly higher with oral minoxidil or improper dosing, where hypotension, tachycardia, and even heart failure have been reported.^[21]Tripathee, S., Benyovszky, A., Devbhandari, R., Quiza, K., Boris, J. (2024). A Very Bad Hair Day: Minoxidil Ingestion Causing Shock and Heart Failure. Cureus. 16(8). E66039. Available at: … Continue reading

To minimize the risk of side effects, many clinicians recommend starting with once-daily application, gradually increasing only if tolerated. Women with reactive skin often benefit from foam formulations, lower-alcohol bases, or liposomal delivery systems, which can reduce irritation and improve comfort during long-term use.

Individuals with active inflammatory scalp conditions, such as psoriasis, eczema, or severe seborrheic dermatitis, are generally advised to first address the underlying condition before beginning minoxidil therapy. Applying treatment to an inflamed or compromised skin barrier can increase irritation, worsen symptoms, and lead to unpredictable absorption patterns.^[22]Junge, A., Jic-Hoesli, S.R., Bossart, S., Simon, D., de Viragh, P., Hunger, R.E., Heidemeye, K., Seyed Jafari, S.M. (2025). Contact Dermatitis Caused by Topical Minoxidil: Allergy or Just Irritation. … Continue reading

Although topical minoxidil has lower systemic absorption than oral formulations, it is generally not recommended during pregnancy or while breastfeeding unless specifically advised by a healthcare provider. Women who are pregnant, trying to conceive, or nursing should consult a qualified medical professional to fully review potential risks and alternative treatment options.

Final Verdict

A range of minoxidil-based options is available to support different needs among women experiencing hair thinning, from strength-focused prescriptions to gentle, sensitivity-friendly alternatives and highly customized compounded formulas. While each product relies on the same core ingredient, differences in concentration, delivery vehicle, add-on actives, and level of medical support can significantly influence both tolerability and long-term adherence.

Whichever option you choose, consistent use of minoxidil remains one of the most evidence-backed ways to slow progression and improve hair density in women with pattern hair loss. With today’s expanded access to prescription platforms, foam-based formulations, and individualized treatment models, it is now easier than ever to find an approach that aligns with your scalp sensitivity, stage of hair loss, and lifestyle needs.

Men’s hair loss is a booming multi-billion-dollar industry, yet the vast majority of over-the-counter products fall short when measured against rigorous clinical evidence. This landscape is cluttered with quick-fix promises, leaving consumers sifting through marketing claims with little scientific support. Among all topical hair regrowth options, minoxidil is one of the most extensively studied. It is also one of two FDA-approved treatments for male pattern hair loss (in its topical form). 

In this comprehensive guide, we rank our top minoxidil picks of 2026 across Best Overall, Best Value, and other categories to help you navigate the crowded hair loss market with more clarity and confidence.

Quick Look: Best Minoxidil for Men in 2026

Product	Strength	Format	Customization	Price	Best:
Ulo	7%	Solution	High	$41.65	Overall
Ulo	1.25 mg / 2.25 mg	Sublingual Minoxidil	High	$39	Convenience for Sublingual Delivery
Kirkland Minoxidil	5%	Solution	None	$17.99	Value
Rogaine	5%	Solution/Foam	None	$49.97	Sensitive Scalp
Keeps	5%	Solution/Foam/Spray	Low	$16.67	Subscription Convenience
Happy Head	5-8%	Solution/Gel	High	$59	Strength

What is Minoxidil and How Does it Work?

Minoxidil was originally developed to treat high blood pressure and is now widely used in both topical and oral forms as a first-line therapy for androgenic alopecia (AGA).

What is Minoxidil?

Minoxidil was first introduced in the 1970s as a powerful oral vasodilator for resistant hypertension. Clinicians soon noticed a frequent side effect, generalized increased hair growth (hypertrichosis).^[1]Gupta, A.K., Talukder, M., Venkataraman, M., Bamimore, M.A. (2021). Minoxidil: a comprehensive review. Journal of Dermatological Treatment. 33(4). 1896-1906. Available at: … Continue reading This led to the development of topical formulations specifically for AGA. Today, 2-5% topical minoxidil is FDA-approved for both male and female pattern hair loss and is used off-label for other alopecias.

How Does Minoxidil Work?

Minoxidil is a potassium-channel opener that causes vasodilation and improves microcirculation around hair follicles.^[2]Hussein, R.S., Dayel, S.B., Abahussein, O., El-Sherbiny, A.A. (2024). Applications and efficacy of minoxidil in dermatology. Skin Health and Disease. 4(6). E472. Available at: … Continue reading It also acts as a prodrug; sulfotransferase converts it to minoxidil sulfate, which prolongs the anagen (growth) phase and shortens the telogen (resting) phase, shifting more hair follicles into active growth.^[3]Pietrauszka, K., Bergler-Czop, B. (2020). Sulfotransferase SULT1A1 activity in hair follicle, a prognostic marker of response to the minoxidil treatment in patients with androgenetic alopecia: a … Continue reading Additional data suggests that induction of key growth factors like vascular endothelial growth factor (VEGF) and activation of Wnt/ꞵ-catenin signaling further support hair regrowth.^[4]Gupta, A.K., Talukder, M., Shemer, A., Piraccini, B.M., Tosti, A. (2023). Low-Dose Oral Minoxidil for Alopecia: A Comprehensive Review. Skin Appendage Disorders. 9(6). 423-437. Available at: … Continue reading 

Although minoxidil doesn’t target dihydrotestosterone, it can improve the effectiveness of other treatments by targeting multiple other targets. When combined with anti-DHT drugs like finasteride, which reduce the hormonal trigger of AGA, minoxidil provides a complementary, non-hormonal pathway. The two treatments have been shown to provide synergistic improvement in hair density in men.^[5]Asad, N., Naseer, M., Ghafoor, R. (2024). Efficacy of Topical Finasteride 0.25% with Minoxidil 5% versus Topical Minoxidil 5% Alone in Treatment of Male Pattern Androgenic Alopecia. Journal of Drugs … Continue reading 

Topical Minoxidil From our partners at Ulo

Get Personalized Topical Minoxidil

Rx-strength topical minoxidil, formulated without propylene glycol. Prescribed 100% online. Choose a multi-month plan and get up to 30% plus a free gift bundle.

Free full-size gifts with 3-month+ plans Prescribed online, shipped to your door

Claim up to 30% off + Free Gifts

Rx-strengthHigh strength growth support

*Only available in the U.S. Prescription requires an online medical consultation at no extra cost. Off-label products are not endorsed by the FDA. Free gifts included with select multi-month plans while supplies last. Ulo is a partner of Perfect Hair Health; we may earn a commission on purchases.

OTC vs Prescription-Strength

Over-the-counter (OTC) minoxidil solutions (2% and 5%) can be effective for many men, but absorption and vehicle limits mean “stronger” drug percentages above 5% often add irritation rather than results unless the entire formulation is engineered and supervised medically. 

Early minoxidil development work showed a clear dose-response between low strengths (1-2%) and mid-strength (5%) solutions, with 5% yielding larger gains in hair counts and shaft diameter in AGA.^[6]Olsen, E.A., Dunlap, F.E., Funicella, T., Koperski, J.A., Swinehart, J.M., Tschen, E.H., Trancik, R.J. (2002). A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and … Continue reading

Other companies offer concentrations of 10% or over; however, recent head-to-head studies have shown that 5% topical minoxidil is moderately superior to the higher concentration.^[7]Ghonemy, S., Alarawi, A., Bessar, H. (2021). Efficacy and safety of a new 10% topical minoxidil versus 5% topical minoxidil and placebo in the treatment of male androgenetic alopecia: a trichoscopic … Continue reading Additionally, the 10% minoxidil was associated with more marked irritation.

So, with that in mind, let’s take a look at some of our top minoxidil picks of 2026.

Best Minoxidil Picks for Men

#1 Best Overall: Ulo Minoxidil Rx

Pros:	Cons:
✓ Clinically-backed combinations	✗Prescription products are only available in the USA
✓ Ongoing medical monitoring and a user-friendly platform
✓ Quality-tested ingredients free of irritants

Ulo’s Minoxidil Rx takes the top spot for men who want a data-driven, medically supervised approach rather than a one-size-fits-all bottle. Custom strengths and evidence-based optional add-ons allow precise targeting for hair regrowth. 

Their high-strength concentration can be combined with tretinoin 0.01% to enhance absorption and efficacy, as well as cetirizine 1%, melatonin 0.01% for antioxidant protection, and caffeine 0.2% to boost circulation, which further improves the product’s effectiveness.

This treatment begins at $49 per month, increasing to $54 if you choose to have all of the add-ons.  

Bottom Line: Ulo’s customizable, science-driven minoxidil prescription offers one of the most advanced, value-conscious options for men who are serious about long-term hair regrowth.

#2. Best for Convenience: Ulo Sublingual Minoxidil

Pros:	Cons:
✓ Rapid-dissolve, orange-flavored chewable tablet	✗ Premium pricing
✓ No water required, just let it dissolve under the tongue
✓ Available with 1.25 mg or 2.25 mg oral minoxidil
✓ Option to combine minoxidil with 1 mg finasteride in one daily dose
✓ Prescription and ongoing support from licensed providers

Ulo’s Dissolving Chews are designed for men who want the convenience of oral minoxidil but with the benefits of sublingual minoxidil. These orange-flavored tablets dissolve rapidly in the mouth and taste delicious.

Ulo is the only telehealth company currently offering a convenient sublingual tablet for dosing minoxidil. By administering minoxidil sublingually, it bypasses the sulfotransferase enzymes in the liver responsible for converting minoxidil into its active form. When activated in the liver, it transports active minoxidil throughout the body, supporting hair growth, but also impacting the cardiovascular system.

Sublingual minoxidil still produces active minoxidil in the hair follicles, however, it is theorized to reduce the delivery of active minoxidil to sensitive cardiovascular tissue. In one clinical trial, no palpitations were reported in the sublingual minoxidil group versus 9% of the conventional oral minoxidil group.^[8]Sanabria, B., Miot, H.A., Sinclair, R., Chaves, C. and Müller Ramos, P. (2025), Sublingual Minoxidil 5 mg versus Oral Minoxidil 5 mg for male androgenetic alopecia: A double-blind randomized … Continue reading

The formula is available with 1.25 mg or 2.25 mg minoxidil, with the option to add 1 mg finasteride for men who want to address both hair growth and DHT-related miniaturization in a single daily treatment. This makes it particularly convenient for those already using both medications separately or who find topical applications difficult to maintain.

Bottom Line: For men who prefer oral minoxidil, Ulo’s Sublingual Minoxidil offer a convenient, delicious way to implement sublingual delivery, with the added option of combining minoxidil and finasteride in one daily dose.

Sublingual Minoxidil From our partners at Ulo

Sublingual Minoxidil

A rapidly-dissolving sublingual tablet with minoxidil. Available in 1.25 mg and 2.5 mg doses. Prescribed 100% online. Choose a multi-month plan and get up to 30% plus a free gift bundle.

Free full-size gifts with 3-month+ plans Prescribed online, shipped to your door

Claim up to 30% off + Free Gifts

Sublingual deliveryDissolves under the tongue

*Only available in the U.S. Prescription requires an online medical consultation at no extra cost. Off-label products are not endorsed by the FDA. Free gifts included with select multi-month plans while supplies last. Ulo is a partner of Perfect Hair Health; we may earn a commission on purchases.

#3 Best Value – Kirkland Signature Minoxidil 5%

Pros:	Cons:
✓ Lowest cost we could find for 6 months’ worth.	✗Contains propylene glycol, which can cause irritation or dryness in some users.
✓ Same core 5% minoxidil strength.	✗ No customization possible for strength or add-on ingredients.
✓ Widely available at multiple stores, including Amazon, Costco, etc.	✗ No medical consultation or tailoring of treatment included.
✓ Simple formula.

Kirkland Signature Minoxidil 5% is the classic value choice for me who want an over-the-counter treatment without paying for branding or bundled medical services. You get a standard 5% solution similar in strength to more expensive competitors, making it ideal for cost-conscious users who are happy to follow a simple twice-daily routine and do not need personalized compounding. 

Bottom line: If you want the most affordable entry point into 5% minoxidil, Kirkland’s no-frills formula is hard to beat for sheer value per effective dose.

#4 Best for Sensitive Scalps: Rogaine 5% Foam

Pros:	Cons:
✓ Clinically proven 5% minoxidil strength	✗On the higher end in terms of price.
✓ Foam vehicle is propylene glycol-free, so it is usually better tolerated on sensitive or irritated scalps.	✗ Fixed strength for men with no customization or add-on actives.
✓ Quick drying, less greasy texture	✗ No medical consultation or tailoring of treatment included.
✓ Widely available OTC

Rogaine 5% is a strong pick for men who need minoxidil but find traditional liquid formulas too irritating or cosmetically heavy. The foam format avoids common irritants found in many solutions and tends to be more comfortable for daily use, which can improve adherence and long-term outcomes.

Bottom Line: For sensitive scalps that still need full-strength 5% minoxidil, Rogaine Foam provides a gentler, easy-to-use option that balances proven efficacy with better tolerability.

#5 Best Subscription Convenience: Keeps Minoxidil

Pros:	Cons:
✓ Automatic subscription refills so you rarely run out or miss doses.	✗More expensive than buying generic minoxidil in bulk.
✓ Offers both 5% foam and 5% solution to suit different scalp and styling preferences.	✗ Limited to preset strengths and formulas with no true custom compounding.
✓ Option to bundle with finasteride and other treatments for a complete regimen.
✓ Online prescribing and follow-up.

Keeps Minoxidil is designed for men who value a set-and-forget routine, trading a price increase ($16.67 for 3 months compared to Kirkland’s $17.99 for 6 months) for automatic deliveries and integrated telehealth support. The ability to pair minoxidil with finasteride and keep everything managed through a single platform could make adherence simpler for busy users.

Bottom Line: If you want 5% minoxidil with minimal hassle, Keeps’ subscription model is a strong fit for convenience-focused men who prefer not to manage refills and prescriptions on their own. 

#6 Best High-Strength Formula: Happy Head

Pros:	Cons:
✓ Offers high-strength minoxidil concentrations beyond standard 5%.	✗Higher strengths may carry a greater risk of irritation or systemic absorption.
✓ Can be combined with topical finasteride and other actives in a single solution.	✗ More expensive than generic 5% minoxidil and some standard telehealth offerings.
✓ Telehealth model with online consultation and prescription management.	✗Corticosteroids used to offset irritation from propylene glycol.
✓ Multiple formula options aimed at men who have plateaued on basic OTC products.

Happy Head is built for men who want to move past entry-level minoxidil and explore higher-strength, prescription-only blends under medical oversight. By pairing elevated minoxidil concentrations (8%) with agents like tretinoin and topical finasteride, Happy Head targets users seeking a more comprehensive protocol. With that said, some ingredients included, like the carrier agent propylene glycol, which is used in their base formula, can cause irritation. To offset this, Happy Head uses corticosteroids; however, this may cause skin thinning long-term.

You can read more about corticosteroid usage in hair loss treatments here.

Bottom Line: Happy Head delivers a good jump in strength for minoxidil users who need to increase efficacy. 

Timeline: What Results to Expect from Minoxidil

It’s important that realistic expectations are set for regrowth when starting out on your minoxidil usage journey.

Timeframe	What to Expect	Clinical Evidence
Months 0-3	This is the initial shedding phase, which usually resolves in the first 4-8 weeks.	[9]Nohria, A., Desai, D., Sikora, M., Mandal, S., Shapiro, J., Lo Sicco, K. (2024). Combating “dread shed”: The impact of overlapping topical and oral minoxidil on temporary hair shedding during … Continue reading
Months 3-6	Early visible improvements, like the appearance of new hairs, can be expected.	[10]Amit, K., Mansukh, G., Satyaprakash, M., Dhiraj, D., Hanmant, B. (2023). Real-World Effectiveness, Safety, and Tolerability of Cetosomal Minoxidil 5% Alone and a Fixed Drug Combination of Cetosomal … Continue reading
Months 6-12	Cosmetic changes peak, with stronger hair, increased density, and most coverage is seen.	[11]Katz, H.I., Hien, N.T., Prawer, S.E., Goldman, S.J. (1987). Long-term efficacy of topical minoxidil in male pattern baldness. Journal of the American Academy of Dermatology. 16(3). 711-718. Available … Continue reading
Months 12+	Further gains plateau, continued use needed to maintain improvements.	[12]Katz, H.I., Hien, N.T., Prawer, S.E., Goldman, S.J. (1987). Long-term efficacy of topical minoxidil in male pattern baldness. Journal of the American Academy of Dermatology. 16(3). 711-718. Available … Continue reading

Consistency is Everything

Minoxidil works by prolonging the anagen phase and shortening the telogen phase. Regular dosing maintains these effects at the follicle level; repeatedly missing applications reduces the cumulative time that hair follicles spend in a pro-growth, anagen-biased state.^[13]Messenger, A.G., Rundegren, J. (2004). Minoxidil: mechanisms of action on hair growth. British Journal of Dermatology. 2(1). 186-194. Available at: … Continue reading

Because human scalp follicles cycle slowly (anagen can last years), many follicles need months of uninterrupted exposure before visible density gains can be seen.^[14]Hoover E, Alhajj M, Flores JL. Physiology, Hair. [Updated 2023 Jul 30]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: … Continue reading This is why most guidance recommends at least 6 months of continuous use before judging the response.

Why Stopping Reverses Progress

Minoxidil is not disease-modifying for AGA, meaning that it does not correct androgen-driven miniaturization but counteracts it while present by improving hair cycle dynamics and follicle size. When treatment is stopped, these pharmacologic effects wane, and follicles gradually revert toward their genetically determined, androgen-sensitive pattern.

Clinical and patient information sources consistently note that any gain from minoxidil is maintained only while therapy continues. After discontinuation, increased shedding and loss of density over months are typical, ultimately leading to a reversal of gains to the original starting point.

What Minoxidil Formulations are Available?

You can buy minoxidil in several different vehicles that differ mainly in tolerability, practicality, and how well they fit a given scalp and routine. Choosing the “best” format is less about raw efficacy and more about matching the base to skin sensitivity and your preference of application.

• Foam – Best for Sensitive Skin: Propylene glycol-free foams were developed to reduce contact dermatitis and dryness seen with classic liquid solutions. Reviews note lower rates of irritation and quicker drying, which makes them better for patients with reactive or dry scalps.^[15]Purnak, T., Senel, E., Sahin, C. (2011). Liquid formulation of minoxidil versus its foam formulation. Indian Journal of Dermatology. 56(4). 462. Available at: https://doi.org/10.4103/0019-5154.84714

• Liquid – Best for Cost-Effectiveness: Traditional solutions with alcohol and propylene glycol are widely available, inexpensive, and easy to use, but they may cause increased itching, flaking, and stinging. This formulation may suit users with non-sensitive skin who are price-conscious.

• Spray – Easiest for Coverage: Spray tops or aerosolized formats can make it faster to hit broad thinning areas, especially in longer hair. However, the product may end up more on the hair shafts or adjacent skin.

• Gel – Targeted and Controlled: Gel or cream-gel vehicles (often from compounders) sit where you place them, minimize dripping, and are useful for localized areas such as temples or post-transplant zones. 

• Liposomal Delivery: Newer liposomal or phospholipid bases aim to enhance follicular penetration while limiting systemic absorption and irritation. This is usually marketed as an “advanced delivery” method.

Side Effects and Safety

Minoxidil is generally well tolerated, but like any active drug, it can cause local irritation, a transient shedding phase, and very rare systemic effects, especially in people with underlying skin or cardiovascular issues.

Common local side effects include:

• Itching
• Flaking
• Redness
• Burning
• Temporary shedding 

Systemic and heart-related side effects are very rare with correctly used topical minoxidil, but case reports and product information advise seeking medical help if symptoms like chest pain, palpitations, dizziness, or unexplained swelling occur, as these could reflect systemic absorption or accidental ingestion. Risk is higher with oral minoxidil or overdose, where hypotension, tachycardia, and even heart failure have been documented.^[16]Tripathee, S., Benyovszky, A., Devbhandari, R., Quiza, K., Boris, J. (2024). A Very Bad Hair Day: Minoxidil Ingestion Causing Shock and Heart Failure. Cureus. 16(8). E66039. Available at: … Continue reading 

To minimize problems, many clinicians suggest starting once daily and titrating up, choosing foam or gentler vehicles to reduce dermatitis, and using custom compounded formulas (for example, lower alcohol, lower strength, or liposomal bases) in those with sensitive or disease-prone scalps. 

People with chronic inflammatory scalp conditions such as active psoriasis, eczema, or severe seborrheic dermatitis are typically advised to get the primary condition under control before adding topical minoxidil or other actives, as applying them to an inflamed barrier increases irritation, may worsen the disease, and can unpredictably alter absorption.^[17]Junge, A., Jic-Hoesli, S.R., Bossart, S., Simon, D., de Viragh, P., Hunger, R.E., Heidemeye, K., Seyed Jafari, S.M. (2025). Contact Dermatitis Caused by Topical Minoxidil: Allergy or Just Irritation. … Continue reading 

Final Verdict – Best Minoxidil for Men in 2026

In 2026, several minoxidil-based options stand out for different priorities, from cost to customization. All of them rely on the same core ingredient, but vehicle, strength, and add-ons make a real-world difference in adherence and results. 

Whichever route you choose, there is strong evidence that consistent minoxidil use can stabilize loss and improve density for many men, and modern platforms make it easier than ever to find a formulation that fits your scalp, schedule, and risk tolerance.

Oral minoxidil has become a widely used off-label option for androgenic alopecia (AGA) in men and women, despite initially being approved only as an antihypertensive medication decades ago.

Oral minoxidil is increasingly offered to address specific unmet needs in AGA treatment: 

• Topical non-responders: Some people don’t see satisfactory results with topical minoxidil, possibly due to inadequate absorption, variations in scalp skin properties, or genetic factors affecting drug metabolism.
• Scalp sensitivity/irritation: Topical minoxidil can cause local side effects such as itching, flaking, or dermatitis due to the vehicle (especially propylene glycol) or the active ingredient itself. Switching to oral minoxidil bypasses these local reactions.
• Simpler routines/adherence: Oral dosing eliminates the need for daily topical application, which can be messy, time-consuming, or interfere with hair styling. For some, this leads to better long-term adherence and quality of life.

Regrowth with oral minoxidil can be variable, however. This variability mainly stems from biological differences between patients. Because minoxidil is a prodrug that requires conversion by the enzyme sulfotransferase (SULT1A1) into its active form, individual variation in enzyme activity strongly influences response.^[1]Ramos, P.M., Goren, A., Sinclair, R., Miot, H.A. (2020). Oral minoxidil bio-activation by hair follicle outer root sheath cell sulfotransferase enzymes predicts clinical efficacy in female pattern … Continue reading  

Oral Minoxidil From our partners at Ulo

Interested in Oral Minoxidil?

Get growing with a once-daily pill for growth support with no application, drying time, or residue. Prescribed 100% online. Choose a multi-month plan and get up to 25% plus a free gift bundle.

Free full-size gifts with 3-month+ plans Prescribed online, shipped to your door

Claim up to 25% off + Free Gifts

Once dailyNo topical application

*Only available in the U.S. Prescription requires an online medical consultation at no extra cost. Off-label products are not endorsed by the FDA. Free gifts included with select multi-month plans while supplies last. Ulo is a partner of Perfect Hair Health; we may earn a commission on purchases.

Unfortunately, what most people see online are extremely successful oral minoxidil before and after photos (which you’ll see below), which can lead people to believe that they will experience more regrowth than they actually might.

In this article, we will explore what the likely (not just possible) results are and what the clinical trials show.

But first, let’s have a quick refresher on what oral minoxidil is.

What is Oral Minoxidil?

Oral minoxidil is a tablet medication originally developed as a vasodilator for severe hypertension, but now increasingly used off-label at low doses to treat AGA and other hair loss conditions. It enhances scalp flow and prolongs the growth phase (anagen) of hair follicles, primarily by increasing prostaglandin E2 and vascular endothelial growth factor (VEGF). 

Oral minoxidil acts by opening ATP-sensitive potassium channels in vascular smooth muscle, which increases perifollicular blood flow. It also prolongs the anagen phase of the hair cycle. Unlike topical minoxidil, which requires local sulfotransferase enzyme activity in the scalp for conversion to its active form, oral minoxidil is metabolized systemically via hepatic sulfotransferase, potentially bypassing poor scalp enzyme activity in some individuals.^[2]Kaiser, M., Abdin, R., Gaumond, S.I., Issa, N.T., Jiminez, J.J. (2023). Treatment of Androgenetic Alopecia: Current Guidance and Unmet Needs. Clinical, Cosmetic and Investigational Dermatology. 16. … Continue reading 

For hair loss, oral minoxidil is prescribed at significantly reduced dosages compared to antihypertensive therapy – typically:

• 0.25 mg – 1.25 mg for women
• 2.5 mg – 5 mg for men
• Adverse effects are much less frequent at these low doses but may include hypertrichosis (excess unwanted body hair), fluid retention, and, rarely, cardiovascular effects.^[3]Bloch, L.D., Carlos, R.M.D. (2024). Side Effects’ Frequency Assessment of Low Dose Oral Minoxidil in Male Androgenetic Alopecia Patients. Skin Appendage Disorders. 11(1). 14-18. Available at: … Continue reading 

While oral minoxidil is not FDA-approved for hair loss, a number of studies show its efficacy. 

Sublingual Minoxidil From our partners at Ulo

Sublingual Minoxidil

A rapidly-dissolving sublingual tablet with minoxidil. Available in 1.25 mg and 2.5 mg doses. Prescribed 100% online. Choose a multi-month plan and get up to 30% plus a free gift bundle.

Free full-size gifts with 3-month+ plans Prescribed online, shipped to your door

Claim up to 30% off + Free Gifts

Sublingual deliveryDissolves under the tongue

*Only available in the U.S. Prescription requires an online medical consultation at no extra cost. Off-label products are not endorsed by the FDA. Free gifts included with select multi-month plans while supplies last. Ulo is a partner of Perfect Hair Health; we may earn a commission on purchases.

The Evidence

You can see a complete table of oral minoxidil studies here, but we have picked a few to show.

Study One – AGA (Female)

Vahabi-Amlashi et al (2021) conducted a triple-blind, randomized clinical trial in 72 women with female pattern hair loss, comparing oral minoxidil 0.25 mg daily to 2% topical minoxidil twice daily over 36 weeks.^[4]Vahabi-Amlashi, S., Layegh, P., Kiafar, B., Hoseininezhad, M., Abbaspour, M., Khaniki, S.H., Forouzanfar, M., Sabeti, V. (2021). A randomized clinical trial on the therapeutic effects of 0.25 mg oral … Continue reading 

• Measured outcomes included hair shedding, Sinclair scores by three independent evaluators, trichoscopy assessments of hair density and diameter, and safety labs (liver, kidney, electrolytes).
• Both groups showed significant improvement in hair diameter and density:
  • Group 1 (oral): 13% improvement in hair density.
  • Group 2 (topical): 6% improvement in hair density.
• Sinclair and shedding scores decreased significantly in both groups by the end of the study.
• There was no significant difference between groups in any measured endpoint. 
• Oral minoxidil showed slightly better improvement in hair density; topical minoxidil showed slightly better improvement in hair diameter.
• Adverse events:
  • Group 1 (oral): hirsutism (7.7%), gastrointestinal intolerance (7.7%), weight gain (3.8%), hypotension (3.8%), leading to withdrawal.
  • Group 2 (topical): hirsutism (8%).

Study Two – AGA (Male)

Panchaprateep and Lueangarun (2020) conducted an open-label, prospective single-arm study in 30 men with AGA, treated with 5 mg oral minoxidil once daily for 24 weeks.^[5]Panchaprateep, R., Lueangarun, S. (2020). Efficacy and Safety of Oral Minoxidil 5 mg Once Daily in the Treatment of Male Patients with Androgenetic Alopecia: An Open-Label and Global Photographic … Continue reading

• Statistically significant increase in total hair count at 24 weeks (+35.1±18.9 hairs/cm2; p=0.003).
• Hair diameter improved by 15.2% from baseline (p<0.001).
• Global photographic assessment: 43% of patients achieved an “excellent improvement” score by study end.
• High rate of hypertrichosis (93.3% at 24 weeks); pedal edema was reported in 3 patients, resolving after 2-3 months in all cases.
• No serious cardiovascular side effects were observed.

Study Three – AGA and TE (Male and Female)

Feaster et al. (2023) performed a multicenter retrospective study in 210 patients (50 men, 160 women) with AGA and/or telogen effluvium (TE), comparing low-dose oral minoxidil (0.625 – 2.5 mg daily) to a control (no minoxidil or other non-minoxidil treatments) over 52 weeks.^[6]Feaster, B., Onamusi, T., Cooley, J.E., McMichael, A.J. (2023). Oral minoxidil use in androgenetic alopecia and telogen effluvium. Archives of Dermatological Research. 315(2). 201-205. Available at: … Continue reading 

• Group 1 (oral minoxidil): 52.4% of patients showed clinical improvement in hair growth; 41.9% had hair loss stabilization; 5.7% experienced worsening.
• These results were significantly better than the control group (p=0.001). 
• The mean duration of oral minoxidil use was 25.1 months (range 12-54); the most common dose was 1.25 mg daily.
• Adverse effects were uncommon (9.5% of patients), generally mild, and included:
  • Hypertrichosis (4.8%)
  • Edema (1.9%)
  • Hair shedding (1%)
  • Lower extremity cramping (1%)
  • Palpitations (1%)
  • Scalp dysesthesia (1%)
• There were no serious side effects or study withdrawals due to adverse events in the analyzed population.

Overall, these studies demonstrate that oral minoxidil is an effective and generally well-tolerated treatment option for both AGA and TE in men and women. Across the studies, clinical improvements were observed, with similar efficacy to topical minoxidil.

However, the results that people show online are usually more dramatic than what is seen in clinical studies. 

What’s Possible ≠ What’s Probable

When reviewing outcomes, such as oral minoxidil before and after photos, it’s essential to distinguish what can happen from what is likely to happen. Take a look at the example we have created below. The scattered data points represent the full spectrum of possible individual results, while the central trendline shows the average, reflecting the most common or expected response.

These anecdotes (arrows on the graphs) often highlight “hyper-responders”. These are individuals who experience notably dramatic hair regrowth. They may have higher SULT1A1 activity, leading to higher levels of minoxidil activation.

These accounts, although genuine, illustrate results that surpass what most people can achieve. Problems can then arise when people fixate on these exceptional outcomes and assume that their experience will be similar. If their own hair growth is slower or less impressive, they might discontinue treatment early, or wrongly conclude that it isn’t working.

Impressive results are more frequently shared than modest improvements as a result of survivorship bias. This bias happens when only the most impressive successes receive attention, while the many cases with typical or less remarkable outcomes are overlooked or not reported.

Survivorship bias can distort our understanding of how hair loss treatments perform. Online narratives often draw attention to the most extreme cases, either astonishing successes or clear failures, while the more typical moderate outcomes that most people experience are rarely seen or discussed.

Now that we have covered the clinical evidence, strategies, and reasonable expectations for oral minoxidil, let’s now look into 10 firsthand accounts of oral minoxidil before and after photos shared by real users on Reddit.

Oral Minoxidil Success Stories

Keep in mind that the experiences below are purely anecdotal in nature and are not subject to any independent verification. They strictly reflect the individual journeys of each poster and should not be construed as reliable clinical evidence or medical advice.

Case 1: Male (29), Oral minoxidil monotherapy (11 months, 5 mg nightly)

This Redditor began oral minoxidil monotherapy at a dose of 2.5 mg before increasing to 5 mg once nightly. He had switched from topical minoxidil after a year of subpar results. He experienced shedding in the early months of therapy, with visible regrowth by month 3, and a major improvement in hair density by 11 months. Overall, the patient was satisfied with thicker scalp coverage, a fuller beard and brows, and did not report any significant side effects.

Case 2: Male (26), finasteride and oral minoxidil (2 years total; 1 mg finasteride and 2.5 mg oral minoxidil daily)

This 26-year-old used a combination of 1 mg finasteride and 2.5 mg oral minoxidil once daily, having switched from topical to oral minoxidil one year into treatment. He reported notable improvement one year into therapy, with visible regrowth by the 4-month mark. He did not report any shedding or other side effects after switching from topical to oral formulations. After two years of treatment, the patient reported marked hair thickening and cosmetic improvement.

Case 3: Female, oral minoxidil monotherapy (2 years; 2.5 mg daily, titrated up from 1.25 mg)

This user reported one her progress with oral minoxidil monotherapy over 2 years. She started at a daily dose of 1.25 mg, before increasing to 2.5 mg. She had tried vitamins, spironolactone, oils, and Nioxin/Nizoral without benefit for one year prior. Shedding started shortly after beginning the protocol and normalized by the fourth month. She reported visible improvement within one year, and by the end of the second year, she had notable improvement in ponytail thickness and part density. She also reported that her hair looked and felt close to pre-loss baseline. The user did not report any significant side effects.

Case 4: Female (24), Oral and topical minoxidil (9 months topical 5% foam; 6 months oral 0.625 – 1.25 mg nightly)

This 24-year-old began minoxidil monotherapy with 5% foam nightly, before adding oral minoxidil 0.625 mg three months later, and titrating to 1.25 mg nightly the following month. She continued both nightly for six months. She did not note any noticeable shedding on the foam, nor after incorporating 0.625 mg orally. She reported steady baby hairs and a reduction in hair loss at ~6-9 months alongside thickening compared to the baseline, and mentioned that her hair felt and looked much closer to its pre-loss condition overall. She also reported faster growth of facial/body hair (hypertrichosis), water retention, and bloating after salt meals, and occasional stronger heartbeat at night, after incorporating oral minoxidil, though this last symptom did resolve.

Case 5: Male, oral minoxidil (6 weeks shown; 5 mg daily) and weekly microneedling

This male Redditor used oral minoxidil 5 mg once daily in addition to microneedling once weekly with a pen device. The poster also noted no side effects from finasteride, implying that they might have used it alongside the other treatments. He reported an initial shedding phase at around week 3 and rapid visible coverage by week 6 into treatment. In commenting on the progress to date, he noted fuller coverage compared to baseline and said his beard was slightly thicker without any apparent increase in body hair. He did not report any side effects.

Case 6: Female, oral minoxidil + spironolactone (1 year; 1.25 mg oral minoxidil daily, 50 mg spironolactone daily)

The poster took oral minoxidil 1.25 mg once daily, in addition to spironolactone 50 mg once daily (started at 100 mg but reduced the dose due to drowsiness). She noted visible improvement after about 5 months of consistent use, with shedding slowing markedly around weeks 7-8. At the one-year mark, she reported noticeably fuller hair at the part and temples, with ongoing gradual thickening, and “good hair days”. She reported increased body and facial hair from oral minoxidil, which she managed by waxing, and did not report any noticeable weight gain or low-blood-pressure symptoms. 

Case 7: Female, oral minoxidil monotherapy (6 months; 1.25 mg daily, titrated from 0.625 mg)

This female Redditor took oral minoxidil 1.25 mg once daily for six months, having started from the initial dose of 0.625 mg. She supplemented with vitamin B12 injections every two weeks for pernicious anemia, daily shampooing, higher protein intake, and therapy/stress management. She reported steady improvement in hair through month 6, despite a brief “dread shed” in the initial month. Unfortunately, the images don’t show the same hair pulled back, so we can’t see exactly how much improvement was gained. She did report increased facial hair, which she has been managing by shaving/dermaplaning.

Case 8: Female, oral minoxidil monotherapy (1 year; 1.25 mg daily)

This user took oral minoxidil 1.25 mg once daily for one year. She also used Nizoral shampoo on the same timeline. Her hair loss was first diagnosed as telogen effluvium that did not resolve, and she now suspects AGA. She reported modest shedding in the first 2 months, then gradual thickening over the year. The photos showed some improvement, but the patient stated that she is not fully back to baseline. Regarding side effects, she noted increased body hair growth and mild dizziness in the first month that resolved.

Case 9: Male, self-made oral minoxidil (3 months; ingested diluted topical solution)

This male Redditor switched from applying topical minoxidil to drinking a diluted solution mixed with water. He reported taking “a few drops” per dose, having discontinued application of the topical preparation to the scalp. At the three-month mark, the Redditor reported clearly greater overall density and said results were still improving. He did not report any side effects, except for some extra body hair. 

We should mention that we do not recommend ingesting topical minoxidil – if oral therapy is pursued, it is advised to use a prescribed oral dose under medical supervision to control dosing and avoid health risks.

Case 10: Female, oral minoxidil monotherapy (12 months; dose not reported)

This user reported taking oral minoxidil at an unspecified dose for about one year. The photos show modest improvements around the parting. The poster did not report any side effects. Notwithstanding the sparse information provided by this Redditor, multiple commenters observed hair thickening and density gains in the before-and-after photos.

Strategies to Optimize Oral Minoxidil Response

To maximize the benefits of oral minoxidil, consistent use and patience are essential as optimal regrowth often takes 6-8 months to fully manifest. Combining oral minoxidil with other treatments like finasteride or dutasteride, platelet-rich plasma (PRP), or low-level laser therapy (LLLT) can improve results for those who do not respond sufficiently to minoxidil alone. Recent studies support the efficacy of combination regimens, particularly oral minoxidil plus finasteride, with one retrospective study finding significant and clinically meaningful improvements.^[7]Johnson, H., Huang, D., Clift, A.K., Bersch-Ferreira, A., Guimaraes, G.A. (2025). Effectiveness of Combined Oral Minoxidil and Finasteride in Male Androgenetic Alopecia: A Retrospective Service … Continue reading 

People using oral minoxidil, especially at 2.5 mg or more and in combination with other treatments, should keep an eye on potential side effects. This can help catch rare but potentially serious side effects like edema or changes in blood pressure. Regular follow-ups can ensure that any adverse effects are detected early and that the regimen can be safely adjusted to maintain a balance between safety and efficacy. This patient-tailored management increases the likelihood of achieving the best possible outcomes while minimizing health risks.

Probable Regrowth Timeline

Based on the available evidence, the expected regrowth timeline for oral minoxidil is around 8 months.

Months 0-3: Possible increased shedding; no visible gains

• Temporary shedding can occur as follicles transition into a new growth cycle.
• This process often resolves within the first 4-8 weeks and is seen as an early sign that the treatment is starting to take effect.

Months 3-6: First positive density changes for many

• Early visible improvements, such as reduced shedding and appearance of fine new hairs, can be expected.
• Thicker, darker regrowth starts to become apparent for most users during this period.

Months 6-8: Maximal visible benefits

• Cosmetic changes peak, with stronger hair, increased density, and the greatest coverage observed. 
• This is the period of maximum regrowth for most individuals. 

Months 8-12+

• Further gains plateau.
• Continued daily use is needed to maintain improvements.
• Some might consider combination treatment at this point to increase growth outcomes.

Safety and Side Effects

While oral minoxidil can avoid local irritation occurring with the topical formulation, some safety concerns do remain.

Oral minoxidil use does carry a risk of cardiovascular issues like pericardial effusion, especially at the high doses used for blood pressure control. At hair loss doses (0.25 – 5 mg), such events are rare and tend to be individual rather than predictable. 

The majority of side effects, such as excess body hair, mild ankle swelling, lightheadedness, or palpitations, are mild and usually resolve with dose adjustments or stopping the medication. 

Large safety studies have shown that serious side effects are exceedingly rare in otherwise healthy individuals taking low-dose oral minoxidil, with only a small percentage discontinuing treatment due to adverse effects. 

A gradual dose escalation is recommended to minimize side effects with oral minoxidil. Recent studies have shown that a 2.5 mg daily dose is as effective as 5 mg for treating male pattern hair loss, but with a better safety profile, and this supports 2.5 mg as a preferred starting dose for men.^[9]Fonseca, L.P.C., Miot, H.A., Chaves, C.R.P., Ramos, P.M. (2025). Oral Minoxidil 2.5 mg vs 5 mg for Male Androgenetic Alopecia: A Double-Blind Randomized Clinical Trial. Journal of the American … Continue reading 

If you want to use a higher dose, sublingual minoxidil may be beneficial for reducing the risk of cardiovascular side effects.^[10]Gupta, A.K., Bamimore, M.A., Williams, G., Talukder, M. (2025). Comparative Efficacy of Minoxidil and 5-Alpha Reductase Inhibitors Monotherapy for Male Pattern Hair Loss: Network Meta-Analysis Study … Continue reading 

Practical Takeaways

• Oral minoxidil is an effective and generally well-tolerated alternative for people who cannot use topical minoxidil or do not respond to it.
• Clinical trial results typically show stabilization or modest regrowth. Hyper-responder cases seen online are possible but not common. 
• Careful dose selection (0.25 – 2.5 mg daily) minimizes side effects while maintaining efficacy.
• Consistent, long-term use is key; optimal results generally take 6-8 months to appear and require ongoing treatment to maintain gains.
• Combining oral minoxidil with other therapies such as finasteride, dutasteride, PRP, or LLLT may improve outcomes for partial responders.

Final Thoughts

Oral minoxidil use is growing, but should be recognized as an off-label option (albeit backed by a solid body of emerging evidence.. Most users can expect stabilization or noticeable yet modest regrowth rather than dramatic transformation. The best outcomes come with realistic expectations, consistent use over several months, and regular medical supervision to ensure safety. By focusing on average, evidence-based results rather than rare hyper-responder anecdotes, patients can make balanced decisions and maintain long-term adherence to their treatment plan.